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The overall aim of this thesis was to investigate the cause of high prevalence of Clostridium 
difficile in patients with cystic fibrosis (CF), to monitor it and ultimately to control its spread. 
 Initially the carriage rate of C. difficile and characterisation of the strains present in 
patients with CF was investigated (Chapter 2). C. difficile was found in 50% (30/60) of CF 
patient stool, compared to just 2% (2/99) of healthy controls. C. difficile toxin was detected in 
the stool of 31.66% (19/60) of CF patients, all of which contained C. difficile strains capable of 
producing toxin. Toxin was not detected in any stool samples containing toxin negative C. 
difficile strains. C. difficile strains detected were typed using PCR-ribotyping. This revealed 
sixteen distinct ribotypes in CF patients. The most prevalent of which was ribotype 140 which 
did not produce toxin. However, the second most prevalent was ribotype 046 which is closely 
related to the hyper-virulent ribotype 078 which was also reported in this study. All strains 
detected were susceptible to commonly prescribed anti-C difficile drugs including, 
metronidazole, vancomycin, fusidic acid and rifampicin, while they were highly resistant to 
drugs commonly prescribed to treat Pseudomonal lung infections. No correlation was observed 
between the carriage of C. difficile and any recorded patient clinical parameters or treatment 
received. 
 The aim of Chapter 3 was to investigate the effect of CF and its treatment on the 
composition of the intestinal microbiota of patients with CF by comparing it to that of a healthy 
volunteer group. Overall, the CF associated microbiome had reduced microbial diversity relative 
to the healthy volunteer group. This was accompanied by a shift towards an increased Firmicutes 
to Bacteroidetes ratio. The most profound differences in composition were observed between the 
CF associated microbiota and that of healthy controls, with eight phyla, twenty-seven families, 
and forty-nine genera significantly increased or decreased between these two groups. However, 
compositional differences were also reported between CF patients grouped by patient clinical 
ix 
 
parameters and treatments received. The CF associated microbiome is therefore altered from that 
of healthy controls by a combination of the disease and its treatment. 
 In Chapter 4, multilocus sequence typing (MLST) was assessed as an alternative to PCR-
ribotyping (PCR-RT) for typing C. difficile in patients at high risk of C. difficile infection. 
Comparison of the discriminatory power of MLST and PCR-RT was performed and compared to 
that of pulsed field gel electrophoresis (PFGE) for typing C. difficile strains. The index of 
discrimination (ID) of MLST (0.93) compared favourably with that of the more commonly used 
PCR-RT (0.95). However, both were found to be less discriminatory than the lesser used PFGE 
method. While MLST yielded easily interpretable and transferable results allowing for rapid 
identification and typing of C. difficile in high risk patient groups, its current cost may prove 
prohibitive to its wide-scale adoption. 
 In chapter 5, the C. difficile bacteriophage ΦCD6356 and its biologically active 
endolysin were assessed as novel antimicrobials for the treatment of C. difficile infection. The 
bacteriophage was effective at reducing viable C. difficile by 1.75 logs over 24h in an in vivo 
model of the human distal colon. However, following initial infection all surviving C. difficile 
were immune to infection due to the uptake of the prophage (super infection). The endolysin 
encoded by ΦCD6356, an n- acetylmuramoyl -l-alanine amidase named LysCD was cloned and 
expressed in Escherichia coli. The recombinant endolysin was biologically active as evident 
bylysis of C. difficile cells in a zymogram. Treatment of mid log phase C. difficile cells with a 
crude preparation of the endolysin resulted in roughly a 3 log reduction in viable C. difficile after 
3h. The endolysin was modelled on the previously determined structure of a similar endolysin, 
CD27l. This revealed the presence of zinc coordination at the active site which was 
experimentally determined to be required for lytic activity. Due to its lysogenic nature, the C. 
difficile bacteriophage ΦCD6356 is not suitable for the treatment of C. difficile infection. 
However, its endolysin shows potential as a novel antimicrobial for treating C. difficile infection.  
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Chapter 1       
A review of the effects of cystic fibrosis and its treatment 
on the intestinal microbiota  
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1.1 Abstract: 
Cystic Fibrosis (CF) is an autosomal recessive disease resulting from a mutation in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene. Progressive pulmonary failure 
resulting from chronic infection of the CF lung is the number one cause of death in people with 
CF. The lung microbiome of CF has extensively been studied, however, the effect of CF 
associated gastrointestinal disorders, and intensive therapies prescribed to treat pulmonary 
infection on the composition of the CF gut microbiota have received comparatively little 
attention. The disease itself and the antibiotics used to treat it undoubtedly cause a constant state 
of flux in the gut microbiota which will in itself impact on patient health. In this review, we 
discuss the impact of CF and its treatment on the gut microbiota, and suggest strategies to 
minimize this impact to improve patient care.  
 
1.2 Introduction: 
Cystic Fibrosis (CF) is the most common fatal autosomal recessive disease among people of 
European decent, affecting one in every 2,500 live births (Welsh MJ, 1995). The disease affects 
multiple organs and manifests itself in the pancreas, liver, gastrointestinal tract, and most 
notably, the lungs. Cystic fibrosis results from a mutation in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, which codes for a chloride ion transport protein expressed 
in exocrine epithelial cells (Bear et al., 1992). Dysfunction of this transport protein causes 
abnormal mucus production resulting in airway surface liquid depletion and adhesion of thick 
viscous mucous to pulmonary epithelia. This reduces mucilliary clearance in the lungs, 
facilitating bacterial colonization and consequently the development of chronic pulmonary 
infection (Matsui et al., 1998). Progressive lung disease resulting from chronic pulmonary 
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infection is the most common cause of morbidity and mortality patients with CF  and, therefore 
is the focus of the majority of CF therapeutic strategies (Ramsey, 1996). 
 The term “cystic fibrosis” was first used to describe plugging of glandular ducts in the 
pancreas of malnourished infants. The disease was characterized by malabsorption, failure to 
thrive, and pulmonary infection believed to arise from damage to the pancreas resulting in 
malnutrition. In 1938, the life expectancy of a child diagnosed with CF was only 6 months 
(Andersen, 1938). Now thanks to improvements in disease management, life expectancy has 
improved dramatically. Analysis of US, England and Wales death registry data has revealed that 
CF life expectancy has increased by 0.543 life years per year between 1972 and 2009  (Hurley et 
al., 2014). However, with the CF patient population aging, new challenges are emerging. 
 Development of the human gut microbiota begins at birth. Vaginally-delivered babies are 
predominantly colonized by Lactobacillus and Prevotella species derived from their mother’s 
vaginal canal during delivery (Dominguez-Bello et al., 2010). Bifidobacterium then become the 
dominant genus in the infant gut microbiota (Aires et al., 2011). Subsequently, metabolic niches 
in the GI tract are successively filled until the GI microbiota reaches an “adult-like” state 
(Koenig et al., 2010). The adult human gut microbiota is temporally stable and dominated by the 
phyla, Firmicutes, Bacteriodes, Proteobacteria, and Actinobacteria (Bäckhed et al., 2005). 
Composition of the gut microbiota is influenced by both extrinsic and intrinsic factors including, 
diet, age, environment, and host genetics (Benson et al., 2010, Turnbaugh et al., 2009). These 
environmental and genetic factors may account for large inter-subject variability frequently 
reported in the gut microbiota (Dethlefsen et al., 2008, Duytschaever et al., 2011). However, a 
“core” microbiota, consisting of greater than fifty taxa has been reported in nearly half of human 
faecal samples (Qin et al., 2010).  
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In recent years, the reduced cost of metagenomic sequencing has facilitated the study of the gut 
microbiota and its effects on human health. The gut microbiota has been described as having the 
metabolic capacity equal to that of a virtual organ (Bocci, 1992). In a healthy individual, the gut 
microbiota plays a number of important roles in digestion and health; therefore as with all 
organs, its malfunctioning can have a profound effect on health. A number of studies have 
observed alterations in the gut microbiota in disease situations such as obesity (Turnbaugh et al., 
2006), inflammatory bowel disease (Kassinen et al., 2007), and type II diabetes (Larsen et al., 
2010) when compared to that of healthy individuals. To date no such study has been performed 
on adult patients with CF. We propose that the changes in the intestinal physiology resulting 
from mutation in the CFTR gene, as well as the chemotherapeutic drugs prescribed to patients 
with CF significantly alter the gut microbiota resulting in additional negative effects on the 
patient. In this review, we discuss the GI manifestations of CF, its treatment, and their possible 
effect on the gut microbiota.    
 
1.3 Physiology of CF GI Tract: 
Mutation of the CFTR gene results in poor chloride transport by gut epithelia. Consequently, 
defective chloride regulation in the intestinal lumen results in highly viscous mucus secretions 
which have been implicated in slowed gastric transit and intestinal blockage reported in patients 
with CF (De Lisle, 2007, Hedsund et al., 2012). Gastrointestinal (GI) transit has been studied in 
patients with CF as well as CF animal models. In one study of GI transit in CF mice, it was 
reported that gastric emptying was slightly reduced, while transit in the small intestine was 
significantly increased compared to wild type controls (De Lisle, 2007). Antibiotic treatment 
was also found to increase intestinal transit time in WT mice, but had no effect on intestinal 
transit in CF mice. Therefore it was hypothesised that the gut microbiota may play a role in the 
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regulation of GI transit (De Lisle, 2007). This hypothesis was supported De Lisle et al., 2010 
(De Lisle et al., 2010) who found a reduction in major prostaglandin (PG) degenerative gene 
expression in CF mice as well as in WT mice treated with antibiotics. This resulted in a 
significant increase in PGE2 and PGF2α which impaired intestinal circular muscle activity. 
Resolution of bacterial overgrowth by oral laxative was found to improve CF muscle activity by 
increasing the expression of PG degenerative genes, thereby decreasing PGE2 levels (De Lisle et 
al., 2010). While, Hedsund et al found oro-cecal transit time to be significantly increased in 
patients with CF (Hedsund et al., 2012),  other studies have found inter-digestive mobility to be 
comparable to that of healthy controls (Hallberg et al., 2001, Hedsund et al., 2012). Despite 
these findings, constipation and intestinal obstruction are frequently reported in patients with CF 
(Doef et al., 2011) – both of which likely affect the microbial composition of the gut.   
 Meconium ileus (MI) is a disorder uniquely described in CF, occurring in 13 to 25 % of 
CF neonates (Doef et al., 2011). Meconium ileus occurs in the neonatal period and is 
characterized by complete intestinal blockage resulting from accumulation of viscid meconium. 
Distal intestinal obstruction syndrome (DIOS) is a similar condition which occurs in adults with 
CF (Doef et al., 2011). Blockage occurs after accumulation of viscid faecal material in the 
terminal ileum and proximal colon. DIOS occurs in 14 to16 % of patients with CF throughout 
their lifetime, with prevalence increasing with age (Andersen et al., 1990, Dray et al., 2004). As 
stated above, constipation is another GI manifestation of the disease which is frequently reported 
(Doef et al., 2011). Constipation is distinct from DIOS, resulting from gradual accumulation of 
faecal material and reduction in the frequency of bowel movements; while DIOS is defined by 
acute onset (Houwen et al., 2010). Between 26 and 47% of patients with CF report problems 
with constipation. Previous incidence of MI has been cited as a risk factor for developing 
constipation (Doef et al., 2011, Rubinstein et al., 1986). Typically, constipation and DIOS are 
successfully treated by administration of laxatives, however, some cases of DIOS and MI that do 
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not respond to this may require surgical intervention (Doef et al., 2011).Gastrointestinal 
disorders resulting in delayed gastric transit and intestinal blockage have been suggested to 
predispose patients to bacterial overgrowth (Dukowicz et al., 2007). 
 The efficiency of the host innate immune defence in the CF intestine is reduced due to 
limited dissolution and accumulation of paneth cell granules within intestinal crypts (Clarke et 
al., 2004). This impedes the transport of antimicrobial peptides to the intestinal lumen, 
potentially facilitating overgrowth by pathogenic bacteria (Clarke et al., 2004). Small intestinal 
bacterial overgrowth is an overgrowth of bacteria in the small intestine in excess of 106 CFU/ 
ml, typically with colonic-type microbes (Gasbarrini et al., 2007, Gregg, 2002). Small intestinal 
bacterial overgrowth has been reported to occur in 30 – 50 % of patients with CF, mainly 
determined by the breath test to determine bacterial fermentation resulting in hydrogen or 
methane gas formation (Fridge et al., 2007, Lewindon et al., 1998, O'Brien et al., 1993). Small 
intestinal bacterial overgrowth affects the normal function of the small intestine which can result 
in diarrhoea, steatorrea, and macrolytic anaemia (Hoffmann and Zeitz, 2002). Orocecal transit 
may also be delayed as a result of small intestinal bacterial overgrowth (Virally-Monod et al., 
1998). Resolution of small intestinal bacterial overgrowth by antibiotic therapy in diabetic 
patients has been shown to significantly improve orocecal transit. A study of bacterial 
overgrowth in CFTR null mice, revealed a forty fold increase in bacterial load in the CF mouse 
small intestine compared to controls (Norkina et al., 2004). It was also demonstrated that oral 
antibiotic therapy with ciprofloxacin and metronidazole not only reduced bacterial load by over 
400-fold, but also reduced the expression of inflammatory markers in the small intestine 
(Norkina et al., 2004). Therefore, it is important to treat small intestinal bacterial overgrowth as 
it can have multiple detrimental effects on the CF gut, including but not limited to 
gastrointestinal inflammation. 
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 Pulmonary as well as gastrointestinal inflammation is a typical feature of CF 
pathogenesis. This is evident by the observation of increased expression of inflammatory 
markers, both in patients with CF, and in CF animal models (Bruzzese et al., 2004, Koller et al., 
1996, Norkina et al., 2004, Raia et al., 2000, Smyth et al., 2000). Smyth et al observed that 
paediatric CF patients have increased output of albumin, IgG, IgM, eosinophil, cationic protein, 
neutrophil elastase, IL-1β, and Il-8 in the gastrointestinal tract, indicating immune activation in 
the gastrointestinal tract (Smyth et al., 2000). Kahn et al, reported increased neutrophil and IL-8 
in the lungs of paediatric CF patients prior to colonization with known pathogens using culture-
based techniques (Khan et al., 1995). At the time of this study, highly sensitive molecular based 
techniques were not available and thus un-culturable pathogens may not have been detected. In 
addition, Smyth et al made their conclusion without assessing the bacterial population in the 
small intestine and thus cannot be certain inflammation was not due to the presence of 
pathogenic bacteria.  
 Resolution of bacterial overgrowth in the small intestine by antibiotic administration has 
been shown to reduce inflammatory markers in CF mice (Norkina et al., 2004). Further to this, 
supplementation with the probiotic, Lactobacillus GG has been shown to reduce the intestinal 
inflammatory biomarkers, faecal calpronectin, and nitric acid (Bruzzese et al., 2004). In 
inflammatory bowel disease (IBD) patients, significant decreases in microbial diversity as well 
as significant alteration of their microbial composition have been described relative to that of 
healthy controls (Frank et al., 2007). It is likely that, as in some IBD patients, alterations in the 
CF gut microbiota may be responsible for observed intestinal inflammation.  
 With an aging CF population, the risk of cancer undoubtedly increases. In a retrospective 
cohort study, patients with CF were found to be at increased risk of developing digestive tract 
cancer; however risk of developing all other cancers were comparable (Neglia et al., 1995). 
Similarly, IBD patients have been shown to have an increased risk of developing certain 
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digestive tract cancers (Bernstein et al., 2001). Intestinal inflammation resulting in oxidative 
stress has been proposed for the increased risk of colorectal cancer observed in IBD patients 
(Itzkowitz and Yio, 2004). Therefore the CF gut microbiota might offer a target to reduce the 
risk of digestive tract cancer in patients with CF by reducing inflammation.  
 
1.4 CF intestinal microbiota 
In a study of the development gut and lung microbiota of CF infants Bacteriodetes, 
Bifidobacterium and Veillonella were reported as the most abundant genera in the CF gut, 
accounting for 40% of sequencing reads (Madan et al., 2012). The gut microbiota of CF infants 
increases in diversity over time responding to changes in diet (Dominguez-Bello et al., 2011, 
Madan et al., 2012). In another study by Duytschaever et al, 2011, denaturing gradient gel 
electrophoresis (DGGE) analysis of the gut microbiota of paediatric patients with CF found them 
to have comparable species richness to that of their healthy siblings. However, the gut 
microbiota of patients with CF was found to be more variable in its compositional complexity 
and have more pronounced fluctuations over time than that of their healthy siblings 
(Duytschaever et al., 2011). As part of the same study, selected bacterial groups were 
enumerated by culture based techniques which revealed that levels of Bacteriodes/Prevotella 
were found to be 1.5 mean log CFU g-1 lower in paediatric patients with CF than in their 
siblings with borderline significance (P = 0.07). While counts of Enterobacteriaceae (0.5 mean 
log CFU g-1 difference) and Clostridia (0.2 mean log CFU g-1 difference) were higher in CF 
patients (Duytschaever et al., 2011). Longtitudal analysis of the gut microbiota of these CF 
patients over 2 years revealed higher counts for all bacterial groups in siblings, except for 
Enterobacteriaceae which was again found to be higher in CF patients (Duytschaever et al., 
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2011). Temporal fluctuations in the composition of CF gut microbiota and decreases in bacterial 
numbers are undoubtedly as a result of frequent antibiotic disturbances. 
 
1.5 Effect of CF treatment on gut microbiota: 
Proton pump inhibitors 
Pancreatic insufficiency is a common feature of CF, affecting 80 – 85% of patients with CF 
(Werlin et al., 2010). This is typically corrected by treatment with pancreatic enzyme 
supplementation. However, steatorrea may persist due to failure of pancreatic enzymes to be 
released in an acidic environment (Proesmans and De Boeck, 2003). Duodenal pH has been 
shown to drop post prandial due to impairment of bicarbonate secretion in the CF duodenum. 
Treatment with proton pump inhibitors increases duodenal pH, thereby improving fat absorption 
(Proesmans and De Boeck, 2003). Proton pump inhibitors are widely prescribed and are 
considered very safe (Vanderhoff and Tahboub, 2002). However, gastric acid is a significant 
barrier to bacterial colonization and its neutralization can increase the risk of enteric infection. In 
fact, in a systematic review to evaluate the association between acid suppression and enteric 
infection, Leonard et al., 2007 found an increased risk (adjusted odds ratio [OR] 3.33, 95% 
Confidence Interval [CI] 1.84–6.02) of enteric infection in those taking proton pump inhibitors 
(Leonard et al., 2007). In one study investigating the risk of small intestinal bacterial overgrowth 
in non-CF patients receiving proton pump inhibitors , small intestinal bacterial overgrowth was 
detected by glucose hydrogen breath test in 50% of patients, compared to just 6% of controls. 
The authors also noted an increase in prevalence of small intestinal bacterial overgrowth after 
one year of proton pump inhibitor use (Lombardo et al., 2010). This is of particular interest as 
patients with CF with pancreatic insufficiency who do not respond to pancreatic enzymes alone 
will require proton pump inhibitor therapy for their entire life, greatly increasing their risk of 
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small intestinal bacterial overgrowth. A correlation between the risk of Clostridium difficile 
associated diarrhoea and proton pump inhibitor use has also been reported by a number of 
authors (Kim et al., 2010). This may, in part, explain the high prevalence of C. difficile reported 
in patients with CF (Yahav et al., 2006). 
Antibiotic treatment 
Chronic pulmonary infection resulting in obstructive pulmonary disease is the number one cause 
of morbidity and mortality in patients with CF, accounting for 90% of deaths (Abman et al., 
1991). Colonization of the lungs with Pseudomonas aeruginosa can occur at a very young age 
(Burns et al., 2001) and has been shown to correlate with a more rapid reduction in lung function 
than in those free from P. aeruginosa infection (Govan and Nelson, 1992). Therefore, in their 
life long battle with chronic pulmonary infection patients with CF are likely to undergo countless 
courses of aggressive antibiotic therapy to control this infection. Due to the polymicrobial nature 
of CF pulmonary infection combinations of broad spectrum antibiotics may be required. Early 
treatment with a combination of oral ciprofloxacin and nebulized colistin has been shown to 
eradicate P. aeruginosa in up to 80% of patients with CF (Hansen et al., 2008). Long term 
maintenance therapy with oral azithromycin improves lung function, reduces need for oral 
antibiotics, and results in fewer pulmonary exacerbations (Wolter et al., 2002).  
 But what are the long term implications of prolonged antibiotic treatment for pulmonary 
infections on the gut microbiota? With the advent of next-generation sequencing platforms, such 
as the Roche 454 and Illumina sequencers, it has been possible to make detailed observations of 
compositional shifts in the GI microbiota in response to antibiotic treatment (Southern et al., 
2012). Extensive reviews on the effect of antimicrobial treatment on the gut microbiota are 
available by Rafii, 2008 (Rafii et al., 2008) and Cotter et al, 2012 (Cotter et al., 2012), however, 
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in this section we will focus on antibiotics typically prescribed to treat pulmonary infection in 
CF.  
 Ciprofloxacin is an effective anti-pseudomonal antibiotic frequently prescribed to 
patients with CF (Church et al., 1997). Dethlesfsen et al 2008 (Dethlefsen and Relman, 2011) 
examined the effect of 5 days of twice daily treatment with 500 mg ciprofloxacin in humans and 
reported an initial reduction in species richness, diversity, and evenness in the gut microbiota. 
However, after four weeks, the gut microbiota was found to mostly recover to pre-treatment 
composition. After six months a number of taxa failed to return to pre-treatment numbers, 
including Clostridiales and Bilophia (Dethlefsen et al., 2008). Similar observations were made 
in another study following repeated courses of ciprofloxacin. However, alterations in community 
composition were found to be stable over the final two months of a ten month study (Dethlefsen 
and Relman, 2011). Therefore antibiotics prescribed to treat P. aeruginosa in the CF lung are 
likely to have a profound and lasting effect on the CF gut microbiota.  
 Oral clindamycin can be used to treat Staphylococcal pulmonary infection in patients 
with CF (Shapera et al., 1981). However, clindamycin use has been shown to select for 
clindamycin resistant Bacteriodetes clones, which dominate the community after treatment 
(Jernberg et al., 2007). While these resistant clones were not detected in the gut, it is likely they 
would also be present due to the swallowing of sputum. Antibiotic therapy can reduce clonal 
diversity and select for antibiotic resistant bacteria which can persist in an environment even 
after removal of antibiotic selective pressure (Jernberg et al., 2007). In one study  examining the 
effect of short-term antibiotic treatment on the gut microbiota, high levels of the macrolide 
resistance gene erm (B) were detected up to four years post- treatment, despite a lack of selective 
pressure (Jakobsson et al., 2010). Antibiotic resistance in anaerobic faecal microbiota has also 
been shown to increase relative to the duration of antibiotic therapy as well as hospital stay 
(Stark et al., 1993).  
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 The healthy gut microbiota can act as a barrier to colonization, preventing overgrowth by 
potential pathogens. Disruption of the indigenous gut microbiota can result in a reduction in 
colonization resistance allowing for colonization by opportunistic pathogens, such as 
Clostridium difficile (Croswell et al., 2009, Pépin et al., 2005). Fluoroquinolones, including 
ciprofloxacin, have emerged as a major risk factor for the acquisition of C. difficile (Pépin et al., 
2005). The risk of C. difficile-associated diseases is also increased in respect to duration of 
antibiotic treatment and use of multiple antibiotics in combination (Owens et al., 2008). 
Administration of two antibiotics by intravenous injection for 14-21 days has been suggested as 
appropriate treatment for pulmonary exacerbations in patients with CF (Turpin SV, 1993). 
Therefore antibiotic treatment coupled with the above mentioned proton pump inhibitors are 
likely contributes to the high carriage of C. difficile in patients with CF (Yahav et al., 2006). 
 
1.6 Minimising the effect of antibiotic therapy on the gut microbiota: 
While it is not possible to cease the use of antibiotics in patients with CF, it may be possible to 
reduce their effect of the gut microbiota. Oral and intravenous (IV) antibiotics prescribed to treat 
pulmonary infection can modify the gut microbiota either directly by transit through the GI tract 
or by systemic dissemination, reaching the gut through GI secretions (Edlund and Nord, 1999). 
Aerosolized antibiotic therapy offers a valuable alternative to oral and IV antibiotics for the 
treatment of pulmonary infection. The advantages of aerosolized antibiotics are that the drug 
quickly reaches high concentrations at the site of infection while undergoing minimal systemic 
penetration (Zarogoulidis et al., 2013). This minimizes the impact of the antibiotic on the gut 
microbiota while still providing an effect treatment (Geller et al., 2002). 
 As stated previously, maintenance therapy with azithromycin can result in the 
development of macrolide resistant bacteria (Hansen et al., 2008, Phaff et al., 2006, Tramper-
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Stranders et al., 2007). However, short term (< 6months), treatment with azithromycin has been 
shown to improve lung function (Tramper-Stranders et al., 2007), reduce the frequency of 
pulmonary exacerbations (Southern et al., 2012), and reduce the prevalence of Staphylococcus 
aureus, Streptococcus pneumonia and Haemophilus influenza (Hansen et al., 2009). Despite an 
increase in macrolide resistance among S. aureus strains following long term low doses of 
Azithromycin, no resistance was observed in S. pneumonia or H. influenza. Strict control of S. 
aureus and reduction in its prevalence were proposed to negate the emergence of macrolide 
resistance on treatment outcome (Hansen et al., 2009). Reduction in the frequency of pulmonary 
exacerbation greatly reduces the burden of antibiotic treatment on patients with CF due to the 
length and intensity of treatment required to treat exacerbations (Turpin SV, 1993).  
 There is increasing evidence to suggest host immune modulation occurs in response to 
probiotic administration, both in IBD patients, as well as in patients with CF (Bruzzese et al., 
2004, Meijer and Dieleman, 2011). As well as this, some studies have reported probiotics as 
having a protective role against respiratory infection (Alvarez et al., 2001, Bruzzese et al., 2007, 
Weiss et al., 2010). For instance, Lactobacillus casei has been shown to enhance the clearing of 
P. aeruginosa from the lungs of young non-CF mice (Alvarez et al., 2001). In another study, 
treatment with the commercial probiotic Lactobacillus rhamnosus GG (LGG) was found to 
significantly lower the risk of upper respiratory tract infection in children (Hojsak et al., 2010). 
Interestingly, similar protective effects were observed in two separate pilot studies in patients 
with CF with LGG and, Bio-plus (Lactobacillus bulgaricus, Bifidobacterium bifidum, and 
Streptococcus thermophiles). In both studies, probiotic therapy was shown to significantly 
reduce the frequency of pulmonary exacerbation. (Bruzzese et al., 2007, Weiss et al., 2010). 
Probiotic therapy may therefore be useful in reducing pulmonary exacerbations and thus, the 
burden of antibiotics on patients with CF. However, much larger scale trials are required due to 
the low numbers involved in these studies (36 and 10 respectively). 
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 Therapeutic regimes for patients with CF, while effective may potentially be harmful to 
the GI microbiota. Patients with CF are likely to be at greater risk of enteric pathogens, including 
C. difficile, due to the action of proton-pump inhibitors and antibiotics. Frequent and prolonged 
antibiotic treatment is also likely to select for and maintain antibiotic resistance. Therefore 
patients with CF may act as a reservoir for C. difficile, as well as antibiotic resistant pathogens. 
 
1.7 Conclusions: 
From observations made in patients with CF as well as in other disease states, it is clear that the 
CF gut microbiota is likely to differ significantly from that of healthy individuals, undoubtedly 
undergoing frequent fluctuations due to the disease and its treatment, resulting in lower temporal 
stability and diversity. However, due to a lack a study incorporating high-throughput sequencing 
to examine the composition of CF gut microbiota, the extent to which it differs will largely 
remain unknown. Careful consideration should be taken by clinicians in the treatment of CF so 
as to reduce antibiotic induced alteration of the gut microbiota as well as to prevent the spread of 
C. difficile and antibiotic resistant pathogens. As understanding of the CF gut microbiota 
improves, it may become a target for treatment of gastrointestinal and pulmonary disease in 
patients CF by way of probiotic administration and targeted nutrition. 
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Table 1.1 Gastrointestinal disorders typically associated cystic fibrosis, their treatment, and 
prevalence. 
GI disorder Description Treatment Prevalence 
Meconium ileus Complete intestinal blockage resulting 
from accumulation of viscid mucous in 
the neonatal period. 
Laxatives and/or 
surgical intervention 
13 – 25% 
(neonates) 
Distal intestinal 
obstructive 
syndrome 
Complete blockage of the terminal 
ileum and proximal colon due to 
accumulation of viscid mucus. 
Laxatives and/or 
surgical intervention 
14 – 16% 
(adult) 
Small intestinal 
bacterial 
overgrowth 
Overgrowth of bacteria in the small 
intestine exceeding 10
6
 bacteria /ml of 
luminal fluid. Colonic-type species are 
also typically reported.  
Antibiotics 30 – 50% 
Constipation Infrequent or difficult bowel 
movements. 
Laxatives  26 – 47% 
Steatorrea  Poor fat absorption resulting in excess 
faecal lipid content.  
Pancreatic enzyme 
supplementation and 
proton pump 
inhibitors 
80 – 85% 
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Chapter 2 
Cystic fibrosis suffers have a high incidence (50%) of 
Clostridium difficile carriage including hypervirulent 
strains. 
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2.1 Abstract: 
Clostridium difficile carriage is frequently reported in patients with cystic fibrosis (CF). Despite 
high carriage rates and the presence of C. difficile toxin in stool, patients with CF rarely appear 
to develop C. difficile infection (CDI). In this study, we examined the carriage and ribotype 
distribution of C. difficile in a cohort of 60 adult patients with CF who were pre-transplant. C. 
difficile was detected in 50% (30/60) of patients with CF by culturing for the bacteria. C. difficile 
toxin was detected in 63% (19/30) of C. difficile positive stool samples. All toxin positive stool 
samples contained toxigenic C. difficile strains harbouring toxin genes, tcdA and tcdB. Despite 
the presence of C. difficile and its toxin in patient stool, no acute gastrointestinal symptoms 
suggesting CDI were reported. Ribotyping of C. difficile strains revealed 16 distinct ribotypes 
(RT), including the hypervirulent RT078. All strains were susceptible to vancomycin and 
metronidazole as well as fusidic acid and rifampicin. As expected, all strains were resistant to 
antibiotics prescribed to treat pseudomonal and other gram negative infections in the lungs. No 
correlation was observed between carriage of C. difficile and any recorded patient clinical 
parameters or treatment received. 
 
2.2 Introduction: 
Progressive pulmonary disease resulting in respiratory failure is the leading cause of morbidity 
and mortality in patients with CF. However, median predicted survival continues to increase, 
rising from approximately 28 years in 1990 to 41 years in 2012 using US data (Marshall, 2013) 
Analysis of European data suggests a predicted median survival of 50 yrs for the birth cohort of 
the year 2000 (Dodge et al., 2007). This increasing survival is likely due to a number of factors 
including: the co-ordination of care through specialised CF centres using a multi-disciplinary 
approach, improved nutritional support, and the development of new therapeutic agents to treat 
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CF, including inhaled anti-pseudomonal antibiotics, inhaled mucolytics, maintenance macrolide 
therapy, inhaled hypertonic saline, and the intense use of intravenous antibiotics (Plant et al., 
2013, Ramsey et al., 1999, Fuchs et al., 1994, Elkins et al., 2006, Saiman et al., 2003) However, 
as people with CF survive longer, new focus has been brought on extra-pulmonary disease in 
CF(Yahav et al., 2006a, Theunissen et al., 2008, Smyth et al., 2000, Duytschaever et al., 2011b), 
and its potential role in improving health outcomes and survival. CFTR-dysfunction in the gut 
has long been associated with reduced intestinal motility due to accumulation of mucus in the 
gut (Hedsund et al., 2012), distal intestinal obstruction (Dray et al., 2004), small intestinal bowel 
overgrowth (Fridge et al., 2007), and based on recent data in a murine model, altered 
composition of the gut microbiota (Lynch et al., 2013). Emerging data suggest a role of the gut 
and, specifically, the gut microbiota, in influencing health outcomes for people with CF (Munck, 
Duytschaever et al., 2011a, Duytschaever et al., 2012, Bruzzese et al., 2007, Weiss et al., 2010). 
With increasing survival and increasing cumulative antibiotic exposure (Rabin et al., 2004), 
manipulation of the “gut-lung axis” in the health of people with CF may provide novel 
therapeutic strategies to improve health outcomes. Interestingly, the role of the gut microbiota 
may extend beyond influencing gastrointestinal health in CF. A recent study reported that 
colonization of the respiratory tract by microbes is presaged by colonization of the gut and 
demonstrated a role of nutrition in development of the respiratory microbiota (Madan et al., 
2012).The use of broad-spectrum antibiotics has been shown to influence the gut microbiota in 
non-CF populations causing significant alterations in the gut microbiota, in particular the 
overgrowth of Clostridium difficile resulting in CDI and pseudomembranous colitis (Gorbach, 
1999, Bartlett et al., 1978). Limited data exist regarding the effect of repeated courses of broad-
spectrum antibiotics on alterations in the CF gut microbiota, including the incidence of C. 
difficile (Duytschaever et al., 2011a, Duytschaever et al., 2012, Wu et al., 1983b, Welkon et al., 
1985b, Peach et al., 1986a, Pokorny et al., 1992, Yahav et al., 2006a). Asymptomatic carriage of 
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C. difficile has been reported in up to 46.6% of CF patients (Yahav et al., 2006a), compared to 
1.1% - 15% in healthy adults (Nakamura et al., 1981, Aronsson et al., 1985, Clayton et al., 
2012). Despite high carriage rates and the presence of toxin in stool, CDI in people with CF is 
rare (Nakamura et al., 1981, Viscidi et al., 1981, Yahav et al., 2006a, Wu et al., 1983b, Welkon 
et al., 1985b, Peach et al., 1986a). However, the risk of CDI increases 3-fold in CF patients 
undergoing lung transplantation (Theunissen et al., 2008). This is particularly worrying, 
considering the atypical presentation and high mortality rate (50%) associated with CDI reported 
in post-transplant CF patients (Dallal et al., 2002, Yates et al., 2009). 
 To better understand carriage of C. difficile in people with CF and its influence on health 
outcomes, patients attending the Cork Adult Cystic Fibrosis Centre at Cork University Hospital 
were assessed for carriage of C. difficile and presence of its toxin in their faeces. C. difficile 
isolates were also characterised by ribotype and antibiotic susceptibility. Finally, we examined 
the relationship between C. difficile carriage, CF patient clinical parameters, and a same-site 
healthy volunteer group.  
 
2.3 Materials and methods: 
Subject recruitment and sample collection.  
Consecutive adult patients with CF who were pre-lung transplant were recruited prospectively 
on attendance at routine adult outpatient clinics and at presentation to the Cystic Fibrosis 
Ambulatory Care facility at Cork University Hospital over an 18-month period beginning in 
January 2012. All participants donated a fresh 5 gram stool sample at study entry. Post-
transplant patients with CF were excluded from this analysis. Participant clinical characteristics 
were recorded at time of study entry including age, gender, genotype, pancreatic sufficiency 
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status, clinical status at study entry (i.e. clinically stable patients or patients experiencing a 
pulmonary exacerbation), best FEV1% predicted and body mass index (BMI) over the 12 
months prior to study entry, along with the number of days of intravenous antibiotics and the 
number of inpatient days in the 3 years prior to study entry. Use of macrolides, proton pump 
inhibitors, and H2-antagonist in the 6-months prior to study entry was also recorded. A control 
group consisting of 99 healthy volunteers was recruited from the university. These volunteers 
were aged between 18 and 65 years (61 female) and had not received antibiotics or reported 
gastrointestinal symptoms in the previous 6 months. Informed written consent was obtained 
from all participants in accordance with local research ethics committee guidelines. The study 
was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals.  
Isolation of Clostridium difficile. 
 Samples were collected from subjects at the Cork Adult Cystic Fibrosis centre and frozen at -
20˚C within 24h of sampling. C. difficile were isolated from stool by ethanol shocking and 
plating on cycloserine cefoxitin egg yolk agar (Lab M, Bury, United Kingdom), as previously 
described (Clayton et al., 2009). Isolates displaying characteristic C. difficile morphology and 
“horse-stable” odour were further assessed microscopically and biochemically. Those found to 
be Gram-positive anaerobic spore-forming rod-shaped bacteria that were non-haemolytic, L-
proline aminopeptidase positive and who gave a positive result using the Oxoid Clostridium 
difficile test kit (Oxoid Basinstoke, UK) were determined to be C. difficile. Strains were stocked 
at -80˚C on Microbank beads (Pro-Lab Diagnostics, Ontario, Canada). For routine use, strains 
were sub-cultured onto Fastidious Anaerobic Agar (FAA) (Lab M, Heywod, Lancs UK) 
containing 7% (w/v) defibrinated horse blood and grown anaerobically in a Don Whitley 
anaerobic chamber at 37˚C. 
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Bacterial strains used.  
C. difficile VPI 10463 (ATCC 43255; A+/B+), C. difficile CUG 20309 (A-/B+) and C. difficile 
ATCC 43593 (A-/B-) were used as positive and negative controls respectively for the presence 
of tcdA and tcdB toxin genes. C. difficile ATCC 700057 was used as a control strain for 
antibiotic susceptibility testing. 
 
PCR ribotyping. 
Ribotyping for this study was performed by the C. difficile Ribotyping Network for England 
(CDRNE), at the Microbiology Reference Laboratory, Leeds General Infirmary, United 
Kingdom. Strains were analysed by capillary gel electrophoresis and compared to over 500 
ribotypes housed in the CDRNE ribotype reference library. 
Enzyme immunoassay for C. difficile toxin and detection of toxin genes, tcdA and tcdB by PCR. 
 In vivo toxin production was assessed from stool samples using the commercial kit, Toxin 
A+/B+: ProSpecT II (Oxoid). Assays were performed according to manufacturers’ instructions. 
DNA was extracted from isolates according to Rea et al (Rea et al., 2011). Briefly, C. difficile 
isolates were streaked onto horse blood agar and 5-6 colonies were picked and suspended in 5% 
w/v Chelex-100 resin. Colonies were then heated to 56ºC for 30 minutes, followed by 100ºC for 
8 minutes. The cell suspension was then centrifuged in a desktop centrifuge for 3 minutes at 
16,000 x g to remove cell debris. This was then used as DNA template for amplification of the 
toxin genes tcdA and tcdB using the primers described by Terhes et al, 2004.(Terhes et al., 
2004). Amplification of each gene was performed in separate reaction mixtures (25 μl) 
containing 12.5 μl Biomix Red (Bioline, London, UK), 0.5μl of each forward and reverse primer 
(tcdA or tcdB) 2 μl template DNA and 9.5 μl H2O. Gene amplification consisted of denaturation 
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at 95°C for 20 s, annealing at 62°C for 45 s, and extension at 72°C for 45 s. PCR products were 
visualized following electrophoresis in 1% agarose gel with ethidium bromide (0.5 μg/ml) in  
Tris-Acetate EDTA buffer (40mM Tris, 20mM acetic acid, and 1mM EDTA). 
 
Antibiotic susceptibility.  
The E-test system (BioMérieux, Hamshire, United Kingdom) was used to screen isolates for 
antimicrobial resistance against a range of commonly prescribed antibiotics for treating 
pulmonary exacerbations in patients with CF, as well as vancomycin, metronidazole, rifampicin 
and fusidic acid. The E-test was performed and interpreted as per the manufacturer’s 
instructions; however Reinforced Clostridial Agar (Merck, Darmstadt, Germany) was substituted 
for the recommended media. C. difficile ATCC 700057 was included as an internal control. 
Minimum inhibitory concentration50 (MIC50) and MIC90, defined as the minimum inhibitory 
concentration observed to impede the growth of 50% and 90% of isolates tested respectively 
were calculated as described by Drummond et al (Drummond et al., 2003). Strains were deemed 
susceptible or resistant to the test antibiotic, according to documented pharmacological 
breakpoint values defined by the Swedish Reference Group for Antibiotics (SRGA) 
(http;//www.srga.org) where available. 
 
Statistical analysis. 
All statistical analyses were carried out using IBM SPSS Statistics 21. Chi-square testing was 
used to examine for a relationship between the carriage of C. difficile and gender, genotype, 
pancreatic sufficiency status and macrolide, PPI and H2-antagonist use. Mann-Whitney testing 
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was used to investigate the relationship between carriage of C. difficile, lung function, BMI and 
exacerbation rate.  
 
2.4 Results 
Sixty adult participants with CF were recruited. Table 1 describes the characteristics of the study 
cohort. None of the study participants reported new gastroenterological symptoms that were 
clinically suspicious for CDI at the time of enrolment. 
 
Characterization of C. difficile isolates.  
Standard culturing techniques were used to determine the rate of carriage of C. difficile. C. 
difficile was isolated from 50% (30) of patients with CF (see Table 2) while C. difficile was only 
detected in 2% (2) of healthy volunteers.  
Detection of C. difficile toxin (stool antigen ELISA) and toxin genes (tcdA/tcdB) 
C. difficile toxin was detected in 31.7% of faecal samples from patients with CF by ELISA. All 
C. difficile strains isolated from toxin positive faecal samples carried toxin genes, tcdA and tcdB 
as revealed by PCR amplification. C. difficile strains harbouring toxin genes were not found in 
any toxin-negative faecal samples.  
 
PCR ribotyping and virulence.   
PCR ribotyping of the C. difficile isolates revealed 16 distinct ribotypes (see Table 2). Eleven 
toxigenic ribotypes were detected, including the emerging hypervirulent ribotype 078. The most 
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commonly isolated toxigenic ribotype was 046,  which, although not commonly disease-causing 
locally, this strain has been identified as disease-causing in a geographic cluster in Sweden 
(Akerlund et al., 2011). Four non-toxigenic ribotypes were also revealed, namely 009, 010, 039, 
and 140. One of the detected ribotypes was a novel ribotype not present in the Clostridium 
difficile Ribotyping Network database for England and Northern Ireland. Two distinct ribotypes 
were identified in the healthy control group; the rare toxigenic ribotype 062 and a non-toxigenic 
ribotype 026, neither of which were present in the CF cohort. 
 
Antibiotic susceptibility.  
The range of activity of an array of antibiotics against the C. difficile strains isolated is 
summarized in Table 3. Antibiotics that are commonly used in clinical practice, both in treating 
CF lung disease and in treating CDI were selected. MIC50 and MIC90 values for each 
determined. According to the pharmacological breakpoints recommended by the Swedish 
Reference Group for Antibiotics (SRGA) (http;//www.srga.org), a MIC90 of ≤ 2mg/L indicates 
susceptibility to both metronidazole and vancomycin. All C. difficile isolates tested in our study 
were susceptible to both metronidazole (MIC90 of 0.38μg/ml) and vancomycin (MIC90 of 
0.75μg/ml).While there are no published clinical breakpoints for rifampicin, fusidic acid, 
meropenem or linezolid against C. difficile, these drugs performed favourably against the 
isolates recording MIC90 values of <0.002 μg/ml, 0.19μg/ml, 0.75μg/ml and 1.5μg/ml, 
respectively. High levels of resistance to azithromycin (>256 μg/ml), tobramycin (>256 μg/ml), 
aztreonam (>256 μg/ml), ceftazidime (>256 μg/ml), and ciprofloxacin (>256 μg/ml) were 
ubiquitous among isolates. 
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Relationship between Clostridium difficile and clinical parameters. 
No significant associations were found between the presence of C. difficile and best FEV1  % 
predicted in the previous 12 months (p=0.173), age (p=0.07), PPI use(p=0.796), pancreatic 
insufficiency (p=0.122), BMI (p=0.07),  maintenance macrolide therapy (p=0.953), gender 
(p=0.752), Class 1-3 mutation (p=0.07), clinical stability at time of sample donation (p=0.538), 
number of courses of intravenous antibiotics (p=0.440) or number of inpatient days in the 3 
years prior to study entry (p=0.541). Furthermore, there were no significant associations between 
either the presence of toxigenic C. difficile or the presence of a C. difficile isolate of a known 
disease-causing ribotype (i.e. virulent vs non-virulent) and any recorded clinical parameters. 
 
2.5 Discussion 
 We report a C. difficile carriage rate of 50% in adult patients with CF who are pre-
transplant. Earlier studies show a trending increase in C. difficile carriage in patients with CF 
with reported carriage rates in studies since the 1980s of 22% -50% (Wu et al., 1983b, Welkon et 
al., 1985b, Peach et al., 1986a, Yahav et al., 2006b, Pokorny et al., 1992). However, these earlier 
studies reported carriage rates in cohorts that may not be representative of current-day patients 
with CF. Wu et al from 1983 reported a carriage rate of 31% (n=11/35), with the carriage rate 
increasing to 50% (n=11/22) in patients with CF who were receiving continuous oral or 
intravenous antibiotics for at least 2 months prior to the time of culturing. Peach et al, 1986 
(Peach et al., 1986b) reported a 32 % carriage rate of C. difficile in patients with CF, and 43% in 
adults with CF who were receiving antibiotics. Yahav et al, 2006 (Yahav et al., 2006a) reported 
a carriage rate of 46% (n=14/30) with a carriage rate of 74% (n=11/19) in the subgroup who 
were receiving continuous antibiotics at time of sampling. Wu et al, 1983 (Wu et al., 1983a)  and 
Peach et al, did not isolate C. difficile from any patients not receiving antibiotics, while Yahav et 
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al, isolated C. difficile in 27% (n=3/11) of patients with CF who were not taking continuous 
antibiotics (Yahav et al., 2006b, Wu et al., 1983b). In our study, the carriage rate of C. difficile 
was 46% (n=6/13) in patients with CF receiving antibiotics. All of these patients were receiving 
short courses (≤ 2 weeks) of antibiotics for treatment of an infective pulmonary exacerbation. 
Most modern CF programs, including ours, do not routinely prescribe continuous oral 
antibiotics. While in earlier studies the carriage rate of C. difficile increased in patients receiving 
long-term or continuous anti-pseudomonal antibiotics, we did not see the same effect in the 
small number of patients in our study who were taking short courses of anti-pseudomonal 
antibiotics. This increased C. difficile carriage rate in all patients with CF without an increase in 
carriage rates seen in patients receiving either short-term or continuous antibiotic therapy in our 
study suggests that novel factors other than antibiotic usage that are as yet undetermined may 
contribute.  Despite the relatively high carriage rate and presence of C. difficile toxin in 
faeces, no participants reported new GI symptoms that suggested occult CDI. Asymptomatic 
carriage of C. difficile despite the presence of toxin has been reported previously (Peach et al., 
1986b, Welkon et al., 1985a). This may be due in part to CF patients (without a history of CDI) 
having higher circulating serum anti-toxin A and B antibodies than patients with CDI 
(Monaghan et al., 2013). 
 Cystic fibrosis intestinal dysbiosis has been demonstrated to cause alterations in the 
composition of the gut microbiota (Duytschaever et al., 2011a), which may allow a unique 
commensal microbiota profile that protects the host by preventing potentially pathogenic C. 
difficile from overcoming colonization resistance, proliferating within the colon, and producing 
toxins A and B. Cystic fibrosis patients often present with atypical symptoms and the diagnosis 
of C. difficile colitis can be missed (Binkovitz et al., 1999, Barker et al., 2008, Schmitt-Grohé et 
al., 2002). Furthermore, systemic symptoms of CDI are derived from toxin-induced 
inflammatory mediators (IL-1, IL-6, IL-8, TNF-α, MIP-2,) (Castagliuolo et al., 1998, Flegel et 
39 
 
al., 1991) released locally in the colon. Altered innate immune responses in CF (del Fresno et al., 
2008, del Fresno et al., 2009, O'Connell O.J. et al., 2014) may result in a reduced ability or an 
inability to produce an inflammatory response to C. difficile toxin.  
 We report the detection of toxigenic C. difficile in 32% (n=19) of our total patient cohort 
based on the detection of toxins A/B in faeces and on the presence of toxin-producing genes 
tcdA and tcdB in genomic DNA of these isolates, which corresponds to the detection of 
toxigenic C. difficile in 63% (n=19/30) of all C. difficile isolates detected. The prevalence of 
toxigenic C. difficile in people with CF varies greatly between previous studies. Peach et al 
reports 75% (n=9) of isolates produced toxin B (cytotoxin) in vivo however, toxin B was only 
directly detected in the stool of 3 of these samples; detection of toxin A (enterotoxin) was not 
performed (Peach et al., 1986a). Welkon et al described 22% toxigenic C. difficile carriage based 
on the detection of cytotoxin (Welkon et al., 1985b). Wu et al found that only 27% of isolates 
were positive for cytotoxin while detection of enterotoxin was not performed (Wu et al., 1983b). 
In a more recent study (2006), toxin was detected in 14 of 30 samples tested, with toxin A 
detected in 3 of 14 and toxin A or B detected in 11 of 14 samples tested, while culture detection 
of C. difficile was not reported (Yahav et al., 2006b). The predominance of toxigenic C. difficile 
in these patients is in contrast to a recent study which reported high carriage of non-toxigenic 
strains in CF patients (Bauer et al., 2014). 
 The thirty C. difficile strains isolated in this study were distributed across 16 distinct 
ribotype (RT) groups. Four of the ribotypes reported in this study have appeared in the top five 
most prevalent disease-causing ribotypes reported in Ireland in the last four years (RT002, 
RT014, RT015, RT078), with RT014 and RT078 consistently the most prevalent ribotypes 
across the last 4 years of surveillance data (Executive, 2013). Ribotype 078 is associated with 
increased mortality, and has been responsible for an increasing number of CDI outbreaks in 
recent years, including an outbreak in an Irish population resulting in a mortality rate of at least 
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33% directly attributable to CDI (Burns et al., 2010). Ribotype 046 was the most prevalent 
pathogenic ribotype reported in this study accounting for 13.33% of C. difficile strains isolated. 
While, to date, ribotype 046 has not been associated with significant morbidity or mortality in an 
Irish population, it has been associated with CDI outbreaks in other countries (Bauer et al., 2011, 
Pituch et al., 2006, Akerlund et al., 2011). Both RT078 and RT046 have been found in pigs and 
could suggest zoonotic acquisition (Debast et al., 2009, Norén et al., 2013). The diverse nature 
of the PCR ribotypes reported in this study and the relative under-representation of commonly 
reported Irish ribotypes may support the theory of community acquisition as proposed by 
Clayton et al. (Clayton et al., 2009).  
 Subjects in this study received an average of 1.6 (SD ± 2.2) intravenous antibiotic 
(IVAB) courses spread over an average of 63.8 (SD ± 82.2) days in the 12 months prior to 
donation of their stool sample. The majority of study participants (79.4%) were receiving 
maintenance macrolide antibiotics in the previous 12 months. Antibiotic administration is 
frequently cited as a risk factor for the development of CDI in non-CF cohorts (Bignardi, 1998, 
Owens et al., 2008), with antibiotics commonly prescribed to treat pulmonary infection in people 
with CF (third-generation cephalosporins, fluoroquinolones and macrolides) associated with an 
increased risk of CDI (Bauer et al., Bignardi, 1998, Pépin et al., 2005, Gerding, 2004). Despite 
this, our study revealed no association between the presence of C. difficile and the use of short-
term anti-pseudomonal antibiotics or continuous macrolide therapy over the previous 12 months.  
 Reassuringly, all isolates tested were susceptible to both metronidazole and vancomycin 
according to the breakpoints defined by the European Committee on Antimicrobial 
Susceptibility Testing (Testing, 2013). While breakpoints are not available for the other 
antibiotics tested, all detected isolates were sensitive to fucidic acid, linezolid, meropenem and 
rifampicin. As expected C. difficile isolates were resistant to antibiotics prescribed to treat 
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Pseudomonal and other gram-negative lung infections that have poor activity against Gram 
positive organisms (azithromycin, aztreonam, ciprofloxacin, ceftazadime and tobramycin).  
 
2.6 Conclusion 
C. difficile carriage in people with CF is common and appears to be increasing, with half of the 
adults in this study carrying C. difficile in their gut. The advent of ribotyping analysis allows us 
to comprehensively characterise the strains detected in people with CF, with many toxigenic and 
hypervirulent strains detected in patients who did not manifest symptoms of CDI.  
 C. difficile carriage in an asymptomatic patient with CF is an especially challenging 
clinical scenario given the potential consequences of CDI in the post-transplant period. A 
randomised controlled trial examining the effects of eradication of C. difficile on health 
outcomes in both pre- and post-transplant patients with CF is required to clearly establish the 
optimum strategy for management of C. difficile carriage in this cohort.  
 
2. 7 Limitations 
This study is a single-centre study and examines 60 patients with CF from a single geographical 
area, which may not represent the patterns of C. difficile carriage seen in other geographical 
areas. However the high carriage rate and significant rate of detection of virulent C. difficile 
amongst patients with CF are concerning and supports the role of a larger multi-centre study. 
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Table 2.1: Characteristics of CF patient study cohort. 
Variable n=60 
Age in yrs (median, interquartile range [IQR]) 27 (24-37) 
Male Gender 37 (62%) 
FEV
1
  % predicted (median, [IQR]) 65 (46-83) 
PPI use 31 (52%) 
Macrolide use 46 (77%) 
Pancreatic insufficiency 49 (82%) 
Class 1-3 mutation 45 (75%) 
Exacerbating at time of sample donation 14 (23%) 
On IVAB at time of sample donation 11 (18%) 
On po AB at time of sample donation 2 (3%) 
Not on antibiotic therapy at time of sample donation 1 (2%) 
BMI (median) 22.4 (23%) 
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Table 2.2: Toxin gene detection, direct stool toxin, ribotype and virulence of Clostridium difficile 
strains detected. 
Patient 
(n=30) 
*tcd-A §tcd-B Stool toxin 
(EIA) 
Ribotype Virulent 
CF3 + + + 014 Yes 
CF5. + + + 002 Yes 
CF7 - - - 039 No 
CF8 + + + 126 Yes 
CF9 + + + 001 Yes 
CF10 + + + 001 Yes 
CF13 - - - 140 No 
CF15 + + + 078 Yes 
CF18 - - - 140 No 
CF21 - - - 140 No 
CF22 - - - 009 No 
CF24 - - - 010 No 
CF26 + + + 001 Yes 
CF27 + + + 046 Yes 
CF29 + + + 014 Yes 
CF34 + + + 046 Yes 
CF41 + + + 045 Yes 
CF44 - - - Unknown No 
CF46 - - - 039 No 
CF47 + + + 046 Yes 
CF48 + + + 046 Yes 
CF51 + + + 078 Yes 
CF52 + + + 126 Yes 
CF53 - - - 140 No 
CF61 + + + 011 Yes 
CF64 + + + 092 Yes 
CF65 - - - 010 No 
CF66 - - - 140 No 
CF71 + + + 087 Yes 
CF73 + + + 356 Yes 
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Table 2.3: Susceptibility of Clostridium difficile isolates to commonly used antibiotics 
 
 
 
 
 
 
 
 
 
 
 
*Antibiotic break point represents the defined EUCAST clinical break point for C. difficile  
 
 
 
 
Antibiotic Range of activity (mg/l) *Antibiotic break point 
(mg/L) 
Metronidazole 0.016 – 0.5 2 
Vancomycin 0.19 – 0.5 2 
Fusidic acid 0.016 – 0.75 n/a 
Rifampicin < 0.002 n/a 
Meropenem 0.125 – 1 n/a 
Linezolid 0.38 – 4 n/a 
Ciprofloxacin > 32 n/a 
Ceftazadime >256 n/a 
Tobramycin > 256 n/a 
Aztreonam > 256 n/a 
Azithromycin > 256 n/a 
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Chapter 3       
Cystic fibrosis and its treatment affect the composition of 
the intestinal microbiota. 
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3.1 Abstract 
Cystic fibrosis (CF) is an autosomal recessive disease that affects the function of a number of 
organs, including the lungs and gastrointestinal (GI) tract of patients. The manifestations of CF 
in the GI tract, as well as frequent antibiotic treatment for pulmonary infection, undoubtedly 
disrupt the composition of the intestinal microbiota composition. To analyse the intestinal 
microbiota of CF patients, we compared the composition of 68 CF patients to that of 69 healthy 
non-CF controls through 16S rRNA amplicon sequencing. The impact of the clinical 
manifestation/progression and treatment of the disease were also assessed. Overall, the CF 
associated microbiome had reduced microbial diversity. This was accompanied by a shift 
towards an increased Firmicutes to Bacteriodetes ratio. While the greatest numbers of 
differences in taxonomic abundances of the intestinal microbiota were observed between CF 
patients and healthy controls, compositional differences were also reported between CF patients 
grouped by disease manifestation/progression or treatments received. 
 
3.2 Introduction 
The healthy human gut is populated with in excess of 1011 microbes per millilitre of luminal 
content (Savage, 1977). The composition of this gut microbial community is generally stable 
over time in healthy adults, however, inter-individual variation can be high, which is thought to 
be associated with extrinsic factors including age, diet, environment and host genetics (Costello 
et al., 2009, Malinen et al., 2005). This microbial community plays an essential role in healthy 
intestinal development, maturation of host immune response, and provision of metabolic 
capabilities otherwise unavailable to the host (Hooper, 2004, Hooper et al., 2002, Mazmanian et 
al., 2005, Round and Mazmanian, 2010). Alteration of the normal gut microbiota has been 
linked to a number of diseases including, diabetes, obesity, irritable bowel syndrome, and 
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irritable bowel disease (Kassinen et al., 2007, Larsen et al., 2010, Malinen et al., 2005, Scanlan 
et al., 2006, Turnbaugh et al., 2006). 
 Cystic Fibrosis (CF) is the most common life shortening autosomal recessive disease, 
affecting one in 2,000 Caucasians (Hodson., 1984). It is caused by a mutation in the Cystic 
fibrosis transmembrane conductance regulator (CFTR) gene, which can result in expression of a 
dysfunctional Cl- ion transport protein, or complete non-expression of this protein in epithelial 
cells. This prevents the adequate hydration in the lumen of tubular organs, resulting in viscous 
mucus accumulating along a variety of epithelial surfaces including the lungs and 
gastrointestinal (GI) tract (Greger, 2000). Patients with CF suffer from a number of 
gastrointestinal complications including, pancreatic insufficiency, slowed gastric transit, mal-
absorption, and obstruction (Andersen et al., 1990, Bruzzese et al., 2004, De Lisle, 2007, De 
Lisle et al., 2010, Gasbarrini et al., 2007, Rubinstein et al., 1986). Progressive pulmonary disease 
due to chronic infection is the number one cause of death in CF patients. Therefore CF patients 
undergo frequent courses of broad spectrum antibiotics (Ramsey, 1996, Szaff et al., 1983). 
Previous studies in non-CF patients have shown antibiotic therapy to reduce the diversity of the 
intestinal microbiota as well as altering the relative abundances of susceptible bacterial species 
(Jakobsson et al., 2010, Jernberg et al., 2010).  
 Typically, the intestinal microbiota returns to a normal pre-treatment state within weeks 
of cessation of antibiotic therapy. However, it has been noted that some taxonomic changes can 
persist for long periods after antibiotic treatment (Dethlefsen et al., 2008, Dethlefsen and 
Relman, 2011, Jernberg et al., 2007, Jernberg et al., 2010). Frequent courses of antibiotics are 
also likely to increase the risk of developing antibiotic resistant strains, as well as reducing the 
hosts colonization resistance, allowing for colonization and proliferation of opportunistic 
pathogens such as C. difficile (Hirschhorn et al., 1994, Safdar and Maki, 2002). Previous 
investigations revealed that paediatric CF patients had lower counts of all taxa examined by 
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culture except for  Enterobacteria and lower temporal stability in their gut microbiota relative to 
sibling controls (Duytschaever et al., 2011). Frequent antibiotic therapy to treat chronic 
pulmonary infection as well as the inherent effect of CF on the gastrointestinal tract have been 
proposed as possible causes of this dysbiosis in CF patients gut microbiota (Duytschaever et al., 
2011). This theory is supported by studies conducted in CF mice which have demonstrated 
decreases in the richness, evenness, and diversity of the small intestinal microbiota relative to 
non-CF mice (Lynch et al., 2013). A study into the development of the gut and lung microbiome 
in paediatric CF patients revealed both microbial communities develop simultaneously and share 
a number of colonising species(Madan et al., 2012). It was also revealed that the appearance of 
some species in the gut can foretell of their appearance in the lungs, suggesting the gut 
microbiota may help shape the development of the lung microbiota (Madan et al., 2012). This 
coupled with the success of probiotic trials at reducing GI inflammation and exacerbation 
frequency in CF patients (Bruzzese et al., 2004, Bruzzese et al., 2007, Weiss et al., 2010) 
highlights the importance of understanding the CF gut microbiota and the effect of disease 
manifestation and its treatment on the gut microbiota.  
 Previous studies investigating the CF gut microbiota have varied in approach adopting 
both culture-dependent and culture-independent approaches in either paediatric CF patients 
(Duytschaever et al., 2011, Madan et al., 2012) or CF animal models (Lynch et al., 2013). In this 
study the effect of CF and its treatment on the gut microbiota of 68 adult patients with CF was 
investigated by high-throughput pyrosequencing. This study demonstrates that the gut 
microbiota of patients with CF is significantly different to that of a healthy control group. A shift 
towards an increased Firmicutes to Bacteriodetes ratio was also observed in patients with CF. 
Microbial diversity and composition were also found to be affected by the disease and its 
treatment.  
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3.3 Materials and methods 
 
Study Participants.  
A total of seventy three individuals with CF were recruited from the Cork Adult Cystic Fibrosis 
Centre, Cork University Hospital for this study. None of these patients were suffering any form 
of gastrointestinal illness at the time of sampling. Informed written consent was obtained from 
all subjects in accordance with local research ethics committee guidelines. We were unable to 
produce Amplicons from three patients stool samples, while a further two patients samples did 
not meet the minimum quality scores for sequencing and thus were not included in this study. 
Therefore sixty eight CF patients were entered into the study of which 61.4% were male and 
they ranged in age from 17 – 77 (median age 29) 
 A total of 69 non-CF volunteers were recruited from the greater Cork community as a 
control group for comparison of their gut microbiota. Non-CF volunteers were eligible for 
inclusion provided they were between 20 and 80, reported no gastrointestinal illness at the time 
of sampling, and had not received antibiotics within the previous 6 months.   
The present study was approved by the Clinical Research Ethics Committee of the Cork 
Teaching Hospitals. 
 
Pyrosequencing and bioinformatics 
Genomic DNA was extracted from faecal samples as per the manufacturer’s instructions using 
the QIAamp DNA Stool Mini Kit (Qiagen, Crawley, West Sussex, UK) with the addition of an 
initial bead-beating step. Samples were prepared for compositional sequencing by taq-based 
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PCR amplification of the V4 region of the 16s rRNA gene using universal 16S primers as 
described by Ribosomal Database Projects (RDP) Pyrosequencing pipeline 
(http://pyro.cme.msu.edu/pyro/help.jsp). The resulting amplicons were sequenced using a Roche 
454 GSFLX by using Titanium chemistry at the Teagasc 454 sequencing platform. Raw 
sequences were quality trimmed using the Qiime Suite of programmes, any reads not meeting 
the quality criteria of a minimum quality score of 25 and sequence length shorter than 150bps for 
16S amplicon reads were discarded. Trimmed FASTA sequences were BLASTed against the 
SILVA 16S rRNA (version 106) database. The resulting BLAST outputs were parsed using 
MEGAN (Huson et al., 2007). MEGAN assigns reads to NCBI taxonomies using the lowest 
common ancestor algorithm. Cut off bit scores were from within MEGAN to filter the results 
prior to tree construction an summarization; a cut-off bit score of 86 was used (Urich et al., 
2008). Phylum, family, and genus counts for each individual were extracted from MEGAN. 
Operational taxonomic unit (OTU) assignment, chimera checking, clustering and α and β 
diversities of reads were implemented with QIIME (Caporaso et al., 2010). The resulting 
principal coordinate analysis was visualised within KiNG (http://kinemage.biochem.duke.edu).  
 
Statistical analysis 
The non-parametric Kruskal-Wallis test, applied using Minitab Release 15.1.1.0 (Minitab Inc., 
2007), was used to estimate the relations between groups. Statistical significances were accepted 
at P < 0.05. 
 
 
 
61 
 
3.4 Results 
Compositional differences in gut microbiota of people with CF compared to healthy controls. 
The microbial composition of CF patients gut microbiota of was evaluated through high-
throughput 16S amplicon sequencing derived from faecal samples. A total of 2,099,804 reads 
were sequenced, corresponding to an average 23,331 reads/ sample.  
 Principle coordinate analysis plots generated using weighted and un-weighted Unifrac 
distance matrix showed that CF patients clustered separately to healthy controls (fig. 3.1). 
However, CF patients did not cluster based on carriage of Clostridium difficile (previously 
reported Burke et al, 2014), phenotype (class 1-3 mutation, FEV1% <68%, pancreatic 
insufficiency) or treatments received (proton pump inhibitors, no. of home IVAB days, inpatient 
days, macrolide antibiotics or lung transplantation (figure 3.2). This suggests CF has a greater 
effect on the diversity of the gut microbiota than any individual treatment.  
 The gut microbiota of CF patients was found to be significantly less diverse healthy 
controls based on five   diversity metrics (Chao1, Simpson, Shannon, and phylogenetic diversity 
and species richness) as shown in figure 3.3. Assigned sequence reads were used to assess 
differences in taxonomic abundances between CF patients and healthy controls at phylum, 
family, and genus levels. At the phylum level there was a significant (P < 0.05) decrease in the 
populations of Actinobacteria, Proteobacteria, Cyanobacteria, Verrucomicrobia, RF3, 
Tenericutes, and Lentisphaerae in patients with CF relative to healthy controls (figure 3.4 (a)). 
Notably there was a significant (P < 0.05) increase in Firmicutes of 8.18% in CF patients relative 
to healthy controls. At the family level, a total of 27 families were significantly (P < 0.05) 
different in CF patients compared to healthy controls (11 increased and 16 decreased). The 
largest difference was seen in Lachnospiraceae which was increased in CF patients by and 
5.17% respectively. Conversely, decreases of 7.03%, 9.22% and 4.36% in Rikenellaceae, 
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Ruminococcaceae and Prevotellaceae respectively were found in CF patients relative to healthy 
controls. At the genus level 19 genera were increased and 30 were decreased in patients with CF. 
This included a 5.94% increase in Lachnospiraceae Incertae Sedis and decreases of 4.81%, 
4.04%, and 4.09% in Alistipes, Prevotella, and Faecalibacterium respectively in patients with 
CF. 
 
The effect of macrolide antibiotics on the gut microbiota of people with cystic fibrosis. 
The effect of macrolide antibiotics in previous six months was investigated for its impact on the 
composition of the gut microbiota in CF patients. Macrolide antibiotics had been given to 58 of 
the 68 CF patients in this study in the previous 6 months. The composition of their gut 
microbiota was compared to that of the patients who had not received the antibiotic (n= 10). 
Patients receiving macrolide antibiotics had no significant differences in the diversity or species 
richness of their gut microbiota relative to CF patients who had not received macrolide 
antibiotics. At the phylum level, those receiving macrolide antibiotics showed significant (P < 
0.05) decreases in Verrucomicrobia and Eukaryota. At the family level Bacteroidaceae were 
significantly (P < 0.05) increased however, Bifidobacteriaceae Family XIII Incertae Sedis, 
Gammaproteobacteria, Akkermansiaceae, Pasteurellaceae, and Desulfovibrionaceae were all 
significantly (P < 0.05) reduced. These changes were also evident at the genus level, with a 
significant (P < 0.05) increase Bacteroides and reductions in Pseudobutyrivibrio, 
Bifidobacterium, Akkermansia, Acinetobacter, and Enterococcaceae evident in those receiving 
macrolide antibiotics as can be seen in the supplementary material.  
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The effect of proton pump inhibitors on the gut microbiota of people with cystic fibrosis. 
Proton pump inhibitors (PPI) are commonly prescribed to patients with CF to aid in pancreatic 
enzyme absorption in those that suffer malabsorption. The effect of PPIs on the gut microbiota 
of patients with CF was examined by comparing the composition of the gut microbiota of 
patients on PPIs (n = 37) to those not on PPI therapy (n = 31). No significant (P > 0.05) 
differences were observed in the diversity or species richness of CF patients receiving PPI 
therapy relative to those not receiving PPIs. At the phylum level, CF patients on PPIs had a 
significant (P < 0.05) decrease in Fusobacteria relative to those not receiving PPI. Not 
surprisingly, Fusobacteriaceae was significantly decreased at the family level, in CF patients 
receiving PPI therapy. At the genus level a significant (P < 0.05) increase in Veillonella was 
observed as well as significant (P < 0.05) decreases in the proportions of Dialister, 
Subdoligranulum, Clostridiaceae, and Fusobacterium in CF patients receiving PPI therapy. 
 
The effect of duration of intravenous antibiotic treatment on gut microbiota. 
To examine the effect of duration of intravenous antibiotic (IVAB) treatment on the gut 
microbiota, CF patients were divided into a high IVAB treatment days group (> 55days) and low 
IVAB treatment days group (< 55 days) depending on the number of days spent receiving IVAB 
in the previous year. The gut microbiota of the high IVAB treatment days group (n = 23) was 
compared to the low IVAB treatment days group (n = 45). The high IVAB treatment day’s group 
had significantly (P < 0.05) less diverse gut microbiota and lower species richness relative to the 
low IVAB treatment days group. No significant differences were observed at the phylum level 
between CF patients in the high IVAB treatment days group and those in the low group. Four 
families were significantly different in CF patients in the high IVAB treatment days group. 
Enterococcaceae were significantly (P < 0.05) increased in this group while Alcaligenaceae, 
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Veillonellaceae, and Prevotellaceae were significantly (P < 0.05) decreased relative to CF 
patients in the low IVAB treatment days group. 
 
The effect of duration of hospital stays on the gut microbiota. 
 To examine the effect of duration of hospital stay on the gut microbiota, CF patients who spent 
greater than 18 days as a hospital inpatient (n = 13) in the previous year were compared to those 
who had spent less than 18 days as an inpatient (n = 55). According to two of the five 
measurements used (Simpson and Shannon) CF patients with a high number of inpatient days 
had a significantly less diverse gut microbiota than those with lower than 18 inpatient days. No 
significant (P > 0.05) differences were observed in patients with greater than 18 days as a 
hospital inpatient at the phylum level. At the family level, increased duration of time spent as an 
inpatient was significantly (P < 0.05) associated with reductions in Lachnospiraceae, 
Veillonellaceae, and Clostridiaceae. These CF patients also had significantly (P < 0.05) higher 
proportions of Enterococcus, Clostridium (Clostridiaceae), Coriobacteriaceae, and 
Bifidobacteriaceae at the genus level. While Dorea, Pseudobutyrivibrio, and Blautia were all 
significantly (P < 0.05) reduced in these patients. 
 
The impact of lung transplantation on the gut microbiota. 
To examine the impact of lung transplantation on the gut microbiota of CF patients, the gut 
microbiota of post lung transplantation CF patients (n = 11) was compared to CF patients who 
have not undergone lung transplant (n = 57). No significant (P > 0.05) differences in the 
diversity or species richness were observed between these two groups. At the phylum level a 
shift towards an increased Firmicutes to Bacteriodetes ratio was observed in post-transplant CF 
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patients relative to non-transplant CF patients. Firmicutes were significantly (P < 0.05) increased 
by 20.76% while Bacteriodetes were significantly (P < 0.05) reduced by 21.21% in this group. A 
significant (P < 0.05) increase in Eukaryota was also observed in this group. At the family level 
post lung transplant patients had a significant (P < 0.05) reduction in Bacteroidaceae, while 
Streptococcaceae, Lachnospiraceae, Lactobacillaceae, and Betaproteobacteria were all 
significantly (P < 0.05) increased in this group. At the genus level post-transplantation CF 
patients had significant (P < 0.05) increases in Streptococcus, Lachnospiraceae Incertae Sedis, 
Blautia, Lactobacillus, Veillonella, Weissella, Acinetobacter, and Allisonella. Post-transplant CF 
patients also had a significant (P < 0.05) decrease in their proportion of Bacteroides and 
Alistipes relative to non-transplant CF patients.  
 
Changes in gut microbiota during pulmonary exacerbation. 
To determine if there is an association between pulmonary exacerbation and the composition of 
the gut microbiota in CF patients the gut microbiota of CF patients suffering pulmonary 
exacerbation at the time of sampling (n = 12) were compared to stable CF patients (n =56). 
Exacerbating CF patients had significantly (P < 0.05) less diverse gut microbiota and species 
richness than non-exacerbating CF patients according to four of five measures used (Simpson, P 
= 0.062). No significant differences were observed at the phylum level in CF patients suffering 
exacerbations. However, at the family level, proportions of Lactobacillaceae, Veillonellaceae, 
and Clostridiaceae were significantly (P < 0.05) reduced while Bacilli was significantly (P < 
0.05) increased. At the genus level patients experiencing pulmonary exacerbations had 
significant (P < 0.05) reductions in their proportions of Streptococcus, Pseudobutyrivibrio, 
Blautia, Clostridium (Clostridiaceae), and Lactobacillus. Pulmonary exacerbation was also 
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associated with a significant (P < 0.05) increase in proportions of Erysipelotrichaceae Incertae 
Sedis relative to CF patients not experiencing pulmonary exacerbations. 
 
Alteration of gut microbiota with decreasing FEV1%. 
Forced expiratory volume in 1 second (FEV1) is a measure of lung function used to measure the 
progression of pulmonary disease in CF patients. To assess whether the gut microbiota changes 
with progression of lung disease progression in CF patients, we compared the gut microbiota of 
CF patients with FEV1 <68% to CF patients with an FEV1 >68%. CF patients with depressed 
lung function had significantly (P < 0.05) less diversity and species richness in their gut 
microbiota relative to those with an FEV1 of > 68%. At the phylum level CF patients with 
depressed lung function had significantly (P < 0.05) increased proportions of Proteobacteria. 
While at the family level, these patients had higher proportions of Bacteroidaceae and 
Streptococcaceae. CF patients with depressed lung function also had significantly (P < 0.05) 
lower proportions of Lachnospiraceae and Prevotellaceae at the family level. 
At the genus level, CF patients with depressed lung function had significantly (P < 0.05) 
decreased proportions of Pseudobutyrivibrio, Blautia, Clostridium, and Lactobacillus. These 
patients also had increased proportions of Streptococcus and Clostridiaceae relative to CF 
patients with an FEV1 > 68%. 
 
Changes in the gut microbiota of pancreatic insufficient CF patients.  
Pancreatic insufficiency is a common manifestation of CF. To examine the effect of pancreatic 
insufficiency on the composition of the gut microbiota in CF patients we compared the gut 
microbiota of CF patients with pancreatic insufficiency (n = 59) to those who were pancreatic 
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sufficient (n = 9). No significant differences in diversity or species richness were observed 
between pancreatic insufficient and pancreatic sufficient CF patients. Pancreatic insufficiency 
had no significant impact on the gut microbiota at a phylum level in the CF patients tested. At 
the family level Lachnospiraceae was significantly (P < 0.05) increased while Ruminococcaceae 
was significantly (P < 0.05) decreased in pancreatic insufficient CF patients relative to 
pancreatic sufficient CF patients. At the genus level pancreatic insufficient CF patients had a 
significant (P < 0.05) increase in Lachnospiraceae Incertae Sedis, while Ruminococcus, 
Subdoligranulum, Bifidobacteriaceae, Anaerotruncus, Allobaculum, Clostridiaceae, 
Parvimonas, and Arcobacter were all significantly (P < 0.05) decreased relative to pancreatic 
sufficient CF patients.  
 Cystic fibrosis is caused by a mutation in the CFTR gene which codes for a chloride ion 
transport protein expressed at epithelial cell surfaces. Mutations in the CFTR gene are classified 
into 6 classes according to the mechanism by which they disrupt the action of the CFTR protein. 
Class 1 – 3 mutations are considered the most severe as they tend to result in a complete loss of 
function. To assess the impact of class 1-3 mutations on the composition of the gut microbiota, 
the gut microbiota of CF patients with class 1 – 3 mutations was compared to CF patients with 
less severe mutations. No significant difference in species richness of microbial diversity were 
observed between the CF patients with class 1 – 3 mutations and CF patients with other 
mutations. CF patients with class 1 – 3 mutations had no significant differences in the 
composition of their gut microbiota at phylum level. At the family level Enterococcaceae was 
significantly (P < 0.05) increased while Ruminococcaceae was significantly (P < 0.05) decreased 
relative to those with less severe mutations. At the genus level, Alistipes, Ruminococcus, 
Subdoligranulum, Faecalibacterium, Paraprevotella, Anaerotruncus, and Barnesiella were all 
significantly (P < 0.05) decreased in CF patients with severe mutations (class 1-3). 
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Alterations in gut microbiota of CF patients carrying of Clostridium difficile in their stool. 
To assess whether alterations in the gut microbiota may predispose CF patients to colonisation 
with C. difficile, we compared the gut microbiota of CF patients who were asymptomatic carriers 
of C. difficile to CF patients negative for carriage of C. difficile. 
 A significant (P < 0.05) reduction in microbial diversity was observed in CF patients 
carrying C. difficile. Patients carrying C. difficile had significant (P < 0.05) decrease in 
proportions of Actinobacteria, Proteobacteria, and Fusobacteria at the phylum level relative to C. 
difficile free CF patients. While at the family level significant (P < 0.05) increases in 
Anaerococcus and Erysipelotrichaceae Incertae Sedis were observed in CF patients carrying C. 
difficile as well as a significant (P < 0.05) decrease in Fusobacteriaceae. At the genus level this 
group of patients had significant (P < 0.05) reductions in Parasutterella, Paraprevotella, 
Barnesiella, Fusobacterium, Weissella, and Peptostreptococcaceae (Clostridiales) relative to C. 
difficile free CF patients. A significant (P < 0.05) increase in Erysipelotrichaceae Incertae Sedis 
was also observed in CF patients carrying C. difficile. 
 
3.5 Discussion  
In this study high throughput compositional pyrosequencing of the faecal microbiota was used to 
investigate the impact of cystic fibrosis on the composition of the gut microbiota of patients with 
CF. In addition, patient medical histories were used to establish whether disease 
manifestation/progression or treatment of CF had an impact on the gut microbiota of CF 
patients. The intestinal microbiota of CF patients was shown to be altered to that of healthy 
controls as evident by their separate clustering by principle coordinate analysis. The gut 
microbiota of CF patients was significantly (P < 0.05) less diverse than that of healthy controls 
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and alterations in taxonomic abundances were observed between the two groups at the phylum, 
family and genus level. The disease and its treatment were also found to contribute to the 
dysbiosis of the CF patient gut microbiota with differences in diversity and taxonomic 
abundances observed among CF patient groups.  
 A shift toward an increased Firmicutes to Bacteriodetes ratio was observed in CF patients 
relative to the non-CF control group which may partially be explained by diet. Similar 
observations have been made in studies of obesity (Bervoets et al., 2013, Turnbaugh et al., 2006) 
with diet proposed as a major factor in the development of the gut microbiota (Moschen et al., 
2012). Under nutrition in CF patients is associated with poor clinical outcome, therefore CF 
patients are recommended to consume a diet high in fat and protein (Borowitz et al., 2002). Diets 
high in fat have been shown to increase the Firmicutes to Bacteriodetes ratio in mice 
independent of obesity (Hildebrandt et al., 2009). However, dietary information was not 
collected as part of this study, and therefore no definite conclusion can be made.  
 With the survival rate of CF patients increasing, the risk of patients developing cancer 
also increases. The risk of cancer in CF patients is similar to that of the healthy population, 
however CF patients have a higher ratio of observed to expected digestive cancers (Neglia et al., 
1995, Maisonneuve et al., 2003, Maisonneuve et al., 2013). In this study, Fusobacterium, a 
bacterium which is seen as a risk factor for developing colorectal cancer (CRC) (Flanagan et al., 
2014) was detected in the intestinal microbiota of four CF patients, while it was notably absent 
from healthy volunteers. Fusobacterium nucleatum has been show to induce the growth of CRC 
by inducing oncogenic and inflammatory responses (Rubinstein et al., 2013). Fusobacterium is 
more abundant in the stool of CRC patients (Flanagan et al., 2014) and may play a role in the 
development of digestive tract cancers in CF patients. 
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 The gut microbiota of CF patients was found to be significantly less diverse and had 
lower species richness than that of a healthy control group. CF patient’s intestinal microbiota 
also displayed an increased Firmicutes to Bacteriodetes ratio relative to the control group. 
Intestinal dysbiosis observed in CF patients was influenced by a combination of the disease and 
its treatment. The results presented here further develop the understanding of the intestinal 
microbiota of CF patients. In the future, this may be exploited as a target to improve the 
gastrointestinal, as well as pulmonary health of CF patients. However, longtitudinal studies are 
required to improve our understanding of the influence of CF and its treatment on the gut 
microbiota over time. 
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Figure 3.1 Principle coordinate analysis plots of weighted (a) and unweighted (b) unifrac 
distance matricies of CF patient compared to healthy controls. 
(a)        (b) 
 
 
 
 
 
 
Beta diversities of reads were implemented with QIIME. The resulting principal coordinate analysis was visualised within KiNG 
(http://kinemage.biochem.duke.edu). Cystic fibrosis patients are represented by blue dots, while healthy controls are represented by blue 
dots. Red and blue ovals indicate separate clustering of these groups. 
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Figure 3.2: Principle coordinate analysis plots of weighted unifrac distance matrices of CF 
patients based on clinical parameters and treatments received as well as healthy controls to 
healthy controls. 
 
Healthy controls are represented by yellow dots in all graphs. In graph (a), patients with an FEV1 of > 68% are represented in red and 
those with < 68% in blue. In graph (b), C. difficile negative CF patients are represented by red and C. difficile positive in blue. In graph 
(c) patients with class 1 - 3 mutations are represented in blue and non 1 – 3 mutations in red. In graph (d), patients with a high number of 
inpatient days are represented in blue and those with lower inpatient days in red. In graph (e), non-lung transplant patients are coloured 
in red and transplant patients in blue. In graph (f), pancreatic sufficient patients are coloured in red and pancreatic insufficient patients in 
blue. In graph (g), patients with a high number of home IV antibiotic days are represented in blue and those with a low number in red. In 
graph (h), those receiving proton pump inhibitors are coloured in blue and those not receiving PPIs in red. In graph (i), patients receiving 
macrolide antibiotics are coloured in blue and those not receiving the treatment in red.  
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Figure 3.3 Box plots comparing the diversity of CF intestinal microbiota compared to healthy 
controls using the following diversity metrics; Phylogenetic diversity (a), Chao 1 (b), Shannon 
(c), Simpson (d), and species richness (e). 
 
Alpha diversities of reads were implemented with QIIME and box plots created using Minitab 15. 
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Figure 3.4 Significant differences in microbial abundances observed between CF patient and 
phylum (a), family (b) and genus (c) level. 
(a) Phylum level differences in taxonomic abundance between CF and healthy controls. 
 
(b) Family level differences in taxonomic abundance between CF and healthy controls. 
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(c) Genus level differences in taxonomic abundance between CF and healthy controls. 
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Supplementary figure 3.1: Significant changes in taxonomic abundances at the phylum (a), 
family (b), and genus (c) level in CF patients receiving macrolide antibiotics compared to CF 
patients not receiving the treatment based on assigned reads. The non- parametric Kruskal–
Wallis was test was used to estimate the relationship between the groups. Statistical significance 
was accepted at P < 0.05. 
(a)  
 
(b)  
(c)  
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Supplementary figure 3.2: Significant changes in taxonomic abundances at the phylum (a), 
family (b) and genus (c) level in CF patients receiving proton pump inhibitors compared to CF 
patients not receiving the treatment based on assigned reads. The non- parametric Kruskal–
Wallis was test was used to estimate the relationship between the groups. Statistical significance 
was accepted at P < 0.05. 
(a)  
(b)  
 
(c)  
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Supplementary figure 3.3: Significant changes in taxonomic abundances at the family (a), and 
genus (b) level in CF patients receiving IVAB for >55 days compared to CF patients who 
received the treatment over a shorter duration (< 55 days) based on assigned reads. The non- 
parametric Kruskal–Wallis was test was used to estimate the relationship between the groups. 
Statistical significance was accepted at P < 0.05. 
(a)  
 
(b)  
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Supplementary figure 3.4: Significant changes in taxonomic abundances at the family (a) and 
genus (b) level in CF patients who spent >18 days as a hospital inpatient to CF patients who 
spent < 18 days as a hospital inpatient based on assigned reads. The non- parametric Kruskal–
Wallis was test was used to estimate the relationship between the groups. Statistical significance 
was accepted at P < 0.05. 
 
(a)  
 
(b)  
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Supplementary figure 3.5: Significant changes in taxonomic abundances at the phylum (a), 
family (b) and genus (c) level in post-lung transplant CF compared to non-transplant patients 
based on assigned reads. The non- parametric Kruskal–Wallis was test was used to estimate the 
relationship between the groups. Statistical significance was accepted at P < 0.05. 
(a)  
(b)  
(C)  
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Supplementary figure 3.6: Significant changes in taxonomic abundances at the family (a) and 
genus (b) level in CF patients suffering pulmonary exacerbation compared to non-exacerbating 
CF patients based on assigned reads. The non- parametric Kruskal–Wallis was test was used to 
estimate the relationship between the groups. Statistical significance was accepted at P < 0.05. 
(a)  
(b)  
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Supplementary figure 3.7: Significant changes in taxonomic abundances at the phylum (a), 
family (b) and genus (c) level in CF patients with an FEV1 of less than 68% compared to CF 
patients with an FEV1 of greater than 68% based on assigned reads. The non- parametric 
Kruskal–Wallis was test was used to estimate the relationship between the groups. Statistical 
significance was accepted at P < 0.05. 
(a)  
(b)  
(c)  
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Supplementary figure 3.8: Significant changes in taxonomic abundances at the family (a) and 
genus (b) level in pancreatic insufficient CF patients compared to pancreatic sufficent CF 
patients based on assigned reads. The non- parametric Kruskal–Wallis was test was used to 
estimate the relationship between the groups. Statistical significance was accepted at P < 0.05. 
 
(a)  
(b)  
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Supplementary figure 3.9: Significant changes in taxonomic abundances at the family (a) and 
genus (b) level in CF patients with severe class 1 – 3 mutations compared to CF patients with 
less severe mutations based on assigned reads. The non- parametric Kruskal–Wallis was test was 
used to estimate the relationship between the groups. Statistical significance was accepted at P < 
0.05. 
 
(a)  
(b)  
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Supplementary figure 3.10: Significant changes in taxonomic abundances at the phylum (a), 
family (b), and genus (c) level in C. difficile positive CF patients compared to CF patients not 
carrying C. difficile based on assigned reads. The non- parametric Kruskal–Wallis was test was 
used to estimate the relationship between the groups. Statistical significance was accepted at P < 
0.05. 
(a)  
(b)  
(c)  
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Chapter 4 
Multilocus sequence typing as an alternative to PCR-
ribotyping for typing Clostridium difficile in patients with 
high risk of infection. 
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4.1 Abstract: 
A collection Clostridium difficile strains isolated from a number of patient cohorts with 
increased risk of C. difficile infection (CDI) were typed using multilocus sequence typing 
(MLST). The discriminatory power of MLST for typing C. difficile was compared to that of 
PCR-ribotyping and pulsed-field gel electrophoresis (PFGE). In total, 28 MLST sequence types 
(ST) and 33 ribotypes (RT) were described in 112 C. difficile strains isolated from these patient 
cohorts. A subset of 28 strains was also typed using pulsed field gel electrophoresis (PFGE). 
Pulsed field gel electrophoresis typing of this subset resulted in 18 pulse types (PT), 12 sequence 
types, and 12 ribotypes. Multilocus sequence typing compared favourably with PCR-ribotyping 
for its discriminatory power, having an index of discrimination (ID) of 0.93 compared to 0.95 for 
PCR-ribotyping. However, PFGE was the most discriminatory with an ID of 0.96. Despite this, 
there was a high level of concordance between the three typing techniques. The sequence type, 
ST3, which corresponded to RT001 and RT072 was the most frequently isolated sequence type 
reported in this study accounting for 19.4% of isolates tested. All RT072 strains were isolated 
from elderly patients; however, these strains were not identical according to PFGE analysis. The 
second most frequently reported (11.6%) strain, ST46/RT087 was predominantly found in 
elderly patients with colon cancer. Multilocus sequence typing of C. difficile strains isolated 
from patient cohorts with increased risk of C. difficile infection was comparably discriminatory 
to the widely used PCR-ribotyping scheme. Multilocus sequence typing yielded easily 
interpretable and transferable results, allowing for rapid identification and typing of C. difficile 
in high risk patient groups. 
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4.2 Introduction:  
Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacillus, first described as the 
aetiological agent of pseudomembranous colitis in 1978 (Larson et al., 1978). With the 
widespread use of broad-spectrum antibiotics, C. difficile has increased in both prevalence, and 
severity worldwide, and is now recognized as causing virtually all cases of pseudomembranous 
colitis (Owens, 2007). C. difficile infection (CDI) is mediated by the production of two toxins - 
an endotoxin, toxin A and a cytotoxin, toxin B (Kelly et al., 1994) which cause a range of 
diseases from mild diarrhoea, to life-threatening pseudomembranous colitis. As an opportunistic 
pathogen, CDI typically occurs following disruption of the normal gut microbiota following 
antibiotic treatment (McFarland et al., 1989). C. difficile is also recognised as a significant 
nosocomial pathogen, responsible for the majority of cases hospital acquired diarrhoea (Aslam et 
al., 2005). In addition to antibiotic use and prolonged hospital stay, advanced age, 
chemotherapy, and gastric acid suppression medication have all been shown to increase the risk 
of CDI (Bignardi, 1998). C. difficile spores are highly resistant and can persist in the 
environment for long periods. Spores are spread by a faecal oral route, by person to person 
contact or through contact with contaminated surfaces (Weber et al., 2010). Patients with 
increased risk of acquiring C. difficile due to their comorbidity, or the treatment they receive 
may act as a reservoir for dissemination of C. difficile in hospitals or long stay care facilities.  
 There has been a rise in the incidence and severity of CDI globally since 2003, partially 
attributed to the emergence of a number of highly virulent strains, including ribotype 027 
(RT027). The highly virulent strain, RT027 was first identified in North America in 2003 during 
an outbreak of severe CDI (Pepin et al., 2004, Pépin et al., 2005). The severity of disease  
associated with this ribotype is speculated to be as a result of  production of binary toxin coupled 
with production of a hypertoxic and antigenically variable version of  toxin B (Warny et al., 
Lanis et al., 2013). It has subsequently become a major epidemic strain, frequently isolated in 
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hospitals across North America and Europe (O'Connor et al., 2009, Warny et al.). More recently, 
a second ribotype, RT078 has  also been associated with more virulent cases of CDI and it is 
notable in that in can cause disease in patients with no recent history of  antibiotic treatment or 
hospitalization (Goorhuis et al., 2008). Community acquisition of C. difficile from asymptomatic 
carriers has also been proposed after an association was observed between the presence of strains 
in a hospital with those found in the surrounding community (Angulo, 2007, Curry et al., 2013, 
Thompson, 2008). Cases of CDI are increasing in Europe and therefore active surveillance and 
reporting is important to control its spread and understand its changing epidemiology (Bauer et 
al., Benson et al., 2007, DePestel and Aronoff, 2013). Therefore there is a need for improved 
monitoring of C. difficile to better track and control CDI.  
 Multilocus sequence typing (MLST) has been proposed as a general genotyping 
procedure suitable for tracking the epidemiology of bacterial species, while providing accurate 
data which can easily be shared between laboratories (Maiden et al., 1998). The PCR based 
nature of MLST allows for it to be performed directly on DNA isolated from stool, thereby 
removing the need to culture, thus increasing the speed of strain identification (Griffiths et al., 
2010).  Multilocus sequence typing is performed by amplifying and sequencing several (7-10) 
housekeeping gene loci. Alleles at each locus are assigned an allele number, unique 
combinations of which designate a strain’s sequence type (ST). A number of clinically relevant 
bacterial species have been typed using MLST, including C. difficile (Griffiths et al., 2010, 
Lemee et al., 2004, Maiden et al., 1998). Based on MLST analysis, it has been established that 
C. difficile is distributed across five evolutionary clades, with sequence types from each clade 
being associated with CDI (Dingle et al., 2011, Griffiths et al., 2010, Mamoon A. Aldeyab et al., 
2011, Patterson et al., 2012, England, 2014). An extensive study into the relationship between C. 
difficile strains, host biomarkers, and mortality rates  in CDI using MLST was recently carried 
out by Walker et al, 2013 (Walker et al., 2013). In the study described here MLST was 
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compared to PCR-ribotyping and pulsed-field gel electrophoresis (PFGE) for its suitability as a 
typing scheme to track the epidemiology of C. difficile strains isolated from high risk patient 
groups in addition to identifying the distribution of C. difficile genotypes within these cohorts. 
To this end, a collection of 112 C. difficile strains isolated from a number of patient groups 
including people with inflammatory bowel disease, irritable bowel syndrome, cystic fibrosis, 
colon cancer, patients with CDI, as well as elderly persons (>65 y) and healthy volunteers were 
typed and compared using MLST and PCR-ribotyping, while a subset of 28 isolates were also 
typed using PFGE. 
 
4.3 Materials and methods 
 
Study populations and Bacterial strains 
A total of 112 C. difficile isolates were obtained from the Teagasc Food Research Centre (DPC) 
culture collection, the APC culture collection, Alimentary Pharmabiotic Centre, University 
College Cork, and the Eldermet culture collection, University College Cork. Isolates were 
routinely cultured on Fastidious Anaerobic agar (FAA) (Lab M, Lancashire, UK) supplemented 
with 7% defibrinated horse blood, at 37 ºC under anaerobic conditions. All strains were stocked 
on microbank beads (Pro-lab diagnostics, Cheshire, UK) and stored at -80ºC. 
 
PCR ribotyping (PCR-RT) 
Ribotyping was performed by the C. difficile Ribotyping Network for England (CDRNE), at the 
Microbiology Reference Laboratory, Leeds General Infirmary, United Kingdom. Strains were 
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analysed by capillary gel electrophoresis and compared to over 500 ribotypes housed in the 
CDRNE ribotype reference library. 
 
Pulsed field gel electrophoresis (PFGE)  
Isolates were sub-cultured from -80ºC stocks onto FAA Blood agar and grown for 48h 
anaerobically at 37ºC. Approximately 5 colonies were inoculated into 10ml of BHI broth which 
had previously been boiled and cooled under anaerobic conditions. Following overnight 
incubation 200µl was sub-cultured into a fresh 10ml of BHI broth and grown for ~5h at 37ºC. 
Genomic DNA was prepared in agarose plugs, lysed and subsequently digested with Sma1 as 
described previously (Janezic and Rupnik, 2010). Electrophoresis was performed using the 
Biorad Chef-DR II instrument and DNA macro-restriction profiles visualised using the Alpha 
Imaging system. DNA macro-restriction patterns were stored as TIFF files and imported into 
Bionumerics software (Version 3 Applied Maths, Kortrijk, Belgium) for dendrographic analysis. 
Salmonella Braenderup H9812 restricted with Xba1 at 37°C for 2h was used as a molecular 
weight marker for analysis using the Bionumerics software. Strains were assigned to the same 
pulse types (PT) if they had banding patterns of 95% similarity or greater. 
 
Multilocus sequence typing (MLST) 
Genomic DNA was extracted from isolates according to Rea et al (Rea et al., 2012). Briefly, five 
to six colonies from an overnight culture of C. difﬁcile grown on fastidious anaerobic agar 
containing 7% deﬁbrinated horse blood were resuspended in 200μl of 5% w/v Chelex-100 
(Sigma). Cell suspension was heated for 30min at 56°C, followed by 100°C for 8 min. Cell 
debris was removed by centrifugation at 16,000 x g for 3 min and supernatant containing DNA 
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was stored at -20˚C. Seven housekeeping genes (adk, atpA, dxr, glyA, recA, sodA and tpi) were 
amplified for MLST analysis using primers designed by Griffiths et al, 2010 (Griffiths et al., 
2010). PCR reaction mixtures (15μl) consisted of 5.5 μl molecular biology grade water 
(Millipore), 0.5 μl (10 pM) of each forward and reverse primer, 7.5 μl KAPA HiFi HotStart 
readymix (2x) and 1 μl of genomic DNA. As per manufacturer’s instructions, thermoycycler 
conditions outlined by Griffiths et al (Griffiths et al., 2010) were modified to accommodate the 
use of KAPA HiFi HotStart DNA polymerase, as follows; 95˚C for 5 min, followed by 35 cycles 
of 98˚C for 20 s, 57˚C for 30 s and 72˚C for 40 s, with a final extension of 72˚C for 5 min and 
storage at 10˚C. Amplicons were purified by enzymatic treatment with Exonuclease І 
(20units/μl) and Antarctic Phosphatase (5units/μl) (NEB,). Briefly, a (2x) reaction mixture of 
Exonuclease І, Antarctic Phosphatase, 10x Antarctic Phosphatase buffer and dH2O in a 1:1:1:17 
ratio respectively was added to an equal volume of PCR products, then incubated at 37˚C for 15 
min, followed by 80˚C for 15 min to deactivate the enzyme. Consensus sequencing of both DNA 
strands was performed using the amplication primers by Beckman Coulter Genomics (Hope 
End, Takeley Essex CM22 6TA, UK). Obtained housekeeping gene sequences for each strain 
were queried against the C. difficile MLST reference database (http://pubmlst.org/cdifficile/) and 
allele numbers assigned. Sequence types were assigned based on the combination of alleles 
corresponding to each strain. Reconstruction of evolutionary relationships was performed using 
the MEGA 5 package (Tamura et al. 2011). Concatenated MLST sequence data obtained from 
the MLST online database (http://pubmlst.org/cdifficile/) was used to construct a consensus 
neighbour joining tree from 500 bootstrapping replicates (Tamura et al., 2011) (Fig 4.2). 
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Detection of C. difficile toxin genes tcdA and tcdB.  
Pathogenicity potential of C. difficile isolates was screened for by PCR amplication of the toxin 
genes tcdA and tcdB using the primers designed by Terhes et al.(Terhes et al., 2004). Briefly, 
amplication of each gene was performed in a separate reaction mixture (25 μl) containing, 12.5 
μl Biomix Red (Bioline, London, UK), 0.5μl of each forward and reverse primer (tcdA or tcdB), 
2 μl template DNA and 9.5 μl H2O. Toxin genes were amplified by 30 cycles of 95°C for 20 s, 
62°C for 45 s, and 72°C for 45 s, followed by a final elongation of 72°C for 5 min. 
 
4.4 Results 
MLST, PCR-RT and PFGE typing of C. difficile isolated from different patient groups. 
Multilocus sequence typing of C. difficile has previously been shown to deliver rapidly 
generated, easily interoperable results without then need for an in-house strain library (Griffiths 
et al., 2010).  This makes MLST a more attractive typing scheme for high risk patient groups in 
a healthcare setting. Therefore to compare the type-ability of this typing scheme to established 
methods, MLST and PCR-ribotyping were applied to a collection of 112 human C. difficile 
isolates, while PFGE was applied to a subset of 28 isolates from elderly patients. These strains 
were previously isolated during a number of studies investigating the carriage of C. difficile in 
patient groups at increased risk of CDI or those with CDI (Clayton et al., 2009, Clayton et al., 
2012, Rea et al., 2012). Patient cohorts included those with inflammatory bowel disease, irritable 
bowel syndrome, cystic fibrosis, colon cancer, CDI patients, as well as elderly (>65 y) persons, 
and healthy volunteers. Two C. difficile type strains; C. difficile 630 and C. difficile VPI 10463 
were also included in this study. Genotyping resulted in a total of 28 sequence types and 33 
ribotypes. Pulsed field gel electrophoresis typing of a subset of 28 strains using yielded 18 pulse 
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types  compared to 12 sequence types and 12 PCR-ribotypes, which can be seen in fig. 4.1 
Pulsed field gel electrophoresis was more discriminatory than either PCR-RT or MLST 
revealing subtypes within sequence types and ribotypes. The 12 RT072/ST3 types included in 
the 28 strains typed by PFGE were subtyped into 4 separate PTs. However, these strains 
clustered together at 90% similarity indicating their relatedness (fig. 4.1). Similar observations 
were made for RT027/ST1 and RT216/ST33 strains which were subtyped into separate PTs 
(RT027/ST1 into PT1 and PT2 and RT216/ST33 into PT12 and PT13) while maintaining >90% 
similarity. Both RT308/ST37 strains typed by PFGE were 100% identical. 
 
Toxin production 
All strains included in this study were screened for toxin production capability by PCR 
amplification of the two toxin genes tcdA and tcdB. Toxigenic C. difficile harbouring both toxin 
genes accounted for 88.4% (n = 112) of strains tested. The remainder did not harbour either 
toxin gene and thus were considered non-pathogenic. No tcdA- / tcdB+ toxin variants were 
identified in this study, while strains were not screened for binary toxin. Toxin negative strains 
were typed as; ST15 (RT010), ST7 (RT026), ST26 (RT039, RT140) and ST31 (Unknown RT). 
Pathogenic and non-pathogenic C. difficile strains were distinct and did not share either sequence 
type or ribotype, however, they were not confined to a single MLST clade. 
 
Comparison of typing schemes for epidemiologic study. 
Thirty three distinct RTs, including one novel, previously un-described RT, belonging to ST 31, 
were included in this study. MLST compared quite favourably to PCR-RT for discrimination of 
C. difficile strains (index of diversity [ID] of 0.93 and 0.95 respectively) according to the 
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formula described by Hunter and Gaston (Hunter and Gaston, 1988).  However, for a subset of 
28 strains PFGE was found to be more discriminatory than either typing scheme (ID of 0.96 
compared to 0.80 for MLST and PCR-RT).  
 
Distribution of STs among study cohorts. 
The distribution of the most prevalent sequence types and their corresponding ribotype are 
detailed in table 4.2. The most prevalent sequence type reported was ST3, accounting for 19.6% 
of the strains tested. The twenty two ST3 strains consisted of one RT009, three RT001/072, 
seven RT001, and eleven RT072. All RT072/ST3 and RT001/072/ST3 strains were isolated 
from elderly persons while the seven RT001/ST3 and one RT009/ST3 strains were isolated from 
multiple sources. The eleven 072 strains from elderly patients were found to consist of multiple 
subtypes based on PFGE fingerprinting. This suggests the prevalence of this ribotype in elderly 
patients is not due to horizontal transfer of a single strain. The second most prevalent sequence 
type was ST46 accounting for 11.6% of strains tested. All ST46 strains were isolated from colon 
cancer patients. However likely, we cannot be certain these strains were acquired from a single 
source due to the lower discriminatory power afforded by MLST and PCR-ribotyping compared 
to PFGE. Likewise all seven toxin negative ST26 were solely found in CF patients but could not 
for certain be attributed to single source acquisition.  
 
4.5 Discussion 
This study was undertaken to assess the suitability of MLST as a typing scheme to track the 
epidemiology of C. difficile strains isolated from high risk patient groups in addition to 
identifying the distribution of C. difficile genotypes within these cohorts. Overall, MLST was 
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found to be comparable to PCR-ribotyping for discriminating C. difficile isolates yielding 28 
sequence types versus 33 PCR-ribotypes (ID of 0.93 and 0.95 respectively) from 112 isolates. 
This compares favourably to the discriminatory ability of MLST previously reported by Griffiths 
et al (ID of 0.90) (Griffiths et al., 2010). Contrary to a previous study by Kilgore et al, all three 
techniques could be interpreted with confidence (ID > 0.9) (Hunter and Gaston, 1988, Killgore 
et al., 2008). Pulsed field gel electrophoresis was found to be more discriminatory (ID = 0.96) 
than either PCR-ribotyping or MLST and could identify subtypes within primary types. 
Multilocus sequence typing and PCR-ribotyping on the other hand  could only identify primary 
types as has been reported previously (Killgore et al., 2008). There was good concordance 
between the three techniques for typing this subset of strains. Subtypes of MLST and PCR-
ribotype primary types identified by PFGE all shared >90% similarity indicating they were 
closely related, as can be seen in fig. 4.1. 
  The most common sequence type reported in this study was ST3 which consisted of two 
ribotypes, RT001 and RT072. C. difficile RT001 has previously been associated with CDI in 
Southern Germany and has been reported as one of the most frequently isolated ribotypes in the 
Netherlands (Borgmann et al., 2008, Hensgens et al., 2009). However, neither RT001 nor RT072 
have been reported in the top five ribotypes reported in Ireland between 2010 and the beginning 
of 2013 (Centre, 2013). Despite the fact that all RT072/ST3 strains were isolated from elderly 
patients (>65 years), it is unlikely they were all acquired from a single source due to the 
presence of multiple pulse types based on PFGE analysis. The second most prevalent sequence 
type was ST46 (RT087) which was predominantly found in patients with colon cancer. This 
sequence type also included the  C. difficile type strain VPI 10463 (ATCC 43255) which 
produces large amounts of toxin and is typically used as a positive control in tests for toxin 
production (Åkerlund et al., 2008). The emerging hyper-virulent strain, RT078 (Goorhuis et al., 
2008) was typed as ST11, the third most prevalent ST reported in this study. As well as RT078, 
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RT045 and RT126 also belong to the ST11 sequence type. While RT078 was reported in over 
10% of cases of CDI annually in Ireland between 2010 and 2013 (Centre, 2013), RT045 and 
RT126 are not frequently reported in humans, however, all three have frequently been isolated 
from animal sources (Burns et al., 2010, Indra et al., 2009, Schneeberg et al., 2013, Zidaric et al., 
2012). Therefore ST11 likely represents an emerging zoonotic C. difficile ST that evolved 
separately from the majority of human isolates, as evident from its outlying position in the 
MLST dendogram (fig. 4.2). All epidemic RT027 were typed as ST1 as previously described 
(Griffiths et al., 2010). Of the three RT027/ST1 strains typed by PFGE, two were identical (PT1) 
while the third (PT2) shared 94% similarity. With the exception of RT014 which was typed as 
both ST2 and ST14, all other ribotypes described in this study were associated with a single 
sequence type. 
 The distribution of C. difficile strains can vary both by region as well as time (Wilcox et 
al., 2012). All patients from which C. difficile strains were isolated were recruited from Cork 
hospitals and thus may not be indicative of the entire country. C. difficile strains were also 
isolated between 2006 and 2013. This may partially explain the difference in prevalence of C. 
difficile strains reported in this study to those reported in Ireland between 2010 and 2013 
(Centre, 2013). The majority of C. difficile strains included in this study were isolated from 
patients who were asymptomatic for CDI in contrast to strains reported in the Enhanced 
Surveillance of Clostridium difficile reports are likely from patients with active CDI. This may 
lead to a biased view of C. difficile strains in the community as only those resulting in CDI are 
likely to be reported. Asymptomatic carriers of C. difficile have been proposed as potential 
disease reservoirs as they have higher rates of skin and environmental contamination compared 
to non-carriers (Riggs et al., 2007, Kim et al., 1981, McFarland et al., 1989). However,  the exact 
contribution of asymptomatic carriers to the transmission of C. difficile is unknown (Eyre et al., 
2013). 
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 PCR-ribotyping in an established typing method widely used to tract the epidemiology of 
C. difficile in Europe. Its application coupled with mandatory case reporting was successful in 
stemming the increase in cases of CDI following years of steady rise in the UK. Previous issues 
surrounding pattern interpretation and reproducibility with PCR-ribotyping have been solved 
with the adaptation of high resolution capillary gel electrophoreses PCR-ribotyping (Indra et al., 
2008). However, identification of ribotypes still requires access to a collection of reference 
strains. The Braziers collection of 20 of the most common C. difficile ribotypes is available to 
reference laboratories in Europe, while the CDRNE collection at Leeds houses over 500 
ribotypes. In contrast, sequence data for MLST is freely available online from the C. difficile 
MLST database (http://pubmlst.org/cdifficile/), which is constantly updated. Contrary to PCR-
RT data, MLST sequence data is readily transferable, highly reproducible, and is easily 
interpreted (Knetsch et al., 2013). MLST may also be performed directly on DNA isolated from 
patient stool, removing the need to culture for C. difficile, greatly reducing diagnosis and 
identification time (Griffiths et al., 2010). While PFGE was the most discriminatory typing 
scheme reported in this study, its laborious nature and sometimes difficult to interpret data 
reduce its applicability in high risk patient groups. Despite the number of advantages MLST 
holds over PCR-ribotyping and PFGE, the high cost of sequencing multiple gene targets is still 
prohibitive to its wide scale adoption for typing C. difficile. However, with the rapid advances in 
sequencing technologies these costs are reducing annually. 
 In conclusion, MLST was found to be as effective as PCR-RT for typing C. difficile in 
patients with a high risk of CDI. Although both techniques would need to be combined with a 
more discriminatory typing technique such as PFGE or multilocus variable-tandem repeat 
analysis to study clonal distribution in an outbreak setting. 
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Figure 4.1 Dendrographic analysis of pulsed-field gel electrophoresis Sma 1 restriction 
profiles of C. difficile isolates with their corresponding PCR-ribotype and multilocus 
sequence type.  
 
Pulsed field gel electrophoresis was performed using the Biorad Chef-DR II instrument and DNA macro-restriction profiles visualised 
using the Alpha Imaging system. DNA macro-restriction patterns were stored as TIFF files and imported into Bionumerics software 
(Version 3 Applied Maths, Kortrijk, Belgium) for dendrographic analysis. Salmonella Braenderup H9812 restricted with Xba1 at 37°C 
for 2h was used as a molecular weight marker for analysis using the Bionumerics software. Strains were assigned to the same pulse 
types (PT) if they had banding patterns of 95% similarity or greater. 
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Figure 4.2 Dendrographic analysis of C. difficile sequence type along with their 
corresponding PCR-ribotype and presence of toxin genes.  
Sequence types were assigned based on the combination of alleles corresponding to each strain. Reconstruction of evolutionary 
relationships was performed using the MEGA 5 package (Tamura et al. 2011). Concatenated MLST sequence data obtained from the 
MLST online database (http://pubmlst.org/cdifficile/) was used to construct a consensus neighbour joining tree  from 500 bootstrapping 
replicates. Information to the right of the tree, details corresponding ribotype, toxin genes and the clade for each sequence type. 
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Table 4.1: Table of C. difficile strains, their source of isolation, ribotype and  
sequence type.  
Strain Source Ribotype Sequence type 
APC 1413 Cystic Fibrosis patient 014 ST 2 
APC 1402 Cystic Fibrosis patient 001 ST 3 
APC 1403 Cystic Fibrosis patient 001 ST 3 
APC 1408 Cystic Fibrosis patient 009 ST 3 
APC 1411 Cystic Fibrosis patient 001 ST 3 
APC 1426 Cystic Fibrosis patient 001 ST 3 
APC 1425 Cystic Fibrosis patient 005 ST 6 
APC 1399 Cystic Fibrosis patient 002 ST 8 
APC 1401 Cystic Fibrosis patient 126 ST 11 
APC 1405 Cystic Fibrosis patient 078 ST 11 
APC 1416 Cystic Fibrosis patient 045 ST 11 
APC 1421 Cystic Fibrosis patient 078 ST 11 
APC 1422 Cystic Fibrosis patient 126 ST 11 
APC 1398 Cystic Fibrosis patient 014 ST 13 
APC 1409 Cystic Fibrosis patient 010 ST 15 
APC 1428 Cystic Fibrosis patient 010 ST 15 
APC 1432 Cystic Fibrosis patient 356 ST 17 
APC 1400 Cystic Fibrosis patient 039 ST 26 
APC 1404 Cystic Fibrosis patient 140 ST 26 
APC 1406 Cystic Fibrosis patient 140 ST 26 
APC 1407 Cystic Fibrosis patient 140 ST 26 
APC 1418 Cystic Fibrosis patient 039 ST 26 
APC 1423 Cystic Fibrosis patient 140 ST 26 
APC 1429 Cystic Fibrosis patient 140 ST 26 
APC 1417 Cystic Fibrosis patient Unknown ST 31 
APC 1412 Cystic Fibrosis patient 046 ST 35 
APC 1414 Cystic Fibrosis patient 046 ST 35 
APC 1419 Cystic Fibrosis patient 046 ST 35 
APC 1420 Cystic Fibrosis patient 046 ST 35 
APC 1424 Cystic Fibrosis patient 011 ST 36 
APC 1430 Cystic Fibrosis patient 011 ST 36 
APC 1410 Cystic Fibrosis patient 015 ST 44 
APC 1431 Cystic Fibrosis patient 087 ST 46 
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APC 1415 Cystic Fibrosis patient 092 ST 48 
APC 1427 Cystic Fibrosis patient 092 ST 48 
EM 304 Elderly person Rehab 027 ST 1 
EM 306 Elderly person Rehab 027 ST 1 
EM 011 Elderly person Day 027 ST 1 
EM 156 Elderly person Long stay 220 ST 2 
EM 069 Elderly person Rehab 072 ST 3 
EM 112 Elderly person Long stay 072 ST 3 
EM 113 Elderly person Rehab 072 ST 3 
EM 124 Elderly person Long stay 072 ST 3 
EM 126 Elderly person Long stay 072 ST 3 
EM 139 Elderly person Long stay 072 ST 3 
EM 140 Elderly person Long stay 072 ST 3 
EM 148 Elderly person Rehab 072 ST 3 
EM 218 Elderly person Long stay 072 ST 3 
EM 243 Elderly person Long stay 072 ST 3 
EM 255 Elderly person Long stay 072 ST 3 
EM 286 Elderly person 001/072 ST 3 
EM 359 Elderly person 001/072 ST 3 
EM 420 Elderly person 001/072 ST 3 
EM 045 Elderly person Day 072 ST 3 
EM 321 Elderly person Rehab 026 ST 7 
EM 012 Elderly person Day 002 ST 8 
EM 308 Elderly person Rehab 078 ST 11 
EM 366 Elderly person 078 ST 11 
EM 136 Elderly person Long stay 014 ST 14 
EM 149 Elderly person Community 010 ST 15 
EM 152 Elderly person Rehab 050 ST 16 
EM 188 Elderly person Long stay 018 ST 17 
EM 324 Elderly person Rehab 216 ST 33 
EM 334 Elderly person Rehab 216 ST 33 
EM 336 Elderly person Community 216 ST 33 
EM 146 Elderly person Long stay 308 ST 37 
EM 186 Elderly person Long stay 308 ST 37 
EM 397 Elderly person 106 ST 42 
EM 426 Elderly person 013 ST 045 
EM 436 Elderly person 087 ST 46 
EM 447 Elderly person 087 ST 46 
EM 501 Elderly Colon cancer patient 087 ST 46 
EM 503 Elderly Colon cancer patient 087 ST 46 
EM 504 Elderly Colon cancer patient 087 ST 46 
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EM 505 Elderly Colon cancer patient 087 ST 46 
EM 506 Elderly Colon cancer patient 087 ST 46 
EM 510 Elderly Colon cancer patient 087 ST 46 
EM 524 Elderly Colon cancer patient 087 ST 46 
EM 525 Elderly Colon cancer patient 087 ST 46 
EM 527 Elderly Colon cancer patient 087 ST 46 
APC 11 Healthy volunteer 026 ST 7 
APC 32 Healthy volunteer 018 ST 17 
APC 14 Healthy volunteer 062 ST 75 
APC 40 CDI patient 001 ST 3 
APC 24 CDI patient 001 ST 3 
APC 25 CDI patient 018 ST 17 
APC 26 CDI patient 018 ST 17 
APC 27 CDI patient 106 ST 42 
APC 28 CDI patient 106 ST 42 
APC 41 CDI patient 308 ST 37 
APC 34 Irritable bowel syndrome patient 005 ST 6 
APC 35 Irritable bowel syndrome patient 050 ST 16 
APC 36 Irritable bowel syndrome patient 050 ST 17 
APC 37 Irritable bowel syndrome patient 060 ST 28 
APC 38 Irritable bowel syndrome patient 005 ST 38 
APC 39 Irritable bowel syndrome patient 050 ST 104 
APC 16 Inflammatory bowel disease patient 027 ST 1 
APC 17 Inflammatory bowel disease patient 001 ST 3 
APC 10 Inflammatory bowel disease patient 005 ST 6 
APC 9 Inflammatory bowel disease patient 005 ST 6 
APC 29 Inflammatory bowel disease patient 078 ST 11 
APC 3 Inflammatory bowel disease patient 003 ST 12 
APC 6 Inflammatory bowel disease patient 020 ST 13 
APC 4 Inflammatory bowel disease patient 010 ST 15 
APC 29 Inflammatory bowel disease patient 050 ST 42 
APC 5 Inflammatory bowel disease patient 015 ST 44 
APC 7 Inflammatory bowel disease patient 015 ST 44 
APC 1 Inflammatory bowel disease patient 015 ST 44 
APC 2 Inflammatory bowel disease patient 015 ST 44 
APC 8 Inflammatory bowel disease patient 062 ST 75 
ATCC BAA-1382 , 630 Clinical isolate 012 ST 38 
ATCC 43255, VPI 10463 Abdominal wound 087 ST 46 
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Table 4.2: Table of most prevalent sequence types, their correspondine ribotypes, their 
source of isolaton and precentage of total strains. 
(a) 
Sequence 
type 
Ribotype % of 
strains 
Source 
ST3 RT001, RT009, 
RT072 
19.6 Elderly (14), CDI (2), CF(5), IBD (1) 
ST46 RT087 11.6 Colon cancer (11), CF (1), VPI10463 (1) 
ST11 RT045, RT078, 
RT126 
7.1 CF (5), Elderly (2), IBS (1) 
ST26 RT039, RT140 6.3 CF (7) 
ST17 RT018, RT050, 
RT356 
5.4 CDI (2), CF(1), Elderly (1), HV(1), IBS (1) 
ST1 RT027 4.5 EM (4), IBD (1) 
ST44 RT015 4.5 CF (1), IBD (4) 
    
 
EL = Elderly person, CF = Cystic fibrosis patient, CDI = C. difficile infection, 
IBS = Irritable bowel syndrome, IBD = Inflammatory bowel disease, HV = Healthy volunteer, CC = colon cancer. 
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Chapter 5 
Assessment of the bacteriophage ΦCD6356 and its 
biologically-active endolysin as novel antimicrobials 
targeting Clostridium difficile  
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5.1 Abstract 
Clostridium difficile infection is typically associated with the use of broad-spectrum antibiotics. 
Consequently, there is a need for the development of specific antimicrobials which target C. 
difficile but do not result in collateral effects on the microbiota. The C. difficile bacteriophage 
ΦCD6356 can proliferate in an ex vivo model of the human distal colon resulting in a 1.75 log 
reduction in viable C. difficile over 24 hours. However, due to its lysogenic nature, 100% of C. 
difficile surviving in the presence of ΦCD6356 were found to harbour prophage. The endolysin 
encoded by ΦCD6356 was cloned and expressed in Escherichia coli. This recombinant 
endolysin, LysCD, has lytic activity against heat-killed and live C. difficile cells. Crude LysCD 
was capable of reducing C. difficile by ~ 3 log units within 2 hours. The theoretical 3D structure 
of the endolysin was determined based on amino acid sequence homology to experimentally 
determined endolysins revealing zinc coordination at the endolysins active site. Endolysin lytic 
activity was eliminated by treatment with EDTA but activity was restored when zinc and other 
divalent metal ions were reintroduced. The endolysin also retained activity after heating to 90ºC 
for 5 min. 
 
5.2 Introduction: 
Clostridium difficile is an opportunistic enteric pathogen which causes a wide range of disease, 
from mild diarrhoea to pseudomembranous colitis (Knoop et al., 1993). C. difficile infection 
(CDI) commonly occurs following antibiotic therapy and as such is thought to be the result of 
altering the innate protection afforded by the intestinal microbiota (Bibbò et al., 2014). Indeed, 
C. difficile is responsible for causing between 15 and 25% of cases of antibiotic associated 
diarrhoea (AAD) worldwide (Bartlett, 2002). The organism can form extremely resistant spores 
that can persist for long periods in the environment. This, coupled with its resistance to heat and 
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antiseptic cleaners has allowed C. difficile to become particularly  problematic in hospitals and 
rest homes, where it has emerged as a major cause of nosocomial diarrhoea (Weber et al., 2010). 
Outbreaks of CDI can be extremely costly for healthcare providers with the average case costing 
between $9179 and $11 456 (McGlone et al., 2012). Clostridium difficile infection is typically 
treated with either metronidazole or vancomycin; however, treatment failure is common with a 
failure rate of 22.4% and 14.2% associated with these two antibiotics respectively (Vardakas et 
al., 2012). Relapse after treatment is also common and is likely due to failure of the enteric 
microbiota to recover following treatment with these broad spectrum antibiotics (Vardakas et al., 
2012). This highlights the need for highly effective therapeutics with a narrow spectrum of 
inhibition to target C. difficile while leaving the majority of the intestinal microbiota 
undisturbed. Bacteriophage (bacterial viruses) and the endolysins they produce may offer such a 
solution. 
 While there are two types of bacteriophage replication cycle, lytic and lysogenic, C. 
difficile bacteriophage are typically lysogenic. Lytic bacteriophage replicate in the host then lyse 
the host cell wall releasing new progeny. While lysogenic bacteriophage can do likewise, they 
can also insert into the host genome and replicate with the host as a prophage (Adams, 1959). 
Bacteriophage therapy was first trialled in 1919, however, was mostly abandoned after the 
introduction of antibiotics in the 1930’s (Wittebole et al., 2013). There has been a resurgence of 
interest in bacteriophage therapy in recent times with the emergence of antibiotic resistance. The 
effectiveness of bacteriophage for treating C. difficile induced ileocecitis was demonstrated by 
Ramesh et al, 1999 (Ramesh et al., 1999) in a hamster disease model. The authors reported 
recovery of all but one animal after bacteriophage treatment while all animals in the control 
group died within 96 hours (Ramesh et al., 1999). C. difficile bacteriophage have also 
demonstrated their effectiveness in preventing growth and toxin production by C. difficile in a 
batch fermentation model of the human distal colon. Prophylactic treatment with bacteriophage 
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at a multiplicity of infection (MOI) of 10 eliminated all C. difficile after 48 hours. At an MOI of 
7 the authors reported prevention of growth and reduction in toxin production (Meader et al., 
2010).  
 Recombinant bacteriophage endolysins have also been demonstrated as effective narrow 
spectrum antimicrobials against a number of human pathogens (Daniel et al., 2010, Fenton et al., 
2010, Lim et al., 2012, Mayer et al., 2008, Son et al., 2012). An endolysin is a bacteriophage 
encoded cell wall hydrolase required to cleave the host cell wall, allowing for release of 
bacteriophage progeny (Young, 1992). Recombinant endolysins have also been assessed as 
potential treatment for CDI. Mayer and colleagues achieved rapid lysis of C. difficile in vitro 
using the recombinant endolysin CD27L (Mayer et al., 2008).  
The study reported here was undertaken to assess the efficacy of the bacteriophage ΦCD6356 
and its recombinant endolysin, LysCD as potential treatments for CDI.  
 
5.3 Materials and Methods 
 
Bacterial and bacteriophage culture 
All C. difficile strains used in this study were obtained from the DPC (Dairy Production Centre, 
Teagasc Food Research Centre, Moorepark, Cork, Ireland) culture collection including DPC 
6356 from which the bacteriophage ΦCD6356 was induced (Horgan et al., 2010). C. difficile 
strains were routinely sub-cultured onto Fastidious Anaerobic Agar (FAA) (Lab M Lancashire, 
UK) containing 7% defibrinated horse blood and grown anaerobically in a Don Whitley 
anaerobic chamber at 37˚C. Bacteriophage ΦCD6356 was propagated in early log phase cultures 
and concentrated to a high titre as described previously (Alemayehu et al., 2009, Horgan et al., 
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2010, Moineau et al., 1994). Phage numbers were routinely estimated by plaque assay using 
0.7% Brain Heat Infusion (BHI) agar seeded with 2% overnight culture of C. difficile overlaid 
onto a 1.5% BHI agar base. The spectrum of infection of the bacteriophages was assessed by 
plaque assay on 40 human C. difficile isolates housed in the DPC collection here at Teagasc 
Food Research Centre, Moorepark. Escherichia coli XL1-Blue was grown in Luria broth 
(Merck, Darmstadt Germany) shaking (160 rpm) at 37˚C.  
 
DNA isolation and PCR analysis for prophage 
Genomic DNA was isolated from C. difficile strains recovered from fermentation vessels as 
described by Rea et al (Rea et al., 2012). C. difficile isolates were suspended in 5% w/v chelex-
100 resin and heated to 56 ºC for 30 min followed by 100 ºC for 8 min. The cell suspension was 
then centrifuged at 16,000 x g for 3 min to remove cell debris. The resulting supernatant was 
used as the template DNA for subsequent PCR reactions. Phage DNA was isolated by phenol-
chloroform extraction as described by Moineau, et al (Moineau et al., 1994). Prophage was 
detected by PCR amplication with primers designed to amplify the three structural genes, 
namely the putative major capsid protein A (ORF 5), the putative phage tail protein (ORF 16), 
and the N-acetylmuramoyl-L-alanine amidase endolysin (ORF 28). Primers, product size, and 
annealing temperature are outline in Table 5.1. Isolates were deemed to harbour the prophage if 
all three structural genes were present. All C. difficile strains (40) held in the DPC culture 
collection were also screened for prophage carriage by PCR.  
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Efficacy of the bacteriophage ΦCD6356 in treating C. difficile infection 
Batch fermentations modelling the human distal colon were performed as described by Rea et al 
(Rea et al., 2011). Briefly, the fermentation medium was prepared according to Fooks and 
Gibson,  2003 (Fooks and Gibson, 2003). Fermentation vessels from the Multifors fermentation 
system (Infror UK), containing fermentation media (160ml) were autoclaved at 121˚C for 15 
min. The pH of the media was adjusted to 6.8 and the pH maintained throughout the experiment 
by addition of HCl (1M) and NaOH (1M). Nitrogen was sparged through the fermentation media 
for at least 2h prior to inoculation to remove oxygen and create an anaerobic environment. The 
system was run under anaerobic conditions by sparging continuously with N2. A composite 
faecal sample was prepared by combining fresh faecal samples obtained from two healthy 
donors aged between 21 and 45 years old who had not received antibiotics in the previous three 
months and who tested negative for carriage of C. difficile. Composite faecal samples were 
diluted in pre-reduced 50 mM phosphate buffer (pH 7.2) and homogenised by stomaching for 1 
min at high speed to achieve a 20% w/v suspension. The resulting faecal slurry (35ml) was 
inoculated into each fermentation vessel along with 2ml of an overnight culture of C. difficile 
DPC 6219 (ribotype 001) (1x 106 CFU/ ml final concentration) as well as 1ml of CaCl2 (1M). 
Two ml bacteriophage (1x 108 PFU/ml) suspended in 0.1M ammonium acetate was added to the 
experimental vessels, while 2 ml of ammonium acetate (0.1M) was added to the control vessels. 
Batch fermentations were run for 24h and maintained at 37 ºC pH 6.8. Samples were taken at 2, 
4, 6, 8, and 24 h time to estimate the numbers of viable C. difficile and bacteriophage. Samples 
were serially diluted 10-fold in pre-reduced maximum recovery diluent (MRD) and plated on 
Cefoxitin-Cycloserine Egg-Yolk (CCEY) agar for counting C. difficile or filter sterilized and 
used for plaque assay as described above. Plates were incubated anaerobically at 37˚C for 48h, 
after which cell and plaque counts were made. To determine if bacteriophage entered the 
lysogenic phase during infection, 5 colonies of C. difficile from the highest countable dilution 
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were selected from CCEY plates from each vessel prior to inoculation with bacteriophage at 0h 
and again at hour 24h. DNA was extracted and screened for prophage structural genes by PCR 
amplification. 
 
Sub-cloning of bacteriophage endolysin gene into E. coli 
The endolysin gene (ORF 28) of bacteriophage ΦCD6356 described by Horgan et al (Horgan et 
al., 2010), here after referred toas lyscd, was amplified from genomic DNA using primers 
designed to introduce an NcoI restriction site at the 5’ end (5’- 
ATATCCATGGAGGTTGTACTAACAGCAG -3’ where underlining indicates restriction site) 
and a BglII site downstream of the coding site (5’- 
CCCAGATCTTTTCTTAATAAAATCTAATACT -3’). Amplicons were restriction digested 
with NcoI and BglII, then ligated into the expression vector pQE-60 (Qiagen) using T4 DNA 
ligase (NEB). The resulting construct, pQE-60lyscd, was transformed into chemically competent 
E. coli XL1-Blue and selected for by ampicillin (100μg/ml). Endolysin gene was identified by 
restriction analysis of the vector using NcoI and BglII and PCR amplication with lyscd primers.  
 
Protein expression 
The endolysin was induced by addition of 1mM isopropyl β-D-thiogalactopyranoside (IPTG) to 
a culture of E. coli XL1-Blue.(pQE-60lyscd) at an optical density (600nm) of 0.3, followed by 
incubation at 26ºC for 14h to avoid inclusion bodies as previously described (Horgan et al., 
2009). Bacterial cells were suspended in TN buffer (20 mM Tris-HCl, pH 8.0, 50 mM NaCl) and 
disrupted by four rounds of bead beating with 0.1mm acid washed beads (Sigma) with 1min on 
ice between 1min bursts. Cell debris was removed by centrifugation at 16,000 x g x 20 min 
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followed by filter sterilization using a 0.45 μM pore filter (Merck Millipore, Darmstadt, 
Germany). His-tagged endolysin was partially purified under native conditions using the 
HisTrap FF system (GE healthcare). Protein was eluted in 20mM sodium phosphate, 500 mM 
NaCl, 500 mM imidazole, pH 7.4. Protein lysate and partially purified endolysin were stored at -
20ºC until required. 
 
SDS-PAGE and Zymogram analysis 
Lytic activity of the crude endolysin preparation was visualized by zymogram analysis. 
Zymograms were prepared by incorporating a 20-fold concentration of heat killed (100ºC for 10 
min) mid log phase C. difficile DPC 6219 cells into a 12% SDS-PAGE as described by Donovan 
et al (Donovan et al., 2006). Briefly, zymograms were run in parallel with a sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, with the same gel mix used 
for both. A mid–log phase culture of C. difficile in 100ml of BHI broth was centrifuged at 
16,000 x G for 5 min to remove cells. The resulting pellet was washed once in sterile distilled 
water and harvested by centrifuging again before being heated to 100 ˚C for 10 min to kill the 
target cells. Cells were resuspended in 5 ml of the zymogram gel mix prior to the addition of 
TEMED (N,N,N’,N”-tetramethylethylenediamine). Gels were run at 100 V for 2h in a Bio-Rad 
Mini-PROTEAN 3 gel apparatus. Zymograms were washed in distilled water and incubated 
overnight in 2.5% Triton X-100 solution. SDS-PAGE gels were stained with comassie blue. 
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Generation and analysis of a model for ɸCD6356 lysin. 
A model for ɸCD6356 lysin, LysCD, was built using MODELLER (Sali and Blundell, 1993) 
with the amidase domain of the endolysin CD271 (3QAY) as the template structure (Mayer et 
al., 2011). 
 
Effect of EDTA and requirement of divalent ions on endolyisn activity. 
The effect of divalent ions on endolysin activity was determined as previously described 
(Schmelcher et al., 2012b). Endolysin was incubated with 50 mM ethylenediaminetetraacetic 
acid (EDTA), a chelating agent, for 15mins at room temperature to remove metal ions. EDTA 
was removed by passing the sample through an Amicon® Ultra-15 3K filter (Millipore). The 
resultant protein extract was then re-suspended in TN buffer (10 mM Tris-HCl pH 7.6, 10 mM 
NaCl). The EDTA treated endolysin was tested for lytic activity by zymogram with and without 
the addition of metal ions (ZnCl2, MgCl2, MnCl2 or CaCl2, at concentrations of 1mM or10 
mM). The addition of 10 mM Zn2+ resulted in precipitation and therefore was not tested.  
 
Activity of endolysin against live C. difficile 
C. difficile were grown to mid-log phase (OD 600nm 0.6), then harvested and re-suspended in 
pre-reduced MRD to an OD 600 of ~1.2.Washed C. difficile cells (200μl) were incubated with 
protein extract (300 μg final concentration) in TN buffer (100μl)  from induced or uninduced E. 
coli for 2 h anaerobically at 37 ºC. Following incubation C. difficile were 10-fold serially diluted 
and plated on pre reduced BHI agar to enumerate surviving cells. 
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5.4 Results 
The association of C. difficile with antibiotic associated diarrhoea (Bartlett, 2002) as well as the 
emergence of metronidazole resistant and vancomycin insensitive strains (Peláez et al., 2002) 
has led to increased interest in narrow spectrum antimicrobials with activity against C. difficile. 
Therefore we investigated the C. difficile bacteriophage ΦCD6356 and its associated endolysin 
for their ability to kill C. difficile. 
 
Bacteriophage spectrum of inhibition and prophage carriage 
The spectrum of infection of ΦCD6356 was examined by plaque assay against 40 human C. 
difficile isolates housed in the DPC culture collection (Table 5.2). The bacteriophage was 
capable of forming plaques on 11 of 40 strains, including ribotype 078 (1) and ribotype 001(3) 
which are typically associated with CDI (Goorhuis et al., 2008b, Borgmann et al., 2008). C. 
difficile isolates were also examined for carriage of prophage by PCR amplication of phage 
structural genes. Prophage was detected in 6 of 40 isolates tested, including DPC6356 (ribotype 
005) from which the phage was originally induced. Not surprisingly, lysogenic strains were not 
susceptible to infection by the bacteriophage. Prophage was not detected in C. difficile DPC6219 
which was used in the ex vivo model of the distal colon. Isolates harbouring prophage were 
identified as ribotype 106(1), 005 (2), 050 (3).  
 
Efficacy of the bacteriophage ΦCD6356 in treating C. difficile infection 
A model of the human distal colon was used to assess the efficacy of using the bacteriophage 
ΦCD6356 to treat C. difficile infection. Bacteriophage was added to the system at an MOI of 1 
(1x 106 PFU/ml) resulting in a highly significant (P= <0.001) nearly 2-fold reduction in the 
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recovery of C. difficile relative to control vessels at 24 h. A 1.75 log reduction in C. difficile was 
observed over 24 h following a single dose of bacteriophage at an MOI of 1. Rapid proliferation 
of bacteriophage was observed between hour 2 and 4 for the experiment 6 (fig. 5.1B), which 
preceded a sharp decline in C. difficile after 4 hours (fig. 5.1A). Bacteriophage increased rapidly 
during active growth of C. difficile, however, this seemed to cease as C. difficile reached its 
stationary phase at hour 6 (fig. 5.1B).  
 To assess the frequency to which bacteriophage may enter the lysogenic life cycle during 
treatment; five isolates from each vessel were examined for prophage by PCR. Prophage 
carriage was defined by PCR amplication of three phage structural genes from the genomic 
DNA of C. difficile isolates. Prophage was not detected in any C. difficile isolated before the 
addition of bacteriophage or from control vessels. However, prophage was detected in 100% of 
C. difficile isolated from bacteriophage treated vessels at 24 h following bacteriophage 
treatment. 
 
Cloning and expression of the biologically active endolysin in E. coli 
The gene encoding the ΦCD6356 bacteriophage endolysin lyscd was successfully cloned and 
expressed with a six–histidine tag in E. coli under IPTG induction. The ~31 kDa endolysin was 
visible in protein lysate of induced E. coli XL1-Blue(pQE-60lyscd) on SDS-PAGE, but not in 
uninduced lysate. The identity of the endolysin was confirmed by zymogram run in parallel with 
an SDS-PAGE (fig 5.3). Zones of clearing in the zymogram corresponded with the size of the 
endolysin. Partial purification of the endolysin was achieved using the HisTrap FF system 
however; endolysin activity was highly unstable in partially purified fractions. For this reason all 
further experiments were carried out using crude protein extracts. 
131 
 
Generation and analysis of a model for ɸCD6356 lysin 
A model for ɸCD6356 lysin, LysCD, was built using MODELLER (Sali and Blundell, 1993) 
with the amidase domain of the endolysin CD27l (3QAY) as the template structure (Mayer et al., 
2011) (fig. 5.4). Sequence comparisons of the amidase domains from ɸCD6356 and CD271 
indicated there were 69 identities between the two sequences and these were distributed along 
the length of the domain(51% identity overall). Critically, this analysis showed conservation of 
key residues in ɸCD6356 which had previously been implicated in the activity of CD27l (Mayer 
et al., 2011). 
 
 The model of the ɸCD6356 amidase domain shows a typical αβ amidase fold with a 
central six stranded mixed β-sheet flanked by five α-helices (Fig. 5.4). The RMSD Cα for 
superposition of the ɸCD6356 amidase on the CD27l amidase is 0.975 Å. Two loops in the 
ɸCD6356 amidase domain are truncated (labelled Loop I and Loop II in Fig. 5.4) with respect to 
the CD27l template. This is a result of deletion of 2 and 5 residues in the ɸCD6356 amidase 
domain sequence respectively. The active site of the amidase domain found in many 
bacteriophage endolysins is composed of two conserved His residues (His9 and His 84 in 
CD271) and a conserved Glu residue (Glu26 in CD271) which are involved in coordination of 
the catalytic Zn atom (Mayer et al., 2011). The three catalytic residues are augmented by a Glu 
(Glu144 in CD271) which is proposed to act as a proton acceptor during catalysis (Mayer et al., 
2011, Korndorfer et al., 2006). All four residues are conserved in the ɸCD6356 amidase domain 
(His9, His77, Glu24, and Glu 137 respectively) (Fig. 5.6). The solvent exposed nature of the 
active-site cleft in the ɸCD6356 model is consistent with the conformation found in other 
endolysin amidase domains (Korndorfer et al., 2006, Mayer et al., 2011, Yang et al., 2012, 
R.Zhang, 2008, T.Yamane, 2003). The rim of the active site cleft has electropositive character 
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while the region immediately proximal to the catalytic residues has electronegative character 
which is similar to the structure of CD27l (Fig. 5.5). As previously described this distribution in 
charge character was seen in the CD27l amidase domain (Mayer et al., 2011) and has been 
proposed to serve a role in allowing the enzyme’s active site to access its buried substrate.   
 Two other key features of the solved CD27l amidase are preserved in the ɸCD6356 
amidase. There is a series of conserved residues (Asn 86, Glu 96 and Arg 122 in CD271) which 
has been mooted as a proton relay system to the proton accepting Glu (Glu 144 in CD271) in the 
amidase active site (Korndorfer et al., 2006, Mayer et al., 2011, T.Yamane, 2003). These 
residues are present and conserved in the ɸCD6356 model (Asn 79, Glu 91 and Arg 117) (Fig. 
5.5), and in line with the conservation between this model and the CD271 template residue Ile93 
in the ɸCD6356 model corresponds to residue Leu98 of CD27l. This residue is of significance as 
it is part of a spatial cluster of three residues in CD27l proposed to interact with the substrate. 
The additional residues are Leu130/Tyr131 in CD27l, and Leu126/Tyr127 in the ɸCD6356 
model (Fig. 5.5). Studies on the CD27l enzyme have shown that mutation of the Leu98 residue 
to a Trp, analogous to the PlyPSA enzyme, enhanced the activity of the mutant enzyme towards 
cells targeted by the PlyPSA enzyme, i.e. enhanced lysis of Listeria monocytogenes (Mayer et 
al., 2011). 
 
Effect of EDTA and requirement of divalent ions on endolysin activity 
To determine whether zinc was required for lytic activity, EDTA treated and untreated endolysin 
with reintroduced divalent ions were tested for activity using a zymogram. A short treatment of 
15 min with the chelating agent EDTA (50mM) was sufficient to completely remove lytic 
activity. Lytic activity was restored by addition of either 1mM or 10mM of each divalent ion 
(MgCl2, MnCl2 or CaCl2), in the case of ZnCl2 only 1mM was tested.  
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Endolysin kills live C. difficile 
To assess whether the endolysin was capable of lysing live cells, crude LysCD was assayed 
against mid-log phase C. difficile at 37ºC, under anaerobic conditions. Protein extract from 
uninduced E. coli was used as a control. Crude LysCD reduced C. difficile by ~3 logs in 2 hours 
compared to uninduced protein extract (Fig 5.2). 
 
5.5 Discussion 
In this study, we evaluated the bacteriophage ΦCD6356 and its associated recombinant 
endolysin, LysCD for their potential as therapeutics for CDI. The bacteriophage ΦCD6356 was 
examined using an ex vivo model of the human distal colon as previously described (Meader et 
al., 2010, Rea et al., 2011). We demonstrated that a single dose of the bacteriophage at an MOI 
of 1 was sufficient to significantly reduce the number of viable C. difficile by 1.75 log units 
within 24 hours. Previous studies have also demonstrated the effectiveness of a single dose of 
bacteriophage in treating infection (Ramesh et al., 1999, Smith and Huggins, 1982). In fact, 
Ramesh and colleagues found a single dose of bacteriophage (108 PFU) to be sufficient to treat 
hamsters with C. difficile induced ileocecitis. Following 96h, the majority of bacteriophage 
treated hamsters had survived while all control hamsters had died (Ramesh et al., 1999). This is 
likely due to the rapid proliferation of bacteriophage in situ (Smith and Huggins, 1982) as was 
observed in our experiment (fig. 5.1 B). Bacteriophage increased by 1 log preceding the rapid 
reduction in C. difficile as can be seen in graphs 5.1 A and 5.1 B. In a similar experiment, 
Meader et al found that not only did bacteriophage treatment reduce the number of viable C. 
difficile but also prevented toxin production (Meader et al., 2010). As C. difficile have been 
reported to be excreted at between 107 and 109 CFU/g of faeces (Mutters et al., 2009), a 
reduction of 1.75 log units coupled with prevention of toxin production may be sufficient to 
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alleviate symptoms of CDI. In the study by Meader et al they found that by increasing the MOI 
from 7 to 10 resulted in complete elimination of C. difficile after 48 hours (Meader et al., 2010). 
 Typically, the use of lysogenic bacteriophages is not efficacious for bacteriophage 
therapy due to their potential to relysogenise, and thus conferring immunity to the host against 
further infection (called “super infection”). A PCR screen for prophage structural genes 
identified the prophage in all C. difficile recovered from bacteriophage treated vessels but none 
were found in those from control vessels. A similar observation was made by Meader et al after 
treatment with the bacteriophage ΦCD27. Following the 48 hour treatment, bacteriophage was 
present in 100% of surviving C. difficile isolates as evident by induction of bacteriophage using 
mitomycin C (Meader et al., 2010). As well as conferring immunity on the host, prophage have 
also been associated with horizontal gene transfer between bacteria (Casjens, 2003). Prophage 
have also been linked to increased toxin production in hyper-virulent C. difficile ribotype 027 
strains (Sekulovic et al., 2011). Prophage carriage has also been cited as a possible reason for the 
narrow host range of most C. difficile bacteriophages (Ramesh et al., 1999, Raya et al., 
2006).While ΦCD6356 was only lytic against 11 of 40 strains tested; this included two ribotypes 
frequently associated with CDI, 001 and 078 (Borgmann et al., 2008, Goorhuis et al., 2008a). 
This is encouraging as ribotype 001isolates with reduced susceptibility to metronidazole have 
been reported (Baines et al., 2008) and 078 is emerging as a new hyper-virulent strain (Goorhuis 
et al., 2008a). However, due to the lysogenic nature of ΦCD6356 it would not make a suitable 
treatment for CDI. Therefore, the focus of this research shifted towards the bacteriophages 
endolysin (probable N-acetylmuramoyl-l-alanine amidase ORF 28), previously described by 
Horgan et al (Horgan et al., 2010).   
The endolysin, designated LysCD was cloned into E. coli XL1 Blue and expressed by induction 
with IPTG. N-acetylmuramoyl-l-alanine amidase endolysins have previously been reported in C. 
difficile bacteriophages ΦCD27 and ΦCD119 (Govind et al., 2006, Mayer et al., 2008), however 
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these only share 51% and 41% identity to LysCD, respectively. This is likely due to ΦCD27 and 
ΦCD119 belonging to the myoviridae family and ΦCD6356 belonging to the siphoviridae 
family of viruses (Govind et al., 2006, Horgan et al., 2010, Mayer et al., 2008). Crude protein 
extracts containing recombinant endolysin displayed lytic activity against live and heat killed C. 
difficile DPC6219 in vivo. Unfortunately, lytic activity was quickly lost after partial purification, 
and therefore further work needs to be done to stabilize endolysin activity.  
 A model for ΦCD6356 lysin, LysCD, was built using MODELLER (Sali and Blundell, 
1993) with the amidase domain of the endolysin CD271 (3QAY) as the template (Mayer et al., 
2011). This revealed the presence of zinc coordination at the enzymes catalytic domain. 
Removal of zinc by treatment with EDTA eliminated the lytic activity of the endolysin. 
Reintroduction of zinc as well as other divalent metal ions (Mn2+, Mg2+and Ca2+) to EDTA 
treated endolysin restored lytic activity. This flexibility in divalent ions has been reported 
previously in other bacteriophage endolysins (Schmelcher et al., 2012b, Son et al., 2012). In fact, 
Schmelcher et al reported a 2.4 fold increase in activity relative to control after addition of 1 mM 
Mn2+, and thus this could be exploited to increase lytic activity of LysCD (Schmelcher et al., 
2012b).  
 Endolysins have been reported to have similar if not broader host range than that of 
parent bacteriophage while still specifically targeting bacteria within the species or genera 
(Horgan et al., 2009, Mayer et al., 2008, O'Flaherty et al., 2005, Schmelcher et al., 2012a). 
Endolysins have also been shown to have rapid action at relatively low concentrations. To date 
resistance against endolysins has not yet been reported (Schmelcher et al., 2012a).  
 Therefore, while the bacteriophage ΦCD6356 is not suitable for bacteriophage therapy 
due to its lysogenic nature, its cloned, biologically active endolysin, LysCD has demonstrated 
potential as a novel narrow spectrum antimicrobial for the treatment of CDI.  
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Table 5.1: PCR primers, annealing temperatures and product size 
 
 
 
Gene Primer Annealing temperature (ºC) Product size (bp) 
Endolysin LysCD 
(ORF 28) 
F   5’- ATATCCATGGAGGTTGTACTAACAGCAG 
R  5’- CCCAGATCTTTTCTTAATAAAATCTAATACT 
56 804 
Major capsid protein A 
(ORF 5) 
F    5’- GCTGACAGGGCGATACTTGA 
R    5’- CCAGCTGACCCAATTCCCAT 
57 809 
Phage tail protein  
(ORF 16) 
F    5’- TTGCTTTGTGGGTTGGTGAC 
R   5’- ACACCCCCAAATAAAGCGGAT 
57 435 
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Table 5.2: C. difficile strains examined for prophage carriage and susceptibility to infection 
with bacteriophage ΦCD6356. 
 
 
 
 
 
 
  
Strain Source Ribotype Prophage Infection 
DPC6219 CDI patient 001 - + 
DPC6538 Inflammatory bowel disease patient 001 - + 
DPC6534 Irritable bowel syndrome patient 001 - + 
DPC6510 Irritable bowel syndrome patient 005 - - 
DPC6514 Irritable bowel syndrome patient 005 - - 
DPC6353 Ulcerative colitis patient 005 - - 
DPC6355 Ulcerative colitis patient 005 + - 
DPC6356 Ulcerative colitis patient 005 + - 
DPC6507 Crohns disease patient 010 - - 
ATCC BAA-1382 , 630 ATCC, Clinical isolate 012 - - 
DPC6360 Crohns disease patient 015 - - 
DPC6362 Crohns disease patient 015 - - 
DPC6357 Ulcerative colitis patient 015 - - 
DPC6358 Ulcerative colitis patient 015 - - 
DPC6220 CDI patient 018 - + 
DPC6221 CDI patient 018 - + 
DPC6366 Healthy adult 18 - + 
DPC6363 Crohns disease patient 020 - - 
DPC6505 Healthy adult 026 - - 
DPC6511 Irritable bowel syndrome patient 050 + - 
DPC6512 Irritable bowel syndrome patient 050 + - 
DPC6515 Irritable bowel syndrome patient 050 + - 
DPC6513 Irritable bowel syndrome patient 060 - - 
DPC6361 Crohns disease patient 062 - - 
DPC6506 Healthy adult 062 - + 
DPC6359 Ulcerative colitis patient 078 - + 
ATCC 43255, VPI 
10463 
ATCC, Abdominal wound 087 - - 
DPC6350 CDI patient 106 - - 
DPC6351 CDI patient 106 - - 
DPC6539 Inflammatory bowel disease patient 106 + - 
DPC6535 CDI patient 308 - - 
ATCC 43600 ATCC, antibiotic-associated colitis N/A - + 
ATCC 43593 ATCC, Human faeces N/A - - 
DPC6535 CDI patient N/A - - 
DPC6365 Irritable bowel syndrome patient N/A - - 
DPC6365 Irritable bowel syndrome patient N/A - + 
DPC6508 Ulcerative colitis patient N/A - + 
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Figure 5.1 (a): C. difficile counts in control and bacteriophage treated fermentation vessels 
over 24h. 
A.  
 
Figure 5.1 (b): Bacteriophage ΦCD6356 counts in bacteriophage treated vessels over 
24hours.  
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Figure 5.2: Graph of the reduction in C. difficile numbers after 2hours incubation with the 
endolysin, LysCD. 
 
Mid-log phase C. difficile cells were incubated at 37ºC, under anaerobic conditions with crude protein extract from 
uninduced (control) and induced E. coli XL1-Blue (pQE-60lyscd) for 2h. Viable C. difficile were estimated by plate 
count on BHI agar.This experiment was performed in triplicate on two separate days. 
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Figure 5.3: SDS-PAGE of endolysin LysCD and LysCD His6x and corresponding zones of 
clearing in a zymogram gel containing heat killed C. difficile DPC 6219. 
  
 
 
 
 
 
SDS-PAGE lanes from left to right: Lane 1, molecular weight marker; lane 2, uninduced E. coli protein extract of 
histidine tagged endolysin clone; lane 3, uninduced E. coli protein extract of untagged endolysin clone; lane 4, 
induced E. coli protein extract of histidine tagged endolysin clone; Lane 5, induced E. coli protein extract of 
untagged endolysin clone. Zymogram was run in parallel with SDS-PAGE and lanes correspond to their equivalent 
numers in the SDS-PAGE gel. Square boxes indicate the endolysin bands in both SDS-PAGE and zymogram gels. 
 
 
 
 
 
 
 
 
1           2       3       4       5          2          3               4                        5    
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Figure 5.4: Conservation of active site residues in the ɸCD6356 amidase domain. 
 
 
The model of the the ɸCD6356 amidase domain (green) is superimposed on the structure of the CD271 (3QAY) amidase domain 
(orange). Catalytic His and Glu residues are rendered in stick and coloured by atom. The catalytic Zn atom is rendered as a purple 
sphere. Loop structure in the ɸCD6356 amidase domain with sequence deletions when compared to CD271 are labelled Loop I and 
Loop II. 
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Figure 5.5: Electrostatic surfaces of the ɸCD6356 and CD271 amidase domain. 
 
The electrostatic surface was calculated using the Adaptive Poisson-Boltzmann Solver (APBS) for the ɸCD6356 amidase domain (Panel 
A) and the CD271 amidase domain (Panel B). Electropositive surface is rendered in blue and electronegative surface is rendered in red. 
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Figure 5.6: The proton relay and substrate binding residues in the ɸCD6356 amidase 
model. 
 
For clarity the fold of the ɸCD6356 amidase model is rendered in white cartoon. Catalytic His and Glu residues are rendered in green 
stick and coloured by atom. The catalytic Zn atom is rendered as a purple sphere. Residues Asn79, Glu91, and Arg117 are suggested to 
be part of a proton relay system delivery protons to Glu140 in the active site. The path of the transfer is indicated by a black dashed line. 
Residues Ile93, Leu126 and Tyr127 are part of the proposed substrate recognition interface. 
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Chapter 6 
General discussion 
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This thesis concerned the study of the gut microbiota in patients with CF and how various 
antimicrobial treatments affected this bacterial community. Prior to these studies it was known 
that asymptomatic carriage of Clostridium difficile is common in patients with CF. Indeed, it has 
been reported to be as high as 46% (Yahav et al., 2006). Despite high carriage rates and 
detection of C. difficile toxin in stool, patients with CF rarely appear to develop CDI (Peach et 
al., 1986, Welkon et al., 1985, Wu et al., 1983, Yahav et al., 2006). Documented cases of CDI in 
patients with CF report atypical disease presentation which potentially leads to delayed diagnosis 
and increased risk of severe complications (Barker et al., 2008, Egressy et al., 2013, Yates et al., 
2007). 
 In this thesis bacterial culturing revealed that 50% of patients with CF tested were 
colonised with C. difficile compared to just 2% of healthy volunteers. The majority of C. difficile 
strains cultured (19/30) were capable of producing both toxins A and B. Indeed, toxins A/B were 
detected in 32% of stool samples from patients with CF - all of which were confirmed to contain 
C. difficile strains capable of producing toxin by culturing. This is in direct contrast to a recent 
study carried out in Rotterdam (Bauer et al., 2014a). The authors reported a similar carriage rate 
(47%), however the majority of the C. difficile isolates (77%) were non-toxigenic (Bauer et al., 
2014a). Carriage of non-toxigenic C. difficile has been proposed to protect the host from 
colonization with toxigenic strains (Wilson and Sheagren, 1983) and was proposed by the 
authors as an explanation for the low incidence of CDI in CF patients (Bauer et al., 2014a). 
Despite detection of toxin in the stool of our CF patients, none reported any gastrointestinal 
symptoms indicative of CDI. Peach et al 1986 reported similar findings, although they failed to 
detect toxin A (Peach et al., 1986). A commercial C. difficile toxin A/B kit was used in this study 
and therefore it is not possible to determine if one or both toxins were present. However, PCR 
analysis of C. difficile strains revealed the presence of both toxin genes in all strains cultured 
from toxin positive stool. Increased circulating antibody and memory B-cell responses to C. 
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difficile toxin A and B have been observed in patients with CF (Monaghan et al., 2013) which 
may explain the absence of CDI despite the presence of C. difficile toxins in the stool. The 
intestinal microbiota of patients with CF may also help protect against CDI. The stool of patients 
with CF in a previous study was found to contain several bacteria, including Lactobacillus 
species with known inhibitory effects on C. difficile and was proposed to impart protection 
against CDI (Welkon et al., 1985). Interestingly, in this thesis, a significant increase (1.1%) in 
the family Lactobacillaceae was observed in CF patients relative to healthy controls in chapter 
3. Misdiagnosis of mild cases of CDI due to CF patients displaying symptoms of constipation 
rather than diarrhoea may also contribute to the low incidence of CDI in CF patients (Binkovitz 
et al., 1999a).  
 In chapter 2 C. difficile was isolated from 30 patients, comprising 16 distinct ribotypes, 
while only two were detected in the control group; interestingly, neither of the ribotypes found in 
the control group were found detected in our CF patient group. Of the 16 ribotypes detected, the 
non-toxin producing ribotype RT140 was the most prevalent (5/30). In Chapter 4, RT140 was 
found to share a sequence type with the likewise non-toxin producing RT039 (ST26). All seven 
ST26 strains were isolated from CF patients comprising 6.3% of the total isolates tested. The 
most prevalent toxin producing ribotype in CF patients was RT046 (4/30), which was unique to 
this group as seen in chapter 4. This ribotype has previously been associated with out-breaks of 
CDI (Bauer et al., Pituch et al., 2006, Viscidi et al., 1981), however it  is not among the most 
frequently reported ribotypes in Ireland (Executive, 2013). Surprisingly, only three of the sixteen 
ribotypes reported in chapter 2 (RT002, RT014 and RT078) have featured in the top five 
ribotypes reported in Ireland each year from 2010-2013 (Executive, 2013). As well as this, only 
the ribotypes RT078 and RT010 were found in the other patient groups included in chapter 4. 
Intriguingly, six C. difficile ribotypes (RT009, RT010, RT039 RT046, RT078, and RT140) were 
reported in both our CF patients and those in the study by Bauer et al, 2013 (Bauer et al., 2014b). 
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 The emergence of a number of shared ribotypes between geographically distinct CF 
patients groups (this study and that of Bauer et al, 2013) coupled with the infrequency with 
which some of these strains are reported could indicate a core of strains associated with CF 
patients. Further research into C. difficile carriage using a longitudinal study from a young age to 
monitor acquisition and maintenance of C. difficile strains in CF patients may reveal a core of 
strains associated with CF patients or this group’s potential role in the spread of C. difficile. 
  Reassuringly, all C. difficile strains isolated from CF patients were susceptible to 
vancomycin and metronidazole. Fusidic acid, meropenem, linezolid and rifampicin were also 
effective against these strains. Not surprisingly, these strains were highly resistant to antibiotics 
typically prescribed to treat pulmonary infections including, ciprofloxacin, ceftazadime, 
tobramycin, aztreonam, and azithromycin. Further research into C. difficile carriage using a 
longitudinal study from a young age to monitor acquisition and maintenance of C. difficile 
strains in CF patients may reveal a core of strains associated with CF patients or their potential 
role in the spread of C. difficile. 
 Asymptomatic carriers of C. difficile have higher percentage of skin and environmental 
contamination with C. difficile and have been proposed as a significant contributor to the spread 
of C. difficile (Riggs et al., 2007). The high asymptomatic carriage of C. difficile among CF 
patients reported in this thesis is worrying as these patients may act as a reservoir for the spread 
of C. difficile. Therefore monitoring of C. difficile in this group is vitally important for 
controlling C. difficile spread in the hospital environment. In chapter 4, MLST was found to be 
comparable to PCR-ribotyping for typing a collection of 112 C. difficile strains isolated from 
high risk patients (Index of Discrimination [ID] of 0.93 and 0.95 respectively). In total, 28 
sequence types and 33 PCR-ribotypes were reported in the C. difficile collection examined. 
While PCR-ribotyping is the most frequently used typing scheme in the United Kingdom and 
Europe, this method relies on comparison of data to a ribotyping reference library, such as the 
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one housed at the Reference Laboratory, Leeds General Infirmary, UK by the Clostridium 
difficile Ribotyping Network for England (England, 2014). Currently there is no dedicated C. 
difficile ribotyping reference laboratory in Ireland. Multilocus sequence typing has been shown 
to be an effective typing scheme generating easily accessible and interpretable results with an 
ever expanding freely accessible online database (http://pubmlst.org/cdifficile/). Therefore 
MLST could be employed to monitor C. difficile acquisition and carriage in CF patients without 
the need to send strains to England for typing. 
 The risk of acquiring C. difficile is higher for patients with CF due to frequent hospital 
admission and proton pump inhibiter therapy (Bignardi, 1998, Clabots et al., 1992, Dial et al., 
2004, Pépin et al., 2005, Safdar and Maki, 2002). Patients with CF are also frequently exposed to 
broad spectrum antibiotics to treat pulmonary infection (Ramsey, 1996), and this likely 
contributes to the elevated carriage rates observed in this group (Yahav et al., 2006). In fact, 
ciprofloxacin and azithromycin have both been proposed to increase the risk of CDI (McCusker 
et al., 2003, Gorenek et al., 1999). However, no correlation could be made between any recorded 
patient clinical parameters and the carriage of C. difficile in chapter 2. Although, these factors 
combined may contribute to the high carriage rate (50%) observed. Lower microbial diversity 
has been reported in non-CF individuals suffering C. difficile associated disease (Rea et al., 
2012, Chang et al., 2008). High throughput compositional pyrosequencing of the faecal 
microbiota revealed lower species richness and diversity in CF patients relative to healthy 
controls. This is contrary to a report by Duytschaever et al, 2011 (Duytschaever et al., 2011) who 
found species richness to be comparable between patients with CF and healthy siblings; 
However, lower temporal stability was reported (Duytschaever et al., 2011). Further 
investigation revealed that duration of intravenous antibiotic treatment, length of hospital stay 
and decreased lung function were all associated with lower species richness and microbial 
diversity in CF patients. Lower diversity observed in CF patients with decreased lung function is 
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likely due chronic pulmonary infection requiring more frequent antibiotic therapy. Most 
interesting was the observation that patients carrying C. difficile had decreased microbial 
diversity compared to C. difficile free CF patients. This suggests that the acquisition of C. 
difficile in patients with CF is likely due to alteration of the intestinal microbiota by a 
combination of the disease and its treatment. Minimising exposure to antibiotics by increasing 
the use of inhaled antibiotics (Geller et al., 2002) and probiotic supplementation to reduce 
exacerbation frequency (Bruzzese et al., 2007, Weiss et al., 2010) may allow the intestinal 
microbiota to recover and reduce the rate of C. difficile carriage.   
 While CDI is rare among patients with CF, documented cases can be difficult to diagnose 
due to atypical presentation and can be quite severe (Barker et al., 2008, Binkovitz et al., 1999b, 
Egressy et al., 2013, Yates et al., 2007). As well as this patients with CF may also act as a 
potential reservoir for C. difficile and therefore there exists a need for rapidly acting narrow 
spectrum antimicrobials to treat CDI in high risk patient groups such as patients with CF or to 
eradicate it from asymptomatic carriers. In chapter 5 of this thesis, the C. difficile bacteriophage 
ΦCD6356 and its associated endolysin were investigated for their effectiveness at killing C. 
difficile. Bacteriophage have previously been shown to be effective at treating CDI. Ramesh and 
colleagues (Ramesh et al., 1999) found a single dose of bacteriophage to be sufficient to treat 
hamsters with C. difficile-induced ileocecitis. Following 96h, the majority of bacteriophage-
treated hamsters had survived, while all the control hamsters had died (Ramesh et al., 1999). In 
this thesis, we report that a single dose of the bacteriophage ΦCD6356 was sufficient to reduce 
viable C. difficile by 1.75 logs over 24h in an ex vivo model of the human distal colon. However, 
PCR analysis revealed 100% of surviving C. difficile carried the ΦCD6356 prophage by 
detection of bacteriophage structural genes in their genome. These structural genes were not 
detected in C. difficile recovered from the untreated control vessels. A similar observation was 
made by Meader et al, 2008, who induced prophage from surviving C. difficile using mitomycin 
156 
 
C, following treatment with the C. difficile bacteriophage ΦCD27 (Meader et al., 2010). To date, 
no lytic C. difficile bacteriophage have been reported (Hargreaves and Clokie, 2014). The 
lysogenic nature of discovered C. difficile bacteriophage, including ΦCD6356 renders them 
unsuitable for bacteriophage therapy due to the immunity acquired via lysogeny (called 
“superinfection immunity”). As well as conferring immunity on the host, prophage have also 
been associated with horizontal gene transfer between bacteria (Casjens, 2003). Prophage have 
also been linked to increased toxin production in hyper-virulent C. difficile ribotype 027 strains 
(Sekulovic et al., 2011). Therefore C. difficile bacteriophage are not a viable option for the 
eradication of C. difficile from asymptomatic CF carriers. 
 Bacteriophage endolysins have promise as potential alternatives to antibiotics for the 
treatment of a number of infections (Schmelcher et al., 2012). The endolysin gene encoded by 
ΦCD6356 was previously identified as a probable N-acetylmuramoyl-l-alanine amidase, located 
at ORF 28 (Horgan et al., 2010). This gene, lysCD, was cloned into E. coli and expressed under 
IPTG induction. A model for ΦCD6356 lysin, LysCD, was built using MODELLER (Sali and 
Blundell, 1993) with the amidase domain of the endolysin CD27l (3QAY) as the template 
structure (Mayer et al., 2011). This revealed the presence of zinc coordination at the enzymes 
catalytic domain. Removal of zinc by treatment with EDTA eliminated the lytic activity of the 
endolysin. Reintroduction of zinc as well as other divalent metal ions (Mn2+, Mg2+and Ca2+) 
to EDTA treated endolysin restored lytic activity. This flexibility in divalent ions has been 
reported previously in other bacteriophage endolysins (Son et al., 2012, Schmelcher et al., 2012). 
In fact Crude protein extract containing the endolysin was active against live C. difficile in vivo 
resulting in a nearly 3 log reduction in viable C. difficile after 2h. However, enzymatic activity 
was unstable after partial purification. This work proves promising for the development of 
LysCD as a novel C. difficile antimicrobial with narrow spectrum of activity. However, for this 
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to be realised further work on the purification and characterising of the endolysin would need 
optimization and scaling-up. 
 In conclusion, the data presented in this thesis reveals an alarmingly high burden of C. 
difficile carriage in patients with CF. Among the strains recorded were a number of virulent 
strains typically associated with CDI outbreaks. This highlights that good tracking of C. difficile 
and recording of epidemiological data using techniques such as MLST are required to minimise 
the spread of C. difficile in this group and to the community as a whole. The composition of the 
CF intestinal microbiota is significantly altered from that of healthy individuals through a 
combination of the disease and its treatment, potentially creating a niche for colonization by C. 
difficile. C. difficile infection in CF patients, while rare can be potentially life threatening, 
especially in post lung transplant patients (Egressy et al., 2013). Cystic fibrosis patients may also 
act as potential reservoirs for dissemination of a great variety of unrelated C. difficile strains. 
Therefore antimicrobials with minimal effect on the intestinal microbiota are required for the 
treatment and eradication of C. difficile in people with CF to prevent reinfection and spreading 
of C. difficile. Narrow spectrum antimicrobials such as bacteriophage endolysins could therefore 
be of great benefit in patients with CF and thus warrant greater investigation. Further studies into 
longitudinal development of the CF intestinal microbiota in paediatric patients and C. difficile 
carriage in post-lung transplant patients can further inform the treatment and gastrointestinal 
health of patients with CF. 
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Abstract:  
Bacteriocins are ribosomally synthesised, antimicrobial peptides produced by bacteria. Many 
bacteriocins produced by food-grade lactic acid bacteria inhibit food-borne spoilage and 
pathogenic bacteria in food.  Here we reviews the means via which these bacteriocins can/are 
employed by the food industry i.e. through the production of bacteriocins by bacteriocinogenic 
bacteria from within the food  or through the addition of bacteriocin to the food in the form of an 
ingredient or preservative. 
 
Keywords: Bacteriocin, Lactic Acid Bacteria, bacterial fermentation, biopreservatives, 
bacteriocin purification 
 
1. Introduction 
Bacteriocins are ribosomally synthesised, small heat stable, antimicrobial peptides produced by 
bacteria. They are typically active against closely related species but can also have a broad 
spectrum of activity across genera. Bacteriocinogenic bacteria are protected from the 
bacteriocins which they produce as a consequence of the production of dedicated immunity 
(self-protective) proteins (Cotter et al., 2005, Rea et al., 2011). Gram positive bacteriocins can 
be divided into two classes i.e. Class Ι, the post-translationally modified bacteriocins and Class 
ΙΙ, the unmodified bacteriocins (Cotter et al., 2005, Rea et al., 2011). It is estimated that between 
30-99% of bacteria produce at least one bacteriocin (Klaenhammer, 1988, Riley, 1998). Indeed, 
the frequency with which bacteriocin encoding gene clusters occur has been borne out by 
genome sequencing studies (Begley et al., 2009, Marsh et al., 2010). This fact indicates that 
there continues to be great opportunities for the discovery and development of new bacteriocins 
for commercial applications. To date such commercial applications have most frequently 
involved the use of bacteriocins to control spoilage or pathogenic bacteria in food. The lactic 
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acid bacteria (LAB) are the most important bacteriocin producers with regard to such 
applications. LAB have been used for millennia for the preservation and microbial safety of 
fermented foods by inhibiting the growth of pathogenic and spoilage bacteria (Caplice & 
Fitzgerald, 1999). Food preservation is mediated by the production of a number of end products 
of LAB fermentation such as organic acids, ethanol, hydrogen peroxide, and, of course, 
bacteriocins (Jack et al., 1995). 
Many bacteria isolated from food fermentations have been found to produce bacteriocins. 
Examples include nisin and lacticin 3147, which are Class Ι bacteriocins (or lantibiotics). These 
bacteriocins are produced by members of the genus Lactococcus and the benefits of using 
producers of such bacteriocins in cheese manufacture have been highlighted (Roberts et al., 
1992, Ryan et al., 1996). Similarly the Class ΙΙ pediocin PA-1 producing Pediococcus 
acidilactici have been used in the fermentation of dry fermented sausage (Foegeding et al., 
1992) and several bacteriocin producing lactobacilli have been employed in the fermentation of 
sausages and olives (Dicks et al., 2004, Messens et al., 2003, Ruiz-Barba et al., 1994). As a 
consequence of their long history of safe use, LAB have attained a generally regarded as safe 
(GRAS) status. Despite this, nisin remains the only bacteriocin approved for use as a 
preservative in foods. There are however, products such as the pediocin PA-1-containing Alta 
2341® (Kerry Bioscience, Carrigaline, Co. Cork, Ireland) and other fermentates which are 
employed by the food industry. As a consequence of its approved status, nisin has been the focus 
of much attention. It was first discovered in 1928 (Rogers & Whittier, 1928) and was first 
marketed in England in 1953. In 1969, nisin was assessed as safe for use in food by the Joint 
Food and Agriculture Organization/World Health Organization (FAO/WHO) and was later 
added to the European food additive list and given the number E234 by the EEC (EEC, 1983). It 
has also been approved for use in food by the U.S. Food and Drug Administration. While nisin is 
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widely available as Nisaplin™ (Danisco, Copenhagen, Denmark), other commercial 
preparations are also available. 
 
There are numerous benefits to the use of bacteriocins to preserve and increase the microbial 
safety of food. Firstly, as bacteriocins are metabolites of bacteria they are seen as “natural” 
products that can be used in place of chemical preservatives in foods, therefore gaining wider 
acceptance by consumers. Bacteriocins can also be applied in combination with other treatments 
such as high pressure or temperature to improve food preservation. This is exemplified by 
lacticin 3147 which, when combined with hydrostatic pressure, has an increased killing effect on 
Staphylococcus aureus and Listeria innocua than was observed with either treatment alone 
(Morgan et al., 1999). Similarly, a combination of the Enterococcus-produced enterocin AS-48 
with a mild heat treatment (80-95˚C for 5 mins) caused a considerable reduction in the viability 
of Bacillus coagulans CECT 12 endospores when compared to the heat treatment alone, which 
did not impact significantly on the endospores (Lucas et al., 2006). Thus the effective use of 
bacteriocins in hurdle technology can result in increased food safety and nutritional quality 
through the improved killing of contaminating bacteria and reducing the need for harsh 
processing procedures, respectively.  
This chapter will focus on the use of bacteriocins for the preservation of food through their 
production by microbes in-situ in foods and their incorporation as preservatives/fermentates, and 
will review the different approaches which have been taken to optimise their yield.  
 
2. In-situ production of bacteriocins in food 
As previously stated, LAB have been used for millennia in food fermentations. However, 
defined starter cultures have replaced traditional undefined mixed culture starters in modern 
commercial fermentations. Use of defined starter culture systems allows for improved control 
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over fermentations as well as the selection of strains that possess specific beneficial traits, such 
as bacteriocin production. In the last few decades bacteriocinogenic strains have been studied 
extensively with regard to their potential as starter cultures, starter adjuncts and protective 
cultures to control the growth of pathogenic and food spoilage bacteria. This section shall 
explore the topic of the in-situ bacteriocin production for food preservation. 
 
2.1 Bacteriocinogenic starter cultures. 
 
Unbeknownst to us, mankind may have been reaping the benefits of in-situ bacteriocin 
production in fermented foods since the practice of fermentation first began. Ancient 
fermentations were the result of the outgrowth of microflora naturally present on the raw 
material from which the fermented product was made. Backslopping i.e. the practice of 
inoculating a new fermentation with a small quantity of fermented product from a successful 
fermentation was later used as a means of replicating successful fermentations. In effect this 
process lead to the selection of the best starters, although the underlying science was not 
understood at the time (Leroy & De Vuyst, 2004). Modern industrial fermentations utilise well 
characterized defined starter systems with properties which are beneficial from the perspective 
of the end product. Such properties include rapid acid production, phage resistance, and the 
formation of aromatic compounds and, of course, the production of bacteriocins. Bacteriocin 
production by starter cultures can contribute to food safety and preservation thereby limiting the 
need for chemicals preservatives. 
 
Lactococci are commonly used as starter cultures in the dairy industry, most notably as starters 
in the manufacture of cheese. As previously stated, nisin is produced by a number of L. lactis 
strains, some of which have been investigated with a view to their use as starter cultures for the 
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control of pathogenic and spoilage bacteria in various food systems. Rodríguez et al (1998) used 
a nisin producing L. lactis strain, ESI 515, in the production of Manchego style cheese made 
from raw ewe’s milk. The strain displayed desirable properties in terms of making this cheese 
but, importantly, also produced sufficient nisin to reduce counts of Listeria innocua by 4.08 log 
units relative to a control cheese produced with a non-bacteriocinogenic starter culture. L. lactis 
DPC 3147 and a transconjugant, L. lactis DPC 4275, both producing the broad spectrum two-
component bacteriocin lacticin 3147 have also been successfully used to manufacture Cheddar 
cheese. Levels of the bacteriocin remained constant over a six month ripening period (see fig. 1) 
and were sufficient to control non-starter LAB (Ryan et al., 1996), which can lead to 
inconsistencies and off-flavours. This strain was also used as a starter for cottage cheese 
manufacture, where it produced 2560 activity units (AU) ml
-1
 of lacticin 3147. There was a 
99.9% reduction in L. monocytogenes Scott A numbers in cheese made with the lacticin 3147 
producing starter after five days whereas no change in pathogen levels was seen in the control 
cheese (McAuliffe et al., 1999). 
 
In addition to inhibiting pathogens, bacteriocins can be of great use with respect to controlling 
spoilage bacteria. Bacterial spores surviving milk pasteurisation is a significant problem as they 
can contaminate cheese and sporulate during ripening causing the formation of off odours and a 
late blowing defect due to butyric acid formation. The latter phenomenon is caused by the out-
growth of clostridial spores and is a major cause of spoilage in hard and semi-hard cheeses 
(McSweeney et al., 2004). Garde et al (2011) successfully prevented the out-growth of 
Clostridium beijerinckii spores in ovine milk cheese by using a bacteriocinogenic L. lactis starter 
culture. Production of nisin and another Class Ι bacteriocin, lacticin 481, by the starter culture 
during fermentation prevented outgrowth of the spores and hence late blowing. After 120 days 
ripening this defect occurred in the control cheese but not in cheese made with the 
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bacteriocinogenic starter. As well as preventing spoilage, the starter also generated the desired 
sensory characteristics for this type of cheese and thus was deemed a suitable replacement 
starter. The use of bacteriocinogenic cultures in the production of cheese to prevent late blowing 
offers a natural alternative to lysozyme, which is commonly added to cheese to prevent this 
defect (Crawford, 1987). This method of prevention is not only more cost effective, but also 
lysozyme has become an increasingly less attractive preservative in recent years as a 
consequence of the fact that it is purified from eggs and thus there are fears associated with its 
potential allergenicity (Carmen Martínez-Cuesta et al., 2010). 
 
Moving away from the topic of dairy products temporarily, the production of dry fermented 
sausages is also worthy of discussion. This practice traditionally involves fermentation followed 
by drying without a heat treatment. This minimal processing can potentially lead to 
contamination and the proliferation of spoilage and pathogenic bacteria, such as L. 
monocytogenes. Pediococci are commonly used as starters in the fermentation of sausages, and 
many Pediococcus-produced bacteriocins (also known as pediocins), are active against 
important pathogenic bacteria, such as those of Listeria and Clostridium sp. (Christensen & 
Hutkins, 1992, Luchansky et al., 1992, Nieto-Lozano et al., 2010). In one such study a pediocin 
PA-1 producer, Pediococcus pentosaceus BCC 3772 was selected as a consequence of its anti-
listerial activity and was evaluated as a starter culture for the fermentation of Nham (Thai 
traditional pork sausage). The strain performed agreeably when used as a starter culture in the 
fermentation of Nham in that it did not significantly alter the sensory characteristics of the 
sausage. In-situ production of PA-1 was sufficient to reduce spiked L. monocytogenes numbers 
by 3.2 logs compared to initial counts, within 18-24 h (Kingcha et al., 2011). Pediococcus 
acidilactici MCH14, a starter culture commonly used in the Spanish meat industry also produces 
pediocin PA-1 and was tested to assess its ability to control the growth of L. monocytogenes in 
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Spanish dry-fermented sausage. Sausages were made using either the bacteriocinogenic starter, 
or a non-bacteriocin producing P. acidilactici as a control, and were spiked with L. 
monocytogenes (10
5
 CFU g
-1
) before being vacuum stuffed and stored for four weeks. After 
ripening, the numbers of L. monocytogenes were reduced by 2 logs (2 x 10
1
 CFU g
-1
) in the 
MCH14-containing sausage compared to the control (7 x 10
3
 CFU g
-1
) but, importantly, no 
significant difference was observed between the two starters with regard to Aw and lactic acid 
production (Nieto-Lozano et al., 2010).  Members of the genus Lactobacillus are also commonly 
used as starter cultures for the fermentation of meat (Hammes et al., 1990). Bacteriocin 
production appears to provide such lactobacilli with a competitive advantage in such 
environments, as a number of bacteriocinogenic lactobacilli have been isolated from fermented 
sausages (Aymerich et al., 2000, Schillinger & Lucke, 1989, Vignolo et al., 1993, Vogel et al., 
1993). For example, Lactobacillus sake CTC 494, which was isolated from dry fermented 
sausage, has been found to have excellent starter capabilities, as well as the ability to produce the 
Listeria-active bacteriocin sakacin K (Hugas et al., 1996), under conditions (pH and 
temperature) similar to that found during the fermentation of dry fermented sausage (pH 5.0 - 
5.5, 20 - 25˚C) (Leroy & De Vuyst, 1999b). This strain was tested for its ability to control the 
growth of L. monocytogenes in three types of fermented sausage; Belgin-type, Cacciatore-type 
and Italian salami. Notably,  L. monocytogenes numbers were reduced by between 0.6 and 1.0 
log CFU g
-1
 when compared to bacteriocinogenic starter free controls after the completion of 
sausage production (Ravyts et al., 2008). Another example relates to Lactobacillus pentosus 31-
1. This strain was isolated from a Chinese meat product (Xuanwei ham) and produces the 
bacteriocin pentocin 31-1. This strain was evaluated as a starter culture for the production of 
fermented sausage. The strain performed very well, producing a product with desirable 
organoleptic properties. During challenge tests with L. innocua and Staphylococcus aureus, 
pathogen cell numbers in the Lb. pentosus 31-1 sausage were reduced by between 4.4 and 5.1 
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log units compared to the control. Antimicrobial activity was detected up to 7 days post 
production in homogenized sausages whereas, as expected, no activity was observed in the 
controls. Activity was lost during the ripening period suggesting that the bacteriocin was 
inactivated over time (Liu et al., 2008a). 
 
2.2 Bacteriocinogenic starter culture adjuncts. 
Bacteriocinogenic strains are not always suitable as starter cultures as they may not be capable 
of the requisite acidification rates or lack the proteolytic activity required. Such problems have 
previously been associated with some nisin producing strains (Lipinska, 1973, Lipinska, 1977). 
This problem can be solved by introducing the bacteriocin encoding genes into a suitable starter 
by conjugation or genetic manipulation or, more simply, by combining the bacteriocinogenic 
culture with a suitable starter culture that is resistant to the bacteriocin being produced.  
A number of authors have described the use of bacteriocinogenic enterococci as starter-culture 
adjuncts (Arantxa et al., 2004, Giraffa et al., 1995, Nascimento et al., 2008, Oumer et al., 2001). 
However due to the ongoing debate with respect to the safety of enterococci in food, these shall 
not be discussed in this section.  
The combination of bacteriocinogenic adjunct cultures with resistant/insensitive commercial 
starter cultures is an economical alternative to the application of either chemical preservatives or 
purified bacteriocin preparations for controlling spoilage and pathogenic bacteria.  Rilla et al 
(2003) successfully controlled the growth of Clostridium tyrobutyricum CECT4011, which has 
been associated with the previously described butyric acid formation/late blowing defect in 
cheese, through the use of a mesophilic mixed starter, IPLA-001, in combination with the nisin Z 
producing strain, L. lactis subsp. lactis IPLA 729. Nisin Z is a variant of nisin (nisin A) which 
differs by one amino acid. Nisin Z levels reached 1600 AU/ml in this cheese after day 1, this 
level of activity was retained for 15 days. The experimental cheese, along with a control and a 
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commercial cheese made with the anti-blowing agent potassium nitrate, were spiked with the 
CECT4011 strain. During ripening, Cl. tyrobutyricum numbers were reduced from 1.2 x 10
5
 
CFU g
-1
 to 1.3x 10
3
 CFU g
-1
 in the nisin Z cheese, but increased to 1.99 x 10
9
 CFU g
-1
 and 3.5 x 
10
7
 CFU g
-1
 in the control and commercial cheeses, respectively. The nisin Z producing starter 
L. lactis subsp. lactis biovar diacetylactis UL719 was also successfully used as a starter adjunct 
by Bouksaim et al (2000) in the production of Gouda cheese. Nisin Z levels reached a maximum 
of 512 AU g
-1
 after 6 weeks ripening but decreased to 128 and 32 AU g
-1
 after 27 and 45 weeks, 
respectively. The level of nisin present is significant as it has been shown that 40 Au g
-1
 is 
sufficient to prevent butyric acid formation (Hugenholtz & De Veer, 1991).  
 
As previously stated, bacteriocins can potentially be used in combination with other treatments 
(or hurdles) to maximise food quality and safety. By utilising two bacteriocinogenic cultures 
producing different bacteriocins, with differing mechanisms of action but with coinciding 
spectrums of activity, it is possible to affect a synergistic killing of a target bacterium. This 
approach can be particularly useful in preventing the emergence of resistance (Vignolo et al., 
2000). Lb. plantarum LMG P-26358, produces an anti-listerial class ΙΙ bacteriocin with 100% 
homology to plantaricin 423 was used as a starter adjunct in combination with a nisin-producer, 
L. lactis CSK65 in laboratory scale cheese production. In challenge trials, cheese produced with 
the Lb. plantarum LMG P-26358 starter adjunct had a greater killing effect against L. innocua 
than observed in cheese produced with the nisin producer alone. It was also noted that when 
used in combination, no viable L. innocua were recovered after 28 days ripening. Mass 
spectrometry also revealed that both bacteriocins were present after 18 weeks ripening (Mills et 
al., 2011). Despite the success of this approach, it is important to ensure the bacteriocins 
produced are not overly antagonistic against the other bacteriocinogenic culture(s) present. Mills 
et al (2011) did observe the inhibition of Lb. plantarum LMG P-26358 by nisin, which slowed 
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its growth during the first eight hours of fermentation. However, despite this, the Lb. plantarum 
strain did reach the optimal cell density required for bacteriocin production (i.e.10
8 
CFU ml
-1
) on 
day one of cheese production in this case. 
In addition to inhibiting spoilage and pathogenic microbes, bacteriocins can also be exploited to 
partially lyse starter and/or adjunct cultures during cheese production which is enhances cheese 
maturation. This is due to the release of intracellular enzymes, such as proteinases, peptidases, 
amino acid catabolic enzymes and esterases, all of which impact upon flavour formation (Lortal 
& Chapot-Chartier, 2005).A number of authors have described the use of bacteriocinogenic 
adjunct starter cultures to increase starter cell lysis (Ávila et al., 2005, Garde et al., 2006, Garde 
et al., 2005, Garde et al., 2002, Lortal & Chapot-Chartier, 2005, Morgan et al., 1997, O'Sullivan 
et al., 2002, O'Sullivan et al., 2003). 
 
2.3 Bacteriocinogenic protective cultures. 
 
In situ bacteriocin production for the protection of foods from pathogenic and spoilage bacteria 
is not an option which is exclusively reserved for fermented foods. Bacteriocinogenic bacteria 
can also be applied to the surface of non-fermented foods, allowing for in situ bacteriocin 
production. A suitable bacteriocinogenic protective culture must not be capable of causing 
spoilage, must grow at the intended storage temperature (usually refrigeration temperatures), 
must not affect the organoleptic properties of the food during storage and must produce 
sufficient bacteriocin to have a protective role under these conditions. 
 
Two Lactobacilli producing bacteriocin-like inhibitory substances were assayed for their ability 
to enhance the preservation of vacuum-packed sliced beef meat stored at 4˚C over 28 days by 
Katikou, et al (2005). The two lactobacilli, Lb. sakei CECT 4808 and Lb. curvatus CECT 904
T
, 
177 
 
were applied to the sliced beef meat either individually and in-combination. Counts of 
Enterobacteriaceae, Pseudomonas spp., LAB, Brochothrix thermosphacta, yeasts and moulds as 
well as the organoleptic properties of the beef were assayed over the 28 days. Beef inoculated 
with either the Lb. sakei or the Lb. sakei in combination with Lb. curvatus had significantly (P < 
0.05) lower counts of spoilage microbes than beef inoculated with Lb. curvatus alone or 
controls. The use of Lb. sakei in isolation was more effective in controlling spoilage microbes 
and the associated product attained greater organoleptic scores than was achieved by the other 
treatments. The sakacin P producer Lb. curvatus CWBI-B28 has also been shown to be effective 
as a protective culture, in this instance when employed on the surface of cold-smoked salmon 
under vacuum-packed and refrigerated conditions. Counts of L. monocytogenes on this product 
were reduced to below the detectable limit (0.7 CFU/cm
2
) within the first week of storage after 
the application of Lb. curvatus as a protective culture. However a 1.3-log increase in colony 
numbers was observed after 14 days (Ghalfi et al., 2006). Lb. curvatus CWBI-B28 has also been 
shown to be effective with respect to controlling L. monocytogenes in raw beef and in raw 
chicken meat when combined with the sakacin G producing Lb. sakei CWBI-B1365 (Dortu et 
al., 2008).  
 
When considering commercial applications for bacteriocinogenic protective cultures storage, the 
retention of antimicrobial activity may become an issue. Spray-drying offers an inexpensive 
method for industrial-scale production of cultures containing high levels of viable 
bacteriocinogenic bacteria suitable for storage and transport. Silva et al (2002) assessed the 
antimicrobial activity of three bacteriocinogenic protective-cultures for their antimicrobial 
activity before and after spray-drying. All three strains, Lb. sakei, Lb. salivarius and 
Carnobacterium divergens, exhibited antimicrobial activity against the target strains, i.e. Staph. 
aureus, L. innocua and L. monocytogenes. After spray-drying, the cultures were stored at either 
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4˚C or 18˚C and at a relative humidity of 0.3%. Although Carn. divergens lost its antimicrobial 
activity against Staph. aureus immediately after spray drying, it retained activity against L. 
innocua and L. monocytogenes. The two lactobacilli retained antimicrobial activity against all 
target bacteria after spray-drying. Storage temperature had a significant impact on survival of the 
bacteriocinogenic spray-dried cultures. Numbers of Carn. divergens and Lb. sakei decreased 
during storage at 4˚C and18˚C, with a greater decrease being seen at 18˚C. Numbers of Lb. 
salivarius didn’t significantly decrease until the 3rd month of storage. Rodgers et al (2002) also 
demonstrated the retention of nisin and pediocin A production by the protective cultures, L. 
lactis CSCC 146 and P. pentosaceus ATCC 43200 respectively, after freeze-drying. On the basis 
of these results spray- and freeze-drying could become an important process in the production of 
bacteriocinogenic cultures for use in food production. 
 
2.4 In-situ bacteriocin production – Conclusion 
 
The use of physical processes (heating, hydrostatic-pressure, gamma radiation etc.) to kill 
undesirable microbes in foods can be expensive and can negatively impact on the sensory 
characteristics of certain foods and therefore are not always suitable. The addition of chemical 
preservatives is highly regulated and is negatively perceived by consumers. For these reasons 
bacteriocin production in-situ is a very attractive alternative for maintaining food safety and 
quality. Also, because the bacteriocin is produced in-situ by GRAS cultures this provides an 
alternative to the use of concentrated bacteriocin preparation as food preservatives and 
associated regulatory restrictions. It is important to note, however, that the bacterial strains to be 
used as starter, adjunct or protective cultures for in-situ bacteriocin production need to be 
extensively tested within the food environment as both their growth rate and levels of bacteriocin 
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production can be affected by environmental factors that prevail within the food environment 
(Leroy & de Vuyst, 1999a, Neysens et al., 2003, Sarantinopoulos et al., 2002). 
 
3. Ex-situ production of bacteriocins: 
Bacteriocins for use as preservatives and food additives can be produced as either purified 
preparations or as fermentates (see Table1). Like many industrial fermentations, maximal 
product formation is only achieved through tight control of fermentation conditions. For this 
reason there have been many studies into the effects of medium composition, temperature, pH, 
and fermentation design on bacteriocin production. 
 
3.1 Media Composition. 
 
Production of bacteriocins on an industrial scale is an expensive process. This is due in part to 
the high cost of commercial media required for the cultivation of the bacteriocin producing 
LAB, examples include; deMan, Rogosa, Sharpe media (MRS), Tryptone, Glucose, Yeast 
extract media(TGY) and All Purpose Tween media(APT) (Daba et al., 1993, De Vuyst, 1995, 
Jensen & Hammer, 1993). While these general media may be ideal for the growth of LAB in the 
laboratory, they may not be optimal for bacteriocin production.  
MRS is commonly used for the production of sakacin A (180 AUml
-1
) from Lb. sakei. Trinetta et 
al (2008) used a ‘one variable at a time’ approach to develop an alternative culture medium for 
the production of sakacin A. Using this approach a medium, optimal for sakacin A production 
and was developed which cost 50% less. In this alternative medium consisting of, bactopeptone, 
meat peptone, milk whey, yeast autolysate, glucose and calcium carbonate, sakacin A production 
was increased to 480 AU ml
-1
. Juárez Tomás et al (2010) designed a medium optimal for growth 
and production of the Class ΙΙ bacteriocin, salivaricin CRL 1328 by Lb. salivarius CRL 1328. 
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Growth and bacteriocin production were assessed under a range of culture conditions. Using a 
desirability function, an optimal medium composition was predicted which cost between 25-40% 
less than commercial alternatives i.e. MRS. 
Cultivation of bacteriocinogenic bacteria in medium based on industrial waste products has also 
been assessed in a bid to reduce the cost of bacteriocin production. LAB require diverse peptic 
sources due to their fastidious nature. Peptones from fish, while uncommon, are a quite good 
alternative to peptone sources commonly used such as bactopeptone, tryptone, yeast extract and 
meat extract (Vázquez et al., 2004). Octopus peptone (OP) media made from octopus tissue (as 
peptone source) was compared to MRS and a medium (medium B) made with commercial 
peptones (bactopeptone), for its ability to support growth and the production of nisin and 
pediocin by strains of L. lactis and P. acidilactici, respectively. Increased nisin and biomass 
production was observed in OP relative to that achieved in either MRS or medium B. OP 
outperformed medium B for biomass and pediocin production but not MRS (Vázquez et al., 
2004). A similar study was performed using peptones derived from fish visceral and muscle 
residues. Nisin and pediocin PA-1 production was assessed in medium prepared with fish 
peptones (FP) or bactopeptone (D medium) as well as in MRS. FP compared favourably to D 
medium and MRS for biomass and nisin production by L. lactis. Pediocin and biomass 
production in P. acidilactici improved 500% with FP compared to medium D or MRS (Vázquez 
et al., 2006). Snow crab hepatopancreas (a by-product of crustacean processing) medium has 
also been shown to be an effective substrate for the production of bacteriocins. A maximum 
activity of 3.7 x 10
4
 AU ml
-1
 of divergicin M35 was produced by Carnobacterium divergens 
M35 in snow crab hepatopancreas medium after 10h (Tahiri et al., 2009). 
Cereal based by-products from various industrial processes have also been investigated for their 
application as low-cost medium for large scale bacteriocin production. Condensed corn soluble 
(CSS) is a by-product of fuel ethanol production. CSS was found to be considerably cheaper 
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than the commercial media Laurel-Tryptose broth (LT broth) for the production of nisin when 
buffered with NaHCO3. Costs were reduced from $600/Kg nisin (LT broth) to $35-40/Kg nisin 
(Wolf-Hall et al., 2009). Malt-sprout extract (MSE) medium is another low cost cereal-based 
medium derived from food industry by-products. MSE medium supplemented with glucose (G) 
and yeast extract (YE) was investigated as an alternative to MRS for the growth and production 
of antimicrobial activity by Lb. plantarum VTT E-79098. MSE(GYE) compared favourably with 
MRS for biomass production and interestingly, was superior for the production of antimicrobial 
activity. The cost of MSE medium was estimated to be 20% that of MRS (Laitila et al., 2004). 
 
A number of studies have demonstrated that milk and by-products of the dairy industry (whey) 
are cost effective food grade substrates for commercial bacteriocin production (Arakawa et al., 
2008, Daba et al., 1993, Dimov, 2007, Goulhen et al., 1999, Guerra & Pastrana, 2001, Liu et al., 
2005, Morgan et al., 1999). Ananou et al (2008) found production of the bacteriocin AS-48 to be 
significantly cheaper in a commercial whey (supplemented with 1% glucose) when compared to 
the cost of production in BHI (€1.53/Kg Vs €140.00/Kg). As well as being cost-effective food 
grade substrates, milk and whey have also been used to produce bacteriocin containing bioactive 
powders by lyophilising the fermentate of bacteriocinogenic cultures, i.e. Nisaplin™ and Alta 
2341®. Due to the fastidious nature of LAB, the low concentration or absence of certain growth 
factors (vitamins and amino acids) in whey may be limiting for bacteriocin production (Guerra 
& Pastrana, 2001). The addition of a complex nitrogen source can facilitate increased bacteriocin 
production through the availability of free amino acids, short peptides as well as additional 
growth factors (Aasen et al., 2000, Cheigh et al., 2002). This is exemplified by addition of yeast 
extract to whey, which has been shown to increase bacteriocin production in a number of studies 
(Anthony et al., 2009, Avonts et al., 2004, Cladera-Olivera et al., 2004, Enan & Al Amri, 2006, 
Liao et al., 1993, Pérez Guerra et al., 2005). The availability of carbon can also impact upon 
182 
 
bacteriocin production. At low concentrations, carbon availability can limit biomass production 
and hence final bacteriocin titres (De Vuyst & Vandamme, 1992). However, it has been shown 
that increasing the initial carbon concentration does not result in a proportional increase in 
bacteriocin titre, and above a certain concentration can result in a reduction in biomass and 
bacteriocin formation (Parente et al., 1997). Maximum bacteriocin titre is usually reached at the 
end of the log phase or early stationary phase, after which time a decrease in bacteriocin activity 
is commonly seen (Callewaert et al., 2000, Leroy & De Vuyst, 2002, Mataragas et al., 2003). 
The depletion of the energy source has been proposed for this decline in bacteriocin activity 
(Callewaert et al., 2000, De Vuyst et al., 1996). Parente et al, (1997) observed that at low 
glucose concentrations (<25g L
-1
) bacteriocin activity dropped after it had reached its peak. At 
higher glucose concentrations, no decline in activity was observed. 
 
3.2 Environmental Conditions  
 
Bacteriocin production has frequently been reported as being greatest during the active growth 
phase, displaying primary metabolite kinetics (De Vuyst et al., 1996). While bacteriocin 
production is growth associated, conditions required for maximum growth rate may not be 
optimal for maximum bacteriocin production (Nel et al., 2001). A number of studies have shown 
that temperatures favouring bacteriocin production are lower than those required for optimum 
growth (Bizani & Brandelli, 2004, Cheigh et al., 2002, Delgado et al., 2007, Delgado et al., 
2005, Mataragas et al., 2003, Messens et al., 2003). Aasen et al (2000) observed that sakacin P 
production ceased earlier when grown at 30˚C (optimum for growth) rather than at 20˚C, and 
that lower quantities of glucose were consumed at 30˚C than was observed when grown at 20˚C. 
The authors proposed that the greater bacteriocin activity observed at 20˚C was due to rate 
limiting reactions dependant on temperature, resulting in more efficient carbohydrate utilization 
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at lower growth rates. It has also been proposed that a decrease in bacteriocin activity at higher 
temperatures could be due to the action of proteases (Bizani & Brandelli, 2004, Messens et al., 
2003). 
 
The pH of the growth medium during fermentation can have a profound effect on the yield of 
bacteriocin. As with temperature, suboptimal pH has frequently been reported as being required 
for optimal bacteriocin production (Drosinos et al., 2006, Herranz et al., 2001, Mataragas et al., 
2003, Matsusaki et al., 1996, Parente & Ricciardi, 1994). Once an optimal pH for bacteriocin 
production has been established, pH controlled fermentations can be used to maintain maximum 
bacteriocin production throughout the fermentation (Abriouel et al., 2003, Liu et al., 2010, 
Mataragas et al., 2003, Naghmouchi et al., 2008, Wolf-Hall et al., 2009). In contrast to this, the 
natural fall in pH resulting from the production of lactic acid by LAB has also been shown to be 
beneficial in increasing bacteriocin yields. Guerra and Pastrana (2003) investigated the effect of 
pH drop on nisin and pediocin PA-1 production in whey. They found that nisin and pediocin 
production rates were higher in un-buffered fermentations than in those buffered with different 
concentrations of potassium hydrogen phthalate-NaOH. Specific bacteriocin production rates 
increased with decreasing pH, until a final pH inhibitory to the producer was reached. Similar 
results were reported by Cabo et al (2001) and Yang & Ray (1994). The adsorption of 
bacteriocins to producer cells at high pH has also frequently been described (Bhunia et al., 1991, 
D'Angelis et al., 2009, Klaenhammer, 1988, Ray, 1992, Wu et al., 2008, Zhang et al., 2009), and 
occurs once growth associated  bacteriocin production has ceased (De Vuyst et al., 1996). In 
such situations, a reduction of the culture pH to around 2.0 once maximum bacteriocin titre has 
been reached can be employed to prevent adsorption to producer cells and release any 
bacteriocin already bound to the producers cells (Yang et al., 1992). 
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3.3 Effect of fermentation processes on bacteriocin production. 
 
Batch fermentation is what is described as a “closed system”, whereby the substrate and 
producing microorganism are added to the system at time zero and are not removed until the 
fermentation is complete. This represents the simplest and most commonly employed method of 
fermentation for the production of bacteriocins. Optimization of bacteriocin production in batch 
fermentation is achieved by the manipulation of growth conditions (pH, temperature etc.) and 
medium composition. Batch fermentation is ideal for studying bacteriocin production in the lab 
or in small scale trials, but is not economically viable on a commercial scale (De Vuyst & 
Vandamme, 1991, Liao et al., 1993). Fed-batch fermentation is a modified form of batch 
fermentation whereby growth limiting substrates are fed into the fermenter at a controlled rate. 
This allows for a tight control over growth rate and can alleviate problems such as catabolite 
repression. By controlling the sucrose feeding rate in a fed-batch system, Lv, Zhang & Chong 
(2005) increased the maximum nisin titre from 2658 IU ml
-1
 in batch fermentation to 4185 IU 
ml
-1
. Controlled carbohydrate feeding facilitated a maximum growth rate without substrate 
inhibition impacting upon the rate of bacteriocin production. A number of studies have 
demonstrated that bacteriocin production can be improved through the use of fed-batch, rather 
than batch fermentations (Ekinci & Barefoot, 2006, Guerra et al., 2005, Lv et al., 2005, Paik & 
Glatz, 1997). While promising, these experiments were performed on a small scale and thus, it is 
difficult to determine how scaling up of the process would impact upon bacteriocin yields. In 
one study, bacteriocin production by Propionibacterium thoenii in small and large scale fed-
batch fermentations has been assessed. Paik & Galtz (1997) found that scaling up of the process 
led to a reduction in bacteriocin activity. Even with the reduced activity, the authors concluded 
that fed-batch fermentations have the potential to facilitate the production of high concentrations 
of bacteriocins by propionibacteria. 
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 While fed-batch fermentation is an improvement over batch fermentation, it has been proposed 
that continuous culture techniques are superior to both. Continuous fermentation is preferred to 
the batch process due to its high productivity, reduced product inhibition and no batch to batch 
variation and ultimately reduced production costs (Tejayadi & Cheryan, 1995). Continuous 
fermentation is an “open system” whereby sterile substrate is added to the system at a specific 
dilution rate (D, volume of vessel h
-1
), while an equal volume of converted substrate containing 
the product along with the producer is simultaneously removed. The continuous flow through the 
system maintains fermentation conditions at the optimum required for bacteriocin production. 
This results in the producer being maintained at the growth rate/phase which results in the 
specific bacteriocin production rate being optimal (Bhugaloo-Vial et al., 1997). The dilution rate 
(D, vessel volume h
-1
) in a continuous fermentation can greatly affect the productivity of the 
process. The maximum dilution rate in a continuous fermentation must not exceed the specific 
growth rate of the bacterial strain being used to prevent cells being washed out of the system. 
Kaiser & Montville (1993) compared the production of the Class ΙΙ bacteriocin Bavaricin MN by 
Lb. bavaricus MN in batch and continuous culture. In a pH and temperature controlled batch 
fermentation a maximum titer of 3200 AU ml
-1
 was reached. However this fell to 800 AU ml
-1
 
after 76h. In a continuous culture at the same temperature and pH conditions a maximum titer of 
6400 AU ml
-1
 was obtained, which was subsequently maintained for 345h. The effect of carbon 
sources as well as dilution rates on the production of the Class Ι bacteriocin, Plantaricin C, by 
Lb. plantarum LL441 was investigated in a continuous culture (Bárcena et al., 1998). The 
carbon sources, glucose, sucrose and fructose were tested at different dilution rates to determine 
the optimum conditions for bacteriocin production. Plantaricin C was only detected at low D 
(0.05 h
-1
) when glucose was used as the carbon source. From this observation it was postulated 
that glucose may mediate catabolite repression, and therefore the use of sucrose and fructose as 
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carbon sources became a priority. With these carbon sources plantaricin C production was 
detected at D (0.1-0.12 h
-1
) i.e. double that of glucose. Under optimum conditions, similar 
bacteriocin titres (~3200 AU ml
-1
) in culture supernatants were achieved for all three carbon 
sources, however bacteriocin yield was doubled in media containing sucrose and fructose due to 
the higher dilution rates. 
It has also been noted that immobilisation of bacteriocin producing cells onto a solid matrix 
facilitates the application of dilution rates far in excess of the maximum specific growth rate, 
without cell washout (Lamboley et al., 1997), and can also provide increased cell density 
(Dervakos & Webb, 1991) and plasmid stability (Huang et al., 1996). In one instance nisin Z 
production by L. lactis UL179 immobilised in κ-carrageenan/locust bean gum gel (IC) and in 
free cell culture (FC) was compared in a continuous fermentation. It was noted that nisin Z 
production increased with increasing D in IC fermentations relative to FC fermentations. 
Sonomoto et al (2000) compared nisin Z production by FC and IC adsorbed to ENTG-3800 in 
continuous fermentation. FC displayed good nisin Z production at a dilution rate of 0.1 h
-1
 but, at 
a dilution rate of 0.2 h
-1
, cell wash out resulted in reduced production. In contrast an increase in 
productivity at higher dilution rates was observed in IC fermentations. This phenomenon was 
also reported by Liu et al (2005) during the production of nisin by L. lactis subsp. lactis ATCC 
11454 i.e. the authors observed that nisin activity increased with increased dilution rates up to a 
D of 0.31 h
-1
, although further increase in D resulted in a decrease in nisin activity.   
 
The immobilisation of bacteriocinogenic bacteria in calcium alginate gel beads has also been 
frequently reported (Bhugaloo-Vial et al., 1997, Ivanova et al., 2002, Naghmouchi et al., 2008, 
Scannell et al., 2000, Wan et al., 1995). Calcium alginate is an appropriate scaffold for cell 
immobilisation due to its low cost, food grade status and relative ease in encapsulation of cells 
(Bhugaloo-Vial et al., 1997). The production of nisin and lacticin 3147 by two L. lactis strains 
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either immobilized in calcium alginate beads (IC) or in free culture (FC) was assessed in 
continuous fermentation (Scannell et al., 2000). The beads were found to be quite stable over 
180h, although some cell leakage from the beads was reported. While both nisin and lacticin 
3147 were detected earlier in FC bioreactors, a sharp decline in production occurred mid way 
through the fermentation. Bacteriocin production took longer to reach its maximum in IC 
bioreactors but, once achieved, maximum production was maintained for the remainder of the 
fermentation. It should be noted, however, that Mg
2+
, MgSO4, acetate, citrate and phosphate ions 
can cause instability in calcium alginate beads (Vignolo et al., 1995, Yang & Ray, 1994) and 
that the stability is also affected by the strain that is being encapsulated (Scannell et al., 2000).  
 
The natural attachment of cells to fibrous surfaces in packed bed bioreactors has also been 
employed when immobilising of bacteriocinogenic bacteria (Cho et al., 1996, Liu et al., 2005). 
Using this design, Liu et al (2005) immobilised the nisin producer, L. lactis subsp. lactis ATCC 
11454, in a packed bed bioreactor. This bioreactor was run continuously for six months without 
encountering any problems. Under optimal conditions a maximum nisin titre of 5.1 x 10
4
 AU ml
-
1
 was achieved. 
  
As well as being used in continuous fermentations immobilised cells have also been investigated 
in repeated-cycle batch (RCB) fermentations. In RCB fermentation, immobilised 
bacteriocinogenic bacteria are used to perform consecutive batch fermentations. After each 
fermentation cycle the fermentate is removed and replaced with fresh media and the process is 
repeated. During 1-h cycle RCB cultures the nisin Z producer L. lactis UL719, when 
immobilised in calcium alginate beads, was capable producing up to 8200 IU ml
-1 
of the 
bacteriocin. This corresponds to a volumetric productivity of 5730 IU ml
-1
. An aerated 
continuous IC culture with the same strain run at a D of 2.0 h
-1
, resulted in a maximum 
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volumetric productivity of only 1760 IU ml
-1
 (Bertrand et al, 2001). RCB fermentations have 
also been assessed with respect to pediocin PA-1 production by P. acidilactici UL5 immobilised 
in κ-carrageenan/locust bean gum gel. Maximum pediocin PA-1 activity, 4096 AU ml-1, was 
obtained after 0.45 and 2 h of incubation in MRS and supplemented whey permeate respectively. 
This corresponded to volumetric productivities of 5461 and 2048 AU ml
-1
 h
-1
. In contrast, 
pediocin activity in pH-controlled batch fermentations with free cells yielded only 4096 AU ml
-1
 
after a12 h incubation, resulting in a much lower volumetric productivity of just 342 ml
-1
 h
-1
 
(Naghmouchi et al., 2008).  
 
3.4 Purification of bacteriocins. 
 
The purification of bacteriocins from culture media is necessary to study their composition and 
mode of action. It is also required for the production of pure peptides for application as natural 
biopreservatives in food. The purification of bacteriocins from the culture media is a notoriously 
difficult process and so many methods have been developed (Saavedra & Sesma, 2011). This 
section will give a brief overview of the methods employed for the purification of bacteriocins. 
For a more detailed review, please refer to the review by Saavedra & Sesma (2011). 
 
When purifying bacteriocins the first step is to concentrate the peptides. This process is 
compounded by the presence of a substantial quantity of small peptides of similar size to that of 
most bacteriocins (3,000 - 6,000 Da) in the complex media required for the cultivation of 
bacteriocinogenic LAB (Parente & Ricciardi, 1999). Therefore, it is not possible to simply 
concentrate the peptides by water removal. The two most widely reported methods for the 
concentration of bacteriocins are acid extraction (Yang et al., 1992) and salt precipitation 
(Muriana & Klaenhammer, 1991). Acid extraction relies on the adsorption and desorption of a 
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bacteriocin to its producing cells at different pHs. Yang et al (1992) studied this phenomenon 
with the bacteriocins nisin, pediocin PA-1, sakacin A and leuconocin Lcm1. It was discovered 
that by adjusting the pH to ~ 6.0 (bacteriocin specific), it was possible to adsorb between 93 - 
100% of bacteriocin molecules to the surface of the bacteriocin producing cells. Cells were 
removed from the culture supernatant by centrifuging and released from the cells by adjusting 
the pH to ~ 2.0 (bacteriocin specific) in the presence of 100mM NaCl. Over 90% recovery was 
reported for nisin, pediocin PA-1 and leuconocin Lcm1. However, sakacin A recovery was lower 
i.e. 44%. This is a relatively simple method that provides good yields of bacteriocin and so could 
be suitable for the concentration of bacteriocin peptides on an industrial scale. The other most 
common method for concentrating bacteriocins from the culture media is salt precipitation with 
ammonium sulphate. Ammonium sulphate is added to the culture supernatant (CS) to the point 
of saturation. The saturated CS is then gently mixed overnight and the peptides are allowed to 
precipitate out of solution. The precipitate is subsequently removed from the culture by 
centrifuging and is washed in buffer (Muriana & Klaenhammer, 1991). While this is the more 
commonly applied method for peptide bacteriocin concentration the percentage recovery can 
vary greatly, from below 10 to nearly 100% (Bayoub et al., 2011, Kamoun et al., 2005, Kumar 
et al., 2010, Liu et al., 2008a). 
 
After concentration, the bacteriocin peptides still need to be separated from the contaminants 
present in the media. Generally this is achieved by applying concentrated peptides to a cation 
exchange column (Callewaert & De Vuyst, 1999, Uteng et al., 2002). Anionic compounds can 
pass freely through the column, while bacteriocins, which are frequently cationic, are retained in 
the columns matrix. Bacteriocins are subsequently eluted from the column using a NaCl solution 
(Uteng et al., 2002). Active fractions containing bacteriocin peptides are then applied to a 
reverse-phase high-performance liquid chromatography (RP-HPLC) column for final 
190 
 
concentration. Bacteriocins are eluted from the column using a gradient of water miscible 
organic solvents (Saavedra & Sesma, 2011). 
 
3.5 Partially purified bioactive powders. 
 
Purification of highly purified bacteriocins on an industrial scale is not viable due to the long 
processing time and low percentage recovery. For these reasons, bacteriocins are more 
commonly produced as partially purified bioactive powders such as Nisaplin™ and Alta 2341™ 
(Danisco, Kerry bioscience). The long term stability and ease of transport associated with 
powdered preparations also make them a more attractive option (Gardiner et al., 2000). Spray 
dried bioactive powders have also been described in the literature (Ananou et al., 2008, Morgan 
et al., 1999). A lacticin 3147 containing powder has been produced by Morgan et al (1999). 
Briefly, L. lactis DPC 3147 was inoculated into reconstituted demineralised whey (10%) and 
fermented for 24 h under constant pH. The resulting fermentate was pasteurized (72˚C for 15s) 
and concentrated by evaporation to 40% solids. The concentrate was then spray-dried to produce 
a bioactive lacticin 3147 powder. The addition of 10% total product weight of lacticin 3147 
powder was required to sufficiently reduce numbers of Bacillus cereus and L. monocytogenes in 
a range of food trials (Morgan et al., 2001). While this exhibits the potential of a lacticin 3147 
based bioactive powder, the addition of 10% total product weight of such a powder is neither 
feasible nor economic. 
  
A spray dried bioactive powder containing the enterocin AS-48 has also been produced. E. 
faecalis A-48-32 was cultivated in the whey derived substrate Esprion-300 (E-300), at 28˚C for 
18-20h under controlled a pH of 6.5. After fermentation AS-48 was recovered from the E-300 by 
cation exchange chromatography on a carboxymethyl Sephadex CM-25. The recovered fractions 
191 
 
were either heat treated (80˚C, 20 mins) or UV light irradiated (5mins) to inactivate the producer 
and subsequently spray dried (Ananou et al., 2010). However, yet again, 5% and 10% wt/vol 
was still required to control the growth of L. monocytogenes and S. aureus in skim milk 
respectively (Ananou et al., 2010). Also while both the lacticin 3147 and the AS-48 powders 
retain full activity for at least 4 months at refrigeration temperatures (4-5˚C), however both 
undergo a 50% reduction in activity after 9 months at room temperature (Ananou et al., 2010, 
Morgan et al., 2001). The stability of these powders clearly does not match that of the 
commercial nisin preparation Nisaplin™ which is stable between 4˚C and 25˚C over 2 years 
from the date of manufacture (Morgan et al., 2001). For such powders to reach their true 
commercial potential, the issues of stability and total activity will have to be addressed. 
 
4. Improvement of bacteriocinogenic bacteria. 
 
Genetic manipulation of bacteriocinogenic bacteria can be exploited to address many of the 
problems associated with bacteriocin production for food applications, such as low production, 
production in suitable bacteria and spectrum of activity. A number of authors have demonstrated 
the effectiveness of genetic manipulation in improving bacteriocin production (Cheigh et al., 
2005, Cotter et al., 2006, Heinzmann et al., 2006). While the genetically modified nature of the 
strains in question usually precludes their use in food, such studies have often provided valuable 
insights and may be of relevance to the food industry in the future. 
 
Cotter et al (2006) investigated the provision of additional copies of the lacticin 3147 genes on 
the production of lacticin 3147 in L. lactis MG1363 (pMRC01), a strain expressing the parental 
lacticin 3147 encoding plasmid (pMRC01). A high copy number plasmid containing the entire 
lacticin 3147 encoding region (pOM02) was introduced into MG1363 by electroporation and the 
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resulting strain, MG1363(pMRC01, pOM02) was found to produce 4-fold more lacticin 3147 
than strains containing either plasmid alone. Further investigation revealed that additional copies 
of the two lacticin 3147 structural genes (ltnA1A2) was not necessary, as addition of a plasmid 
containing all other lacticin 3147 encoding genes resulted in a 3.5 fold increase in production 
relative to the strain carrying pMRC01 alone. In another instance, an increase in the production 
of nisin Z by L. lactis A163 was achieved by introducing a multiple copy plasmid harbouring the 
nisin regulatory genes, nisR and nisK. This resulted in an increase in production from 16,000 AU 
ml
-1
, observed in the control to 25,000 AU ml
-1
 in the strain over-expressing nisRK. This was as 
a consequence of the increased transcription of the nisZ gene (Cheigh et al., 2005). 
As enterocin producing Enterococci can potentially carry virulence genes and therefore are not 
considered GRAS organisms (Eaton & Gasson, 2001, Franz et al., 2001, Shankar et al., 2002), 
there has been a growing interest in producing enterocins in GRAS hosts. An example of this is 
the heterologous expression of the Class ΙΙ bacteriocin enterocin P (EntP) from E. faecium P13 
by a strain of L. lactis. The EntP structural gene, entP, and its immunity gene, entiP were cloned 
into L. lactis NZ9000 under a nisin inducible expression system. The resulting strain, L. lactis 
NZ9000(pJR199), exhibited a higher specific activity than was produced by any other L. lactis 
hosts or the parent strain E. faecium P13 (Gutiérrez et al., 2006). Liu et al (2008b) 
heterologously expressed the Class ΙΙ bacteriocin, enterocin A (EntA) in L. lactis 
MG1614(pLP712). The EntA encoding plasmid pEnt02 was introduced into L. lactis 
MG1614(pLP712) by electroporation and although the resulting strain, L. lactisEnt+ produced 4-
fold less EntA than the parent strain E. faecium DPC 1146, however this was deemed acceptable 
due to the strong anti-listerial properties of EntA. 
 
The natural transfer of bacteriocin-encoding plasmids by conjugation has also been used to 
confer a bacteriocin producing phenotype on strains that are better adapted to specific food 
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environments. Over 30 food-grade starter cultures producing lacticin 3147 have been constructed 
by exploiting the conjugal nature of the lacticin 3147 encoding plasmid pMRC01 (Coakley et 
al., 1997, Trotter et al., 2004), some of which have also been used as protective cultures in food 
fermentations (Coffey et al., 1998, McAuliffe et al., 1999). One such transconjugant, L. lactis 
DPC 4275 was found to produce variable titres of lacticin 3147. In this strain it was found that 
an 80kb cointegrate plasmid, pMRC02 had formed from the incorporation of the lacticin 3147 
genes into the resident plasmid pMT60. It was revealed that when pMRC02 was present at a 
high copy number lacticin 3147 titre was roughly double that of a low copy variant (Trotter et 
al., 2004). 
 
The limited antimicrobial potency and spectrum of inhibition of some bacteriocins restrict their 
value with respect to food related applications. One solution to this problem is the creation of 
multi-bacteriocinogenic bacteria producing two or more bacteriocins to enhance or broaden their 
activity. By combining unrelated bacteriocins with different modes of action, it is also possible 
to prevent the emergence of resistance to either bacteriocin (Horn et al., 1999). Gutiérres et al 
(2006) described the heterologous production of enterocin P in the nisin producing strain L. 
lactis DPC 5598. The resulting transformant was capable of simultaneous production of both 
bacteriocins, although it should be noted that the levels of EntP activity of this strain were lower 
than that observed among other L. lactis host strains. Lower bacteriocin production relative to 
the parent strain was also observed when enterocin A and pediocin PA-1 were heterologously 
co-produced in L. lactis IL1403, although this could be attributed to an inefficient host (Martínez 
et al., 2000).  
 
Genetic manipulation has also been employed to modify bacteriocins with a view to improving 
their spectrum of inhibition, antimicrobial activity and the solubility and stability of the 
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bacteriocins for applications in food environments. This is generally achieved either by 
mutagenesis of the bacteriocin encoding genes or by fusing genes from different species to 
create chimeric bacteriocins (Gillor et al., 2005). Yuan et al (2004) created a number of mutants 
producing derivatives of nisin Z by site directed mutagenesis at the hinge region of the nisin Z 
gene, nisZ. The resulting mutants had decreased activity versus Micrococcus flavus NCIB8166 
and Streptococcus thermophilus. However, peptides with enhanced activity against Gram 
negative, i.e. Shigella, Salmonella and Pseudomonas species, or with increased solubility and 
stability compared to that of nisin Z were identified. Random mutagenesis has also been 
employed to create the largest bank of randomly mutated nisin derivates (Field et al., 2008). Use 
of this approach resulted in the identification of derivatives with enhanced activity against L. 
monocytogenes, S. aureus Streptococcus agalactiae (Field et al., 2008) and various 
mycobacteria (Carroll et al., 2010) and others with apparently enhanced ability to diffuse 
through complex matrices (Rouse et al., 2012). 
Notably, although the initial producers of these variants were genetically modified 
microorganisms (GMM), strategies exist which can facilitate the generation of corresponding 
strains through self-cloning, meaning that such producers would fall outside the scope of 
directives regarding the contained use of GMMs. This fact may ultimately facilitate the 
application of these nisin derivatives for food applications. 
An alternative strategy, i.e. DNA shuffling, was employed to develop an ‘improved’ derivative 
of pediocin PA-1. A DNA shuffling library was created by shuffling four specific regions of the 
N-terminal half of pediocin PA-1 with 10 other class ΙΙa bacteriocins. A library of 280 shuffled 
DNA mutants was created, 63 of which displayed antimicrobial activity. Shuffled mutants 
displayed increased activity against various species of Lactobacillus, Pediococcus, and 
Carnobacterium. One of the mutants identified was also active against L. lactis, which was 
immune to the parent pediocin PA-1 (Tominaga & Hatakeyama, 2007). 
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5. Conclusions:  
The in-situ production of bacteriocins by bacteriocinogenic starter, adjunct or protective cultures 
has been demonstrated to be an effective delivery system with respect to the incorporation of 
bacteriocins into the food environment. As a consequence of the diverse array of 
bacteriocinogenic LAB that are available, and the fact that they can be produced as lyophilised 
bacteriocinogenic starter, adjunct or protective cultures, there is great potential for the use of 
cultures as biopreservatives in food. As there are no regulatory issues that limit the use of 
bacteriocinogenic LAB in food, this approach may be an economical alternative to the 
application of chemical preservatives or purified bacteriocin preparations for controlling 
spoilage and pathogenic bacteria. 
The optimisation of fermentation processes, as well as the development of food grade media 
from industrial waste products, has greatly reduced the cost of producing bacteriocins by large 
scale fermentation. However, the production of purified bacteriocin peptides can still be a 
difficult and expensive process and peptides other than nisin have not been approved for use as 
food preservatives. Therefore, the production of bioactive fermentates containing bacteriocins is 
preferred. Such bioactive fermentates can be added to foods as food ingredients rather than as 
preservatives and thus are not subject to the same regulatory scrutiny as a purified peptide 
preservative. While the production of bacteriocins as bioactive fermentates is relatively cheaper 
and less complex than the production of purified bacteriocin peptides, in some instances the 
antibacterial activity and stability of such preparations would need to first be improved before 
commercial applications could be considered. 
Finally, many strategies have been employed to improve bacteriocinogenic bacteria and the 
bacteriocins they produce, as current regulations prohibit the use of GMMs in foods and 
consumer resistance to GMMs also hinder their application in food production, for the short to 
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medium term there will continue to be an emphasis on the use of food grade strategies to 
generate new and improved bacteriocinogenic strains.  
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